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ABSTRACT OF DISSERTATION 
 
 
 
 
EFFECTS OF INTRANASALLY ADMINISTERED DNSP-11  
ON THE CENTRAL DOPAMINE SYSTEM  
OF NORMAL AND PARKINSONIAN FISCHER 344 RATS 
 
Due to the blood-brain barrier, delivery of many drugs to the brain has 
required intracranial surgery which is prone to complication.  Here we show that 
Dopamine Neuron Stimulating Peptide 11 (DNSP-11), following non-invasive 
intranasal administration, protects dopaminergic neurons from a lesion model of 
Parkinson’s disease in the rat.  A significant and dose-dependent increase in an 
index of dopamine turnover (the ratio of DOPAC to dopamine) was observed in 
the striatum of normal young adult Fischer 344 rats by whole-tissue 
neurochemistry compared to vehicle administered controls.   
Among animals challenged with a moderate, unilateral 6-hydroxy-
dopamine (6-OHDA) lesion of the substantia nigra, those treated repeatedly with 
intranasally administered DNSP-11 exhibited greater numbers of tyrosine 
hydroxylase (TH) positive dopaminergic neuronal cell bodies in the substantia 
nigra and greater TH+ fiber density in the striatum when compared to animals 
treated intranasally with vehicle only or a scrambled version of the DNSP-11 
sequence.  Lesioned animals that received intranasal DNSP-11 treatment did not 
exhibit abnormal, apomorphine-induced rotation behavior, contrasted with 
animals that received only vehicle or scrambled peptide that did exhibit 
significantly greater rotation behavior. 
In addition, the endogenous expression of DNSP-11 from the pro-region of 
GDNF was investigated by immunohistochemistry with a custom, polyclonal 
antibody.  Signal from the DNSP-11 antibody was found to be differentially 
localized from the mature GDNF protein both spatially and temporally.  While 
DNSP-11-like immunoreactivity extensively colocalizes with GDNF 
immunoreactivity at post-natal day 10, the day of maximal GDNF expression, 
DNSP-11-like signal was found to be present in the 3 month old rat brain with 
signal in the substantia nigra, ventral thalamic nucleus, dentate gyrus of the 
hippocampus, with the strongest signal observed in the locus ceruleus where 
GDNF is not expressed.  Results from immunoprecipitation of brain homogenate 
were not consistent with the synthetic, amidated 11 amino-acid rat DNSP-11 
sequence.  However, binding patterns in the literature of NPY, the only 
homologous sequence present in the CNS, do not recapitulate the 
immunoreactive patterns observed for the DNSP-11 signal. 
This study provides evidence for a potential easy-to-administer intranasal 
therapeutic using the DNSP-11 peptide for protection from a 6-OHDA lesion rat 
model of Parkinson’s disease. 
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Chapter One:  Introduction 
Parkinson’s Disease 
A History of Parkinson’s Disease 
Parkinson’s Disease (PD) was characterized in 1817 through the 
observations of James Parkinson in the field of apothecary surgery.  His work, An 
Essay on the Shaking Palsy, characterized through six case studies a motor 
disorder of the extremities which today affects an estimated 1% of the population 
over the age of 65 (Tanner, 1992; de Lau and Breteler, 2006; NINDS, 2006), and 
its prevalence is expected to double every 25 years due to the increased average 
age of the population (Van Den Eeden et al., 2003; Dorsey et al., 2007; Wright 
Willis et al., 2010; Collier et al., 2011).  It was not until sixty years after Parkinson 
produced his Essay that the disease began to carry his name when Jean Martin 
Charcot distinguished the shaking palsy described by Parkinson as “Parkinson’s 
disease”.  Parkinson, in the final chapter of his Essay, describes the potential for 
a cure, saying that, although there … 
“exists no countervailing remedie […] there appears to be sufficient 
reason for hoping that some remedial process may ere long be 
discovered, by which, at least, the progress of the disease may be 
stopped.”  
 
Nearly 200 years later, a cure for the disease described by Parkinson is still 
not available; but, as Parkinson concludes his work, there is reason for hoping 
because:  
“To such researches the healing art is already much indebted for the 
enlargement of its powers of lessening the evils of suffering humanity. 
Little is the public aware of the obligations it owes to those who, led by 
professional ardour, and the dictates of duty, have devoted themselves 
to these pursuits, under circumstances most unpleasant and forbidding.” 
1 
 
Signs and Symptoms 
Although much has changed between 1817 and today with regard to 
research techniques, the signs and symptoms of Parkinson’s disease have 
remained constant.  Primary complaints focus on the cardinal motor symptoms: 
resting tremor, bradykinesia or akinesia, “cogwheel” rigidity, shuffling gait and 
postural instability.  Secondary symptoms can include insomnia, urinary and fecal 
incontinence, and orthostatic hypotension, disorders of olfaction, cognitive 
decline, mood disorders and dementia.  Indeed, as many as 47% of Parkinson’s 
disease patients have symptoms of depression that arose prior to the cardinal 
motor signs (Kummer and Teixeira, 2009; Lohle et al., 2009).  In addition, a 
plethora of secondary motor symptoms, although less common, can be present 
especially in later stages, including muffled speech, loss of facial expression, 
small hand-writing and difficulty swallowing (Jankovic, 2008). 
Parkinson’s disease, as a progressive neurodegenerative disease, primarily 
affects the aged population with a mean age of onset of 60 years with the 
prevalence rising with age; but between 5-10% of Parkinson’s disease cases 
occur in individuals between the ages of 20 and 50 years (NINDS, 2006).  As the 
average age of the population rises, it is expected that prevalence will also 
increase. 
Some estimates of the cost of the disease to the population of the United 
States range from $5.6 billion (NINDS, 2006) to as high as $23 billion (Huse et 
al., 2005; Findley, 2007).  This includes not only the estimated cost of 
pharmaceutical therapies of $10,000 per individual per year, but also surgical 
treatment options, the cost of nursing home stays and the loss of economically 
productive years and quality of life of both the patients and his or her family.   
Pathogenesis of Parkinson’s Disease 
There are two forms of Parkinson’s disease: familial and idiopathic (or 
sporadic).  Familial Parkinson’s disease accounts for approximately 5% of all 
known cases of PD (NINDS, 2006) and always involves an inherited genetic 
mutation.  Several target genes in these population samples have been identified 
and are the subject of study, especially the genes PINK1 (Valente et al., 2004), 
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PARKIN (Kitada et al., 1998), SNCA (Abou-Sleiman et al., 2006a), and LRRK2 
(Mata et al., 2006).  Many of these genes are translated to proteins that are 
associated with either mitochondrial function (Abou-Sleiman et al., 2006b) or 
proteasomal degradation (Dawson and Dawson, 2003; Bender et al., 2006; 
Mizuno et al., 2006; Bueler, 2009).  Familial Parkinson’s disease is also 
associated with early onset of the disease, before the age of 40 years. 
  However, idiopathic Parkinson’s disease comprises the majority of 
cases.  Literally meaning that the cause of the disease is unknown, “idiopathic” or 
sporadic Parkinson’s disease has in fact been linked to several factors, both 
environmental and genetic.  One especially potent non-genetic inducer that has 
been identified is MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Langston 
and Ballard, 1983; Langston et al., 1984).  In 1976, illicit users of MPPP 
(desmethylprodine), an opioid analgesic, were subjected to high levels of 
impurities in the form of MPTP, a potent mitochondrial toxin, resulting in the 
development of parkinsonian symptoms.  One of these patients subsequently 
died of unrelated causes, and an autopsy revealed extensive loss of 
dopaminergic neurons of the substantia nigra (Fahn, 1996).  This finding helped 
lend credence to earlier studies showing a deficit of the neurochemical dopamine 
in both the striatum and substantia nigra (Ehringer and Hornykiewicz, 1960; 
Hornykiewicz, 1963).  MPTP provided additional evidence for the role of 
mitochondrial dysfunction of dopaminergic neurons in Parkinson’s disease. 
Indeed, it has been determined that a loss in excess of approximately 60% 
of dopaminergic neurons of the substantia nigra results in the onset of the 
characteristically parkinsonian motor signs (Braak et al., 2006).  This loss 
correlates to an approximate 80% reduction in dopamine content (Gibb and 
Lees, 1991).  As determined from familial cases of Parkinson’s disease, it is 
postulated that an accumulation of mitochondrial-associated mutations and 
degradations throughout life ultimately are the causative agent of sporadic 
parkinsonism (Bender et al., 2006).  The cause of this accumulation can be 
varied and multimodal. 
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This life-long accumulation can be attributed to environmental elements, 
typically pesticides and herbicides including rotenone and paraquat (Tanner et 
al., 2011), and “Agent Orange” (IOM, 2009), and industrial agents such as 
trichloroethylene (Gash et al., 2008), but can also include traumatic damage from 
head injuries (Davie et al., 1995; Bower et al., 2003; Sauerbeck et al., 2011).  
Many of these insults induce a concomitant inflammatory response within the 
CNS, and in fact neuroinflammation has been implicated in many 
neurodegenerative diseases including Parkinson’s disease (Hunter et al., 2007; 
Whitton, 2007; Choi D. Y. et al., 2009).  It is even thought that reactive oxygen 
species created during normal dopamine metabolism can be a cause of 
progressive dopaminergic neurodegeneration (Stokes et al., 1999). 
A defining histological characteristic of the disease is the presence of 
“Lewy Bodies”, or protein aggregates commonly observable within the cell bodies 
of catecholaminergic neurons (Figure 1.1).  Frederick Henry Lewey in 1912 was 
the first to observe these eosinophilic sphereoidal inclusions encircled by fibrils in 
the CNS of parkinsonian patients.  A major component of Lewy Bodies is the α-
synuclein protein implicated in familial cases of Parkinson’s disease; but α-
synuclein containing Lewy Bodies are also present in several other diseases of 
the CNS including Dementia with Lewy Bodies (or DLB), Multiple Systems 
Atrophy (MSA), and corticobasal degeneration, all of which present with some, 
but not all, of the symptoms of Parkinson’s disease.  Some researchers believe 
these protein aggregates are the causative element in Parkinson’s disease due 
to their high correlation to areas of greatest neuronal loss (Gibb and Lees, 1989).  
However, because of the wide array of neurological disorders characterized by 
the presence of Lewy Bodies, and because Lewy Bodies are also present in 
asymptomatic individuals, others hypothesize that these aggregates may be a 
general protective mechanism against molecular damage to cellular enzymes, 
serving as a kind of “waste dump” when proteasomal degradation processes are 
insufficient (Burke et al., 2008), thus appearing as a marker for neuronal distress 
and not acting as the direct cause of the dysfunction and death itself.   
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Not all of the histological and neurochemical damage occurring in 
Parkinson’s disease is isolated to the substantia nigra.  Other catecholaminergic 
centers of the brain are implicated in Parkinson’s disease as well.  In particular, 
degeneration of the locus ceruleus (Figure 1.2) is thought to be the causative 
element in many of the non-motor symptoms observed in parkinsonian patients, 
especially insomnia and dementia.  The locus ceruleus, literally the “blue spot” 
due to its high neuromelanin content, located in the dorsal tegmental pontine 
brainstem, serves as the norepinephrinergic center of the brain and acts as a 
“gain setting” nucleus for cognitive function.  It sends projections throughout the 
CNS, influencing cortical, subcortical, cerebellar, and brainstem circuitry and is 
implicated in stress-response and attention focusing, memory, sleep-wake 
cycles, and even postural stability.  The locus ceruleus is self-modulatory and 
may also play a role in compensatory mechanisms during pre-symptomatic 
parkinsonism (Rommelfanger and Weinshenker, 2007), possibly explaining the 
insidious loss of dopaminergic neurons without noticed behavioral deficits.  In 
addition to the locus ceruleus, the dorsal nucleus of the vagus nerve is implicated 
in parkinsonian symptoms including incontinence.  Due to the many systems 
typically affected in Parkinson’s disease, a “dual-hit” hypothesis of the etiology of 
sporadic Parkinson’s disease has been proposed, controversially suggesting 
possible dual environmental vectors for entry to the CNS via the olfactory system 
and spinal cord (Hawkes et al., 2007).  The dopamine system, however, remains 
the single most prevalent and consistent area of degeneration observed in 
parkinsonism, and is responsible for the most frequent symptomatic complaints 
in regards to the disease.  As such, the majority of research focuses on 
dopamine and the nigrostriatal system as the key to unlocking an intervention for 
Parkinson’s disease. 
The Discovery of Dopamine 
 Dopamine (DA) was first synthesized in 1910 by George Barger and 
James Ewens, but this monoamine was considered merely to be a precursor in 
the natural synthesis of norepinephrine (NE) (Blaschko, 1942).  It was not 
recognized to be a distinct catecholamine neurotransmitter in its own right until 
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1958, after Arvid Carlsson and Nils-Åke Hillarp in Sweden elucidated the role of 
the dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) as a reserpine 
antagonist (Carlsson et al., 1957; Abbott, 2007), followed closely by the 
discovery of dopamine in the central nervous system (CNS) of the mammalian 
brain (Montagu, 1957) and later in the human brain (Sano et al., 1959).   
Dopamine Biosynthesis and Signaling 
 Dopamine is synthesized along the same enzymatic sequence as, and is 
a precursor compound for, norepinephrine (NE) (Figure 1.3).  The first, and rate-
limiting, step of dopamine synthesis is the conversion of L-tyrosine to L-
dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase (TH) 
(Carlsson et al., 1972; Haavik and Toska, 1998).  This step requires molecular 
oxygen (O2), an iron atom co-factor (Fe2+) and tetrahydro-biopterin (BH4 or THB) 
in order to add a hydroxyl group to the aromatic ring. From here, L-DOPA is 
converted to dopamine by the enzyme aromatic L-amino acid decarboxylase, 
which removes the carboxyl group from L-DOPA.  Dopamine is then packaged 
into synaptic vesicles by vesicular monoamine transporter 2 (VMAT2) for later 
release.  L-tyrosine, consumed in abundance in a normal diet, readily crosses the 
blood-brain barrier, as does L-DOPA, but dopamine cannot and thus its utility is 
spatially restricted.  However, if L-tyrosine levels are low, L-phenylalanine may 
be converted into L-tyrosine by phenylalanine hydroxylase.   
 After release into the synaptic terminal, dopamine interacts with a range of 
receptors on the pre- and post-synaptic terminal, causing either neuronal 
excitation or inhibition in the target neuron.  Two entire families of dopamine 
receptors have been indentified, composed of as many as five different isoforms, 
each of which affect different intracellular signaling pathways.  These two families 
of dopamine receptors, D1 and D2, are both G-protein coupled receptors, but D1 
receptors result in the depolarization of the neuron on which they are expressed, 
whereas D2 receptors inhibit neuronal firing. 
Once in the synaptic cleft, dopamine may either be transported back into 
the pre-synaptic neuron via dopamine transporters (DAT) for repackaging or 
remain in the extracellular space to be taken up by glial cells or metabolized on 
6 
 
cellular membranes.  Dopamine may be metabolized extraneuronally by 
catechol-o-methyltransferase (COMT) to 3-methoxytyramine (3-MT) while 
monoamine oxidase-B (MAO-B) will rapidly metabolize 3-MT to homovanillic acid 
(HVA) (Tank et al., 1981; Kopin, 1985; Shih et al., 1999); or, inside the 
cytoplasm, MAO and aldehyde dehydrogenase (ALDH) work together to convert 
dopamine to DOPAC (Iversen, 2009). 
 As a result of this complex sequence, the modulation of dopamine can 
occur not only at the level of the whole neuron, its projections, and neuronal 
circuitry across the nervous system, but also during synthesis of dopamine 
(transcriptional, translational, and post-translational regulation), synaptosomal 
packaging (regulation of VMAT, transport of vesicle to synapse), dopamine 
release (neuronal depolarization, calcium signaling, vesicle fusion), and via 
reuptake and metabolism through regulation of the respective enzymes and their 
spatial localization relative to their substrate.  Although the cause of 
parkinsonism is well known: a deficit of dopamine in the nigrostriatal pathway, the 
underlying mechanisms for this dysfunction can be diverse. 
Dopaminergic Pathways 
 The study of dopamine has led to the discovery of its central role in 
reward-seeking behavior, wherein dopamine transmission becomes markedly 
increased.  This has resulted in research of the role of dopamine in a variety of 
psychiatric conditions ranging from substance abuse, schizophrenia to attention 
deficit disorder (Iversen, 2009).  These conditions all involve disorders in the 
mesolimbic and mesocortical pathways of dopamine innervation.  The 
mesolimbic pathway originates in the dopaminergic ventral tegmental area (VTA) 
and substantia nigra (SN), which project to the nucleus accumbens and 
amygdala, implicated in reward-stimulation and the fear-response.  The 
mesocortical pathway, while originating in these same anatomical nuclei, 
innervate the prefrontral cortex, responsible for executive functioning, attention, 
and complex planning.  A third pathway, the tuberoinfundibular pathway, is 
mainly responsible for the regulation of the neuroendocrine prolactin from the 
anterior pituitary gland, which is well known for its role as a lactation inducer, but 
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also has lesser roles in water/salt homeostasis and immuno-system and cell-
cycle regulation. 
 The nigrostriatal pathway is the pathway involved in the motor deficits 
observed in Parkinson’s disease.  This pathway is comprised of dopaminergic 
neurons that originate in the substantia nigra and project to the striatum via the 
medial forebrain bundle, forming synapses with several neuronal populations in 
the putamen, caudate nucleus, GPi and STN.  This forms the afferent 
connections of the substantia nigra to the circuitry involved in motor movement, 
the basal ganglia. 
Basal Ganglia 
 The basal ganglia (or, more appropriately, the basal nuclei) are a 
collection of nuclei located in the ventral forebrain which have been implicated in 
voluntary motor control and habitual motor output while also playing a role in 
cognition and emotional functions (Mink, 2007).  The basal ganglia is comprised 
of the striatum, globus pallidus and subthalamic nucleus, and has its 
dopaminergic input from the substantia nigra (Figure 1.4).  Dysfunctions in this 
circuitry are core elements of a variety of motor disorders, including Huntington’s 
disease, hemiballism, Tourette’s syndrome, and obsessive-compulsive disorder 
(Fix, 2008).  The basal ganglia also include the nucleus accumbens, ventral 
pallidum, and VTA, which play a central role in reward learning, and dysfunction 
in these nuclei have been implicated in schizophrenia and attention deficit 
hyperactivity disorder (ADHD). 
 The striatum (Str), the largest of the basal ganglia nuclei, is the major 
destination of the dopaminergic neurons of the substantia nigra.  Named for its 
striated appearance due to the prevalence of bands of white matter tracts, the 
human striatum can be divided into two distinct sections, the caudate nucleus 
more dorsomedially and the putamen ventrolaterally.  The internal capsule and 
its limbs, extensive bands of white matter axons traveling between the cortex and 
the pyramids of the medulla, divide these units.  The striatum of the rodent differs 
from that of the human in that the caudate and putamen are not distinguishable 
due to a poorly defined internal capsule.  Instead, the striatum is separated 
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histologically into “patch” and “matrix” (Desban et al., 1993).  The patch is the 
predominant target for dopaminergic projections, whereas the matrix possesses 
acetylcholinesterase and is the site of arborization of the cortical 
acetylcholinergic connections to the striatum (Gerfen, 1992).  Classical 
descriptions of the caudate and putamen suggested different functions, but 
modern neuroscience attributes those differences to the somatotopic 
organization of the striatum as a whole, so these observed neuroanatomical 
differences may be a false distinction (Choi et al., 2012).  The more dorsolateral 
region of the striatum predominantly receives input from the substantia nigra and 
is involved in motor control, the central region of the striatum is referred to as the 
associative region, while the ventromedial region is involved in limbic function 
receiving mainly VTA projections.  In fact, this continuum may result in the 
manifestation of some of the secondary complaints of Parkinson’s disease, 
including dementia and depression.  Medium spiny, inhibitory GABAergic afferent 
neurons predominate throughout the striatum. 
 The pallidum, or globus pallidus (GP), is divided into two segments, the 
internal and external segments.  Both of these segments are predominantly 
GABAergic, and thus inhibitory in effect, but they are constitutively active, 
tonically inhibiting their targets.   
 The subthalamic nucleus (STN) is the only excitatory nucleus of the basal 
ganglia complex and is one of the nuclei that receive tonic inhibition by the 
globus pallidus (from the external segment). 
 The substantia nigra can be divided into two parts: pars compacta (SNc) 
and pars reticulata (SNr).  The pars reticulata receives glutamatergic innervation 
from the STN and sends GABAergic projections to the ventral anterior and 
ventrolateral nuclei of the thalamus.  The pars reticulata also regulates the firing 
of the pars compacta by sending GABAergic arborizations into this neighboring 
region.  The pars compacta is the dopaminergic center of the basal ganglia and 
serves as midbrain input of the striatum.  The pars reticulata is capable of 
modulating the firing rate of the pars compacta throughout feedback from the 
basal ganglia circuitry.  The substantia nigra pars compacta, being the source of 
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the primary dopamine projections to the motor region of the striatum, is the 
region implicated in the motor symptoms of Parkinson’s disease. 
Direct and Indirect Pathways 
 Motor output is modulated by the substantia nigra indirectly, through this 
complex basal ganglia circuitry (Figure 1.5A) which serves as a “weigh-station” 
for motor-output.  The classical, simplified version of this pathway is described 
below, but far more interconnections are present than defined here.  A more in 
depth review can be found in the literature (Alexander et al., 1986; Albin et al., 
1989; Mink, 2007).  The dopaminergic fibers of the substantia nigra synapse in 
the putamen of the striatum on two different populations of neurons: one 
expressing the D1 family and the other expressing the D2 family of receptors.  
The D1R family of neurons project to the GPi and are referred to as the “direct” 
pathway.  When dopamine is released on to and bound by these D1R neurons, 
the intraneuronal pathways activated result in the excitation of this group of 
striatal neurons.  These “direct” pathway neurons release GABA, inhibiting the 
GPi (Figure 1.5B). 
 The population of striatal neurons expressing the D2R family, when they 
bind dopamine, undergo intracellular signaling that ultimately results in the 
inhibition of this group of neurons.  These D2R neurons, inhibited in firing when 
dopamine is bound, send GABAergic projections to the GPe.  The GPe in turn 
sends constitutively active GABAergic projections to the STN, and the STN 
projects excitatory glutamatergic fibers to the GPi.  This is referred to as the 
“indirect” pathway. 
 Both pathways ultimately synapse on the GPi, which balances the input 
from the two pathways, resulting in a net output to the ventral anterior nucleus of 
the thalamus (VA).  The GPi, like the GPe, is constitutively active, tonically 
releasing GABA into synapses within the VA.  In a sense, motor output is 
normally inhibited by the GPi.  As a result, when the input to the GPi from the 
“direct” pathway is outweighing the input from the “indirect” pathway, the net 
result is inhibition of the inhibitory GPi.  This effectively “disinhibits” motor output. 
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 However, when dopamine is not present or its release has been reduced, 
as is the case in Parkinson’s disease, the “indirect” pathway begins to outweigh 
the “direct” pathway (Figure 1.5C).  The normal inhibition of the VA by the GPi, 
and thus the corresponding motor output, becomes even stronger, resulting in 
poor motor initiation and decreased motor speed in accordance with the 
observed signs of Parkinson’s disease. 
Rat Models of Parkinson’s Disease 
In order to study neurodegenerative diseases, animal models of the 
disease state must be developed.  Many models have been developed, some 
using the genetic mutations or non-genetic toxins discussed above, especially 
rotenone, paraquat, and MPTP (Blesa et al., 2012).  However, not every model 
can perfectly replicate the human disease in the animal.  For instance, due to the 
rat’s tolerance for the MPTP toxin, in contrast with mice and primates, MPTP 
does not make an effective rat model of parkinsonism.   
A widely used and perhaps the oldest model of Parkinson’s disease in the 
rat, and the model used for the present work, is the unilateral 6-hydroxydopamine 
(6-OHDA) lesion model.  As a catecholaminergic-neurotoxin, 6-OHDA selectively 
destroys dopaminergic and norepinephrinergic neurons.  In order to induce 
parkinsonism in rats via dopaminergic cell death, 6-OHDA is injected into points 
along the nigrostriatal pathway in various amounts.  Injection into the striatum 
can produce a partial lesion, while injection into the medial forebrain bundle 
(MFB) typically produces extensive lesions in the nigrostriatal pathway.  Injection 
directly into the substantia nigra typically produces moderate lesions, leaving the 
animal with some intact functionality.  This theoretically produces a disease state 
similar to moderate Parkinson’s disease in humans, a time at which point a 
therapeutic intervention may begin.  Also, it is noted that the pattern of cell loss in 
Parkinson’s disease is mimicked most closely by lesions of the substantia nigra 
directly (German et al., 1989; Goto et al., 1989; Deumens et al., 2002). 
The unilateral nature of this lesion not only is easier for the animal to 
tolerate, but also provides some interesting behavioral consequences.  Because 
the motor system has a deficit in only one hemisphere, the aggregate 
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movements of the animal will result in a net rotation.  This can be quantified to 
provide an accurate estimate of the number of neurons lost due to the toxic insult 
(Perese et al., 1989; Hudson et al., 1993; Deumens et al., 2002), especially with 
the use of dopamine-system modulating compounds to induce elevated activity.  
One such compound, apomorphine, increases activity in the animal by acting as 
a dopamine receptor agonist.  As dopaminergic innervation of the striatum is lost, 
the striatal neurons compensate by increasing the expression of dopamine 
receptors, inducing a state of super-sensitivity.  Apomorphine then binds to this 
upregulated receptor activity in the denervated hemisphere, producing increased 
motor output from that hemisphere.  This results in the animal rotating 
contralaterally, “away from” the lesioned hemisphere; or, in other words, the 
lesioned hemisphere is toward the outside of the imaginary circle formed by the 
animal’s rotation.  Because apomorphine-induced rotation behavior relies on 
striatal super-sensitization due to a denervation of greater than 90%, it produces 
a more binary effect: animals tend to either rotate or not to rotate.   
Some 6-OHDA lesion models may be considered a progressive model of 
the disease (Zigmond et al., 1990).  Lesions of the substantia nigra by 6-OHDA 
result in cell death within a week of injection (Wright et al., 2009), but behavioral 
consequences tend not to stabilize until several weeks after injection (Perese et 
al., 1989).  Although rapid in pace, this progression allows some potential for the 
study of preventive interventions.  6-Hydroxydopamine achieves its neurotoxicity 
by way of its ability to act as a dopamine analogue with catecholamine 
transporters, taking advantage of selective transportation into the cytoplasm.  
From there, 6-OHDA reacts to form reactive oxygen species including hydrogen 
peroxide and the quinone form of the compound.  In order to selectively target 
dopaminergic catecholamine neurons, desipramine may be used to inhibit the 
uptake by norepinephrinergic neurons.  Monoamine oxidase can also be 
administered to prolong the life, and thus enhance the effect of 6-OHDA 
(Zigmond et al., 1990). 
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Treatment Options 
A variety of treatment options are currently available for Parkinson’s 
disease, but all are palliative and do not slow the progression of the disease or 
affect the loss of dopaminergic neurons of the substantia nigra.  These 
treatments can be divided into three categories: dopamine supplementation, 
dopamine replacement, and surgical intervention. 
Dopamine supplementation therapies attempt to increase the natural 
levels of dopamine in the CNS by a number of ways.  The first of these and the 
“gold” standard of such treatment is the administration of L-DOPA, the immediate 
precursor in the synthesis of dopamine, commonly combined with carbidopa to 
reduce peripheral effects by inhibiting DOPA decarboxylase.  L-DOPA has the 
benefit of being able to cross the blood-brain barrier (BBB) and so can be 
administered systemically in oral pill form.  By providing a surfeit of precursor to 
the remaining dopaminergic neurons, this allows for the ready production of 
dopamine. 
Dopamine levels can also be increased on the opposite end, by inhibiting 
the break-down of dopamine that has already been synthesized.  By inhibiting 
monoamine oxidase, dopamine that has been released into the synapse can be 
more readily recycled by the pre-synaptic neuron for later reuse instead of being 
metabolized to DOPAC. 
Elevated levels of dopamine, either in the brain or the periphery, can result 
in a wide array of side effects.  Common neurological effects include 
disorientation, hallucinations, anxiety, increased libido, and somnolence or 
narcolepsy.  Peripheral side effects can be even more severe, including cardiac 
arrhythmias, hypotension, respiratory disturbances, gastrointestinal bleeding, 
nausea and even hair loss.  Chronic L-DOPA administration leads to dyskinesia, 
freezing during motor movement, drug resistance, serotonin depletion, loss of 
impulse control, deterioration of function and dopamine dysregulation syndrome 
(Merims and Giladi, 2008).  In addition, dopamine supplementation therapies 
become ineffective in late stages of Parkinson’s disease, when no dopaminergic 
connections remain that can be supplemented. 
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Other compounds – such as pramipexole, ropinirole, and apomorphine – 
function as a dopamine receptor agonist and have the potential to be true 
dopamine replacement therapy in late stage patients.  Due to apomorphine’s 
highly emetic activity, it is commonly given as a subcutaneous injection.  It can 
enter the CNS and begin affecting the striatum within 20 minutes of injection, and 
its effects can last for as long as 90 minutes, providing motor function for that 
period.  Due to apomorphine’s injection-based delivery and its relatively short 
time of effect, it can only provide brief periods of functional recovery and cannot 
fully ameliorate parkinsonian symptoms.  The constant infusion of apomorphine 
via implantable pump is an available treatment in Europe, but apomorphine is a 
non-selective DA receptor agonist and produces many of the same side effects 
as dopamine supplementation therapy.  In addition to nausea and vomiting, other 
effects are also present including increased sweating, agitation, behavioral and 
mood changes, persistent headache, cardiovascular effects and changes in 
vision.  For these reasons, apomorphine is rarely used as a treatment in the 
United States, but more selective agonists, such as pramipexole or ropinirole, 
may be prescribed with different side effect profiles. 
Surgical interventions for Parkinson’s disease are varied and some are 
currently in the developmental phase.  Deep-brain stimulation (DBS) relies on the 
intracranial implantation of electrodes and is used for several disorders, including 
Parkinson’s disease.  A procedure called subcortical lesioning can produce 
similar effects.  These surgeries attempt to upset the balance between the 
“direct” and “indirect” pathways of the basal ganglia to compensate for the loss of 
dopaminergic innervation in the direct pathway.   
Deep-brain stimulating surgery requires the implantation of the lead, 
placed in the target brain region, an extension that is located under the skin, and 
a battery-powered, implanted pulse generator.  This system is similar to a 
pacemaker, providing electrical pulses to the lead or electrode.  This electrical 
pulse is thought to inhibit the brain region in association with the electrode, and 
thus this system usually targets either the subthalamic nucleus or the internal 
segment of the globus pallidus for Parkinson’s disease, and the 
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ventrointermediate nucleus of the thalamus to treat Essential Tremor.  
Subcortical lesioning is similar in its approach, but its outcome is irreversible.   
None of these approaches affect the disease mechanism, nor slow the 
progression of the disease, and most may have severe side effects or 
complications.  An ideal treatment would be easy to administer without 
complication, would target the specific brain regions affected producing few side 
effects, and halt or reverse the progression of the disease.  This goal led to the 
search for neurotrophic factors that could actually affect the disease progression. 
Neurotrophic Factors 
History 
The groundwork for the discovery of neurotrophic factors was laid in 1948 
by Elmer Bueker.  In grafting a tumor tissue line from the mouse (known as 
sarcoma 180) into embryonic chicks, it was discovered that sensory nerve fibers 
from the nearby dorsal root ganglia, but not motor neurons, invaded the tumor 
(Bueker, 1948).  These results were expanded upon by Rita Levi-Montalcini, who 
not only compared the results to non-tumorous embryonic tissue implants (Levi-
Montalcini and Hamburger, 1951), but later showed that the cause of these 
neurogenic growths was due to a diffusible nerve growth factor (Levi-Montalcini, 
1952; Levi-Montalcini et al., 1954). Stanley Cohen, a member of Levi-Montalcini’s 
group, identified a purification fraction that elicited this nerve growth promotion 
(Cohen et al., 1954), but in the process of purification, which required the use of 
moccasin snake venom to break down the nuclear DNA, discovered that the 
snake venom itself enhanced this neurogenic activity, leading to the discovery of 
a 20 kDa protein that would become known as Nerve Growth Factor (NGF) 
(Cohen and Levi-Montalcini, 1956).  This discovery began a conceptual shift 
resulting in the search for other soluble signaling proteins with neurotrophic 
effects, and in 1993 a potent neurotrophic factor responsible for the protection 
and maintenance of dopaminergic neurons was identified (Lin et al., 1993).  
Purified from the B49 rat glioma cell line, it became known as Glial cell line-
Derived Neurotrophic Factor (GDNF). 
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The Effects of GDNF 
 Natural cell death is an important element of an organism’s development, 
which ensures only properly formed and connected neurons remain.  Indeed, 
natural or developmental cell death is responsible for the elimination of 50% or 
more of the neurons in the CNS (Cowan et al., 1984; Oppenheim, 1991).  In 
order to be spared of this neuronal paring process, a neuron’s projections must 
interact with its target (Barde, 1989).  By releasing neurochemical compounds 
into a synapse with a receptive neuron, the post-synaptic, target neuron releases 
a signal to the pre-synaptic neuron that it has received the message.  This signal 
is the neurotrophic factor.  This is true of the nigrostriatal pathway, in which the 
dopamine-sensitive neurons of the striatum release GDNF as confirmation of the 
dopamine signal from the projections of the substantia nigra.  The developmental 
process of sparing in the nigrostriatal pathway in the rat coincides with maximal 
GDNF expression levels found in the first post-natal week.  The potential of 
exogenous GDNF administration in an aged or diseased-state is in the capability 
of GDNF to spare and restore dopaminergic neurons. 
 To that end, it was demonstrated that the protective effects of GDNF 
extends to protection from cell toxins, including 1-methyl-4-phenylpyridinium ion 
(MPP+) in cell culture (Hou et al., 1996), reducing markers of cell death and 
dysfunction including caspase-3 activation and reactive oxygen species 
production (Zeng et al., 2006).  Exogenous GDNF, administered directly to the 
substantia nigra in the rodent, also protects dopaminergic neurons from a 6-
OHDA lesion (Kearns and Gash, 1995; Kearns et al., 1997), and this treatment 
corresponds to a preservation of evoked-release of dopamine (Cass and 
Manning, 1999).  Glial cell-line derived neurotrophic factor, when administered to 
the striatum, also reduced apomorphine-induced rotation behavior four weeks 
after a unilateral 6-OHDA lesion of the medial forebrain bundle (Hoffer et al., 
1994).  These and other studies in rodents spurred pre-clinical trials in non-
human primate models of Parkinson’s disease.  Intracranial injections of GDNF in 
a MPTP-induced model of Parkinson’s disease in non-human primates resulted 
in significant improvements in parkinsonian symptoms with improved dopamine 
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levels in the substantia nigra and enhancing dopaminergic fiber and cell size in 
these animals (Gash et al., 1996; Zhang Z. et al., 1997; Grondin et al., 2002). 
Clinical Trials of GDNF 
 Glial cell-line Derived Neurotrophic Factor, delivered intracranially via 
pump and catheter system, proceeded to clinical trials.  Two initial open-label 
phase I trials of GDNF resulted in a 24% average increase in “off L-DOPA” 
Unified Parkinson’s Disease Rating Scale (UPDRS) score, and a 39% average 
increase in “on” UPDRS scores (Gill et al., 2003); and in a different study a 30% 
bilateral increase in UPDRS “on” and “off” scores (Slevin et al., 2005).  However, 
a double-blind placebo-controlled phase IIa clinical trial did not meet the trial 
requirements of 25% improvement in UPDRS “off” scores (Sherer et al., 2006).   
For a variety of reasons, these results from the phase II trial were 
controversial.  The variability in UPDRS score effect observed between trials was 
of concern.  However, each of the three trials used different catheter designs and 
infusion parameters which may have contributed to differences in diffusion of 
GDNF, and resulted in differences in the rate and dose of delivery of GDNF 
between studies.  All of these changes are capable of altering the volume of 
efficacious delivery (Salvatore et al., 2006; Sherer et al., 2006), contributing to 
the inter-trial variability.  Supporting this explanation are studies revealing 
variability in the area of GDNF delivery around the catheter tip, and that this 
diffusion area, although adequate in rhesus macaques, only covers 2 to 9% of 
the human putamen (Salvatore et al., 2006).  Safety concerns also arose when 
antibodies to GDNF were found in 10% of the patients undergoing the trial; while 
no adverse effects were observed in the patients (Slevin et al., 2006) the 
possibility of the neutralization of endogenous GDNF by these antibodies and 
observed toxicity in the cerebellum of non-human primates prompted the 
discontinuation of the trial (Gill et al., 2003; Slevin et al., 2005; Lang et al., 2006).  
Cerebellar Purkinje cell loss was observed in rhesus macaques, at a dose three 
times as high as in the clinical trials, and after being subjected to three months of 
withdrawal prior to histological examination (Hovland et al., 2007b).  In contrast 
to that study in non-human primates is MRI data from patients who participated in 
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the GDNF clinical trials which indicated no cerebellar changes were present, in 
agreement with clinical motor-function examination (Chebrolu et al., 2006).   
Due to these obstacles, including the volume of diffusion of GDNF, its 
potential side effects, the need for the implantation of the pump and catheter for 
delivery of GDNF and the patent issues surrounding GDNF, the search for 
mimetics of GDNF began. 
The Search for Mimetics, Signal and Pro-Proteins 
 Mimetics for GDNF, compounds with similar function but with a different 
structure, are attractive areas of research for a variety of reasons.  Mimetics may 
have the advantage of being smaller compounds with the capability of being 
chemically or biologically engineered for greater efficacy or more specific 
targeting for their effect.  For this reason, such compounds could be more 
versatile in their delivery approach, utilizing oral or nasal administration.  
Mimetics can also avoid economic barriers to the pharmaceutical market by 
being more easily synthesized and by avoiding patent infringement.  To that end, 
several compounds are being researched that may activate the same signaling 
pathway as – or stimulate the endogenous release of – GDNF for the treatment 
of Parkinson’s disease.   
 Glial cell-line derived neurotrophic factor itself is synthesized as a larger 
pro-protein of 211 amino acids before being cleaved to produce the mature, 
soluble GDNF protein targeted for clinical trials of Parkinson’s disease.  
However, the pro-region of many neurotrophic factors produce biological effects 
on their own (Lu, 2003).  For this reason, attention was given to the pro-region of 
many neurotrophic factors, including GDNF. 
Development of DNSP-11 
 John Glass, Ph.D. (Stony Brook, NY USA) predicted the proteolytic 
cleavage of 3 peptide sequences in the preproGDNF protein by in silico studies 
of known post-translational cleavage pathways, and these sequences were 
independently reported on by a team at the University of Helsinki (Immonen et 
al., 2008) that also predicted a fourth peptide cleavage product.  Of these 
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theoretical cleavage products (Figure 1.6), one of them, named Dopamine 
Neuron Stimulation Peptide -11 (DNSP-11) for its 11 amino acid sequence length 
(PPEAPAEDRSL-NH2), has been the most studied (Immonen et al., 2008; 
Bradley et al., 2010; Kelps et al., 2011). 
 Previously published data (Bradley et al., 2010) show that an antibody 
raised against the DNSP-11 sequence produces strong signal in the midbrain 
substantia nigra and ventral tegmental area that is highly colocalized with 
tyrosine hydroxylase positive neurons.  Exogenously administered DNSP-11 is 
rapidly and specifically taken up by TH+ neurons after intracranial injection.  In 
cell culture, DNSP-11 potently increases the percentage of TH+ neurons in E14 
rat primary cell culture at a greater range of doses than GDNF.  In these primary 
cell cultures, both DNSP-11 and GDNF significantly increased cell survival, 
combined neurite length, and average number of branches per neuron, while not 
affecting soma size. In normal rats, the baseline concentrations of dopamine and 
its metabolites DOPAC and HVA are significantly elevated in animals 
administered DNSP-11 up to 28 days prior to striatal microdialysis.  In rats 
subjected to a 6-OHDA lesion of the medial forebrain bundle and their lesion 
allowed to stabilize for four-weeks, a single DNSP-11 treatment reduced 
apomorphine-induced rotation behavior and increased striatal dopamine levels 
as determined by HPLC-EC analysis of substantia nigra and dorsolateral striatal 
tissue punches.   
 In that same body of work (Bradley et al., 2010), it was reported that 
DNSP-11 is protective of MN9D cultured cells from a variety of toxins.  DNSP-11 
reduces TUNEL positive cells similarly to GDNF when co-administered with 6-
OHDA, and it also reduces caspase-3 activity to control levels in these cultures.  
When co-administered with staurosporin, DNSP-11 reduces cytotoxicity beyond 
control levels, whereas GDNF does not protect against this toxin, in B65 cells.  
Similary, DNSP-11 but not GDNF protects against gramicidin cytotoxicity in cell 
culture.  Staurosporin triggers the release of cytochrome c and the loss of 
mitochondrial potential, while gramicidin is a mitochondria depolarizing 
substance, suggesting a mitochondrial protective role of DNSP-11, which is quite 
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dissimilar to the cell preservation signaling pathway of GDNF, involving GFRα1 
and RET.  A direct ELISA binding assay confirmed that DNSP-11 does not bind 
to GFRα1.  A cytosolic homogenate pull-down assay identified an array of 
proteins (by MALDI-TOF mass spectrometry), many of which possess metabolic 
functions in the cell.  Most notable of these is GAPDH (glyceraldehyde-3-
phosphate dehydrogenase), which has been linked to Parkinson’s disease 
(Tatton N. A., 2000) and apoptosis (Tatton W. G. et al., 2000; Hara et al., 2005), 
and is thus a target for drug development (Kragten et al., 1998; Carlile et al., 
2000; Tatton W. et al., 2003; Hara et al., 2006).  Later work (Kelps et al., 2011) 
shows that DNSP-11 protects against a 3-NP toxin that targets succinate 
dehydrogenase of the mitochondrial complex II, in non-neuronal HEK-293 cells, 
again suggesting powerful mitochondrial protection.  It was also shown that 
DNSP-11 remains stable in citrate buffered saline at 37 °C for 31 days, a critical 
element of any pharmacological compound.  It has also been shown that DNSP-
11 increases both mitochondrial potential and the uncoupled rate of 
mitochondrial oxygen consumption indicating an increased respiratory reserve 
capacity (Turchan-Cholewo et al., 2010). 
 Not only do these studies characterize DNSP-11 as being potently 
protective of mitochondria both in vitro and in vivo for protection from models of 
Parkinson’s disease, but they comprise a body of bioassays that can be used for 
analysis of dosing optimization and bioavailability enhancements, as well as for 
engineered alterations to the sequence or structure.  Through such biochemical 
engineering, the potency, stability, and versatility of the peptide may be further 
enhanced in future studies. 
Delivery of Drugs to the Central Nervous System 
Blood-Brain Barrier 
One problem in the use of pharmacological compounds for 
neurodegenerative diseases is the safe delivery of the drug to the central 
nervous system (Pardridge, 2005). Due to extensive tight-junctions between 
endothelial vasculature, only very small non-polar compounds, typically less than 
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500 Daltons, may pass this so-called blood-brain barrier (Pardridge, 2003) and 
reach the CNS by systemic-vascular delivery.  An alternative method of infusing 
drugs in the CNS requires the intracranial implantation of a catheter.  This 
catheter is placed at the disease’s focal point and is anchored to the skull; a 
connecting tube runs subcutaneously to a subcutaneously implanted infusion 
pump .  These pumps can be refilled by injection with a common needle, and 
recharged and reprogrammed by induction field.  Such an approach provides 
precise targeting and control of delivered quantity of a therapeutic compound to a 
brain region of interest.  However, this surgical implantation itself can introduce 
complications in addition to any side-effects a delivered compound may produce.  
One peer-reviewed survey of a similar surgery, deep-brain stimulation surgery, 
observed a 12.8% overall complication rate from the surgery itself.  
Complications ranged from misplacement of the lead, to intracranial infections, 
hemorrhaging, and even death (Umemura et al., 2003).  While complication rates 
have improved over the past decade, not all patients are good candidates for the 
surgical implantation and recovery is still lengthy.  For these reasons other 
approaches to deliver therapeutics to the CNS need to be considered. 
Penetration 
Although surgical penetration of the blood-brain barrier is prone to 
complication, there are alternative approaches that may temporarily disrupt the 
barrier.  One such possibility is disruption by ultrasound (McDannold et al., 
2008b; McDannold et al., 2008a).  It is believed that certain frequency ranges of 
ultrasound produce microbubbles that temporarily affect the microvasculature 
(Reed and Leighton, 1994).  With focused ultrasound, a highly targeted region of 
the brain can be transiently permeabilized to systemic blood-flow, allowing the 
transport of a systemically delivered drug to enter the CNS in bulk.  This 
approach is still experimental and is not yet approved by the US FDA for use in 
human patients.  As such, the safety of the technique is unknown.  This also 
requires systemic delivery of the drug, either intravenously or intraorally, which is 
not suitable for the delivery of peptide or protein therapeutics which are quickly 
inactivated and broken down in the gastrointestinal tract and blood circulation.  
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Also, penetration by ultrasound requires expensive equipment and must be 
performed by a trained individual, so is not ideal for use at home by the patient. 
Compounds have been identified that can transiently enhance transport 
across the blood-brain barrier (Cannon et al., 2012).  A major active component 
of the blood-brain barrier is P-glycoprotein, a membrane-bound transport protein 
with broad substrate specificity ranging from lipids to peptides and 
glucocoriticoids as well as a variety of therapeutic chemical compounds.  This 
pump is ATP-dependent and can be inhibited by sphingolipid signaling.  This 
approach enhances intracellular trafficking of a therapeutic compound, because it 
does not affect the intercellular tight junctions that comprise the blood-brain 
barrier. Because of this the delivered compound must have blood-brain barrier 
crossing characteristics, such as being lipophilic and nonpolar.  In effect, 
inhibition of P-glycoprotein prevents the efflux of compounds that have already 
entered the CNS.   
Circumvention 
Research is also being performed on the circumvention of the blood-brain 
barrier.  As opposed to physically affecting the continuity of the endothelial 
junctions, these approaches attempt to utilize natural transports into the CNS.  
For instance, immune cells such as activated monocytes readily cross into the 
CNS (Miller, 1999; Engelhardt and Ransohoff, 2012).  By masking a compound 
intracellularly, it can bypass the barrier and potentially be released within the 
CNS.   In a similar vein, encapsulation of compounds within liposomes allows 
compounds which are otherwise too large, hydrophilic, or polar to be protected 
within systemic circulation and to cross the blood brain barrier (de Lima et al., 
2005; Frank et al., 2011).  These approaches may allow a compound to enter the 
CNS, but once there, it remains in this encapsulated state, masked not only from 
the blood-brain barrier but also from key receptors to affect their ultimate 
function. 
Natural openings in the blood-brain barrier exist in the form of 
circumventricular zones.  These zones lack the extensive network of tight 
junctions in the vasculature.  However, these zones are typically in areas of 
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outward flow, for instance where hormones from the pituitary are released into 
systemic circulation.  Without specific retrograde transport, these 
circumventricular zones provide little therapeutic use in terms of delivering drugs 
to the CNS. 
More interesting approaches to bypassing the barrier involve conjugating 
a therapeutic compound to natural sequences that target compounds for entry to 
the CNS.  One such conjugation element is the Tat-protein.  Tat is a regulatory 
protein encoded by the Tat gene of HIV.  The Tat protein consists of a protein-
transduction domain which allows it to penetrate cellular membranes.  By 
conjugating the Tat protein transduction domain to other compounds, it is 
possible to induce cellular penetration, and even the circumvention of the blood-
brain barrier after systemic delivery (Kilic et al., 2005; Rapoport and Lorberboum-
Galski, 2009).  However, due to its broad functionality, Tat will deliver the 
conjugated compound across any and all cellular membranes, thus producing a 
possible increase in side effects, and even reactions to the Tat protein itself.  A 
combined approach, liposomal-encapsulation with membrane-bound rabies viral 
transduction elements (rabies virus glycoprotein peptide), attempts to enhance 
delivery across the blood-brain barrier (Tao et al., 2012), but downsides of both 
techniques still exist.   
An ideal technique for targeting the CNS with a therapeutic compound 
would not subject the patient to increased risk of infection by opening the blood-
brain barrier, it would specifically target the brain and anatomical subregions of 
interest, and it would be easy-to-administer requiring no specialized equipment or 
requiring new FDA approval.  Intranasal administration for delivery to the CNS 
may provide many of these benefits. 
Intranasal Administration Bypasses the Blood-Brain Barrier 
 The concept behind a passage-way between the nasal cavity and the 
brain dates back to 1929 when Le Gros Clark proposed such a route for the 
transit of infections from the nasal epithelium to the central nervous system.  
Indeed, Braak’s “dual-hit” hypothesis of Parkinson’s disease suggests a nasal 
route as one vector for the entry of Parkinson’s-inducing factors to the brain 
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(Prediger et al., 2012).  This pathway relies on the patency of the perineural 
space around the olfactory receptor neurons and their olfactory ensheathing cells 
(Brierley and Field, 1948) due to a purported lack of tight-junctions (Steinke et al., 
2008), the proteins that normally seal cells together especially in the formation of 
the blood-brain barrier.  But it wasn’t until 1986 that this open pathway was 
visualized with electron microscopy using an intranasally administered tracer 
molecule (Balin et al., 1986).  This process was found to be primarily extracellular 
in nature; however, a variety of routes may be responsible for transport to the 
brain.  These routes are thought to include extracellular routes such as perineural 
routes described above, perivascular routes fascilitated by pulsatile arterial flow, 
and intracellular routes such as specific receptor-mediated endocytosis or non-
specific pinocytosis followed by retro-grade transport (see Figure 1.7) (Illum, 
2003).  Since that time much work has been done not only to visualize 
(Lochhead and Thorne, 2012) but to also quantify the delivery of compounds 
from the nasal cavity to the brain (Thorne et al., 2004; Dhuria et al., 2010).  
Evidence in the literature also implicates not only the olfactory receptor route to 
the olfactory bulb, but also the trigeminal nerve as providing transport to the 
brainstem (Thorne et al., 2004).  Furthermore, administration along a number of 
cranial nerves has been identified, including the optic nerve via intraocular 
administration (Rapoport and Lorberboum-Galski, 2009) and by way of the 
trigeminal and facial nerves through transdermal buccal patch (Yang, 2010; Yuan 
et al., 2011). Traumatic forces, such as those in a motor-vehicle collision, can 
often tear the olfactory nerves at the cribriform plate; however, intranasal and 
other administrations, due to the variety of routes for transit, may still be suitable 
even in cases of such olfactory denervation. 
 Much work has been done since the pathway was first identified using 
molecular tracer molecules, and in 1989 William Frey II, Ph.D. patented the 
concept of intranasal delivery of therapeutics to the brain by intranasal delivery 
(Frey II, 1997; Frey II, 2002).  With mounting scientific data to validate intranasal 
delivery (Illum, 2000; Lochhead and Thorne, 2012), phase II United States Food 
and Drug Administration clinical trials began with the goal of delivering insulin to 
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the brain to prevent Alzheimer’s Disease in humans (Craft, 2006; Craft et al., 
2012).  Data from this trial suggest that intranasal insulin slows the progression in 
patients from mild cognitive impairment to entering full-on dementia (Craft et al., 
2012), improves verbal memory (Reger et al., 2008a) and modulates β-amyloid 
in early stage Alzheimer’s disease, without affecting systemic blood-glucose and 
insulin levels (Reger et al., 2008b).  Due in part to the successes of this trial, 
other trials that utilize the nose-to-brain route for delivery of therapeutics to the 
CNS have entered pilot stages (Liu, 2011).  These include the use of NAP (or 
AL-108) for schizophrenia and dementia (Javitt, 2007) to oxytocin for treatment of 
autism (Anagnostou, 2010).   
 This pathway between the olfactory epithelium and the deeper regions of 
the brain parenchyma may serve a developmental role in the organism.  Neurons 
that secrete gonadotropin-releasing hormone (GnRH) develop in the olfactory 
placode, or epithelium, and migrate along the olfactory receptor neurons to enter 
deeper regions of the brain, especially the pre-optic area of the hypothalamus 
(Hilal et al., 1996; Wray, 2010).  In addition, olfactory receptor neurons 
themselves constantly turn-over.  As an olfactory receptor neuron dies, another 
takes its place through the constant replenishment from both the rostral migratory 
stream, which replaces and restructures granule and glomeruli layers in the bulb, 
and differentiation of olfactory precursor neurons in the olfactory epithelium to 
replace peripheral, olfactory receptor neurons.  This constant turn-over may 
result in the open extracellular pathways that allow the passage of compounds to 
the brain. 
 The mucociliary clearance mechanisms in the nasal epithelium are 
extensive and rapid (Illum, 2003).  The mechanical action of ciliated cells in the 
epithelium ensure the rapid movement of substances to the posterior nasal cavity 
in as little as 20 minutes (Soane et al., 1999) where it is swallowed and degraded 
in the gastro-intestinal tract.  In addition, the nasal epithelium contains high 
concentrations of oxidizing enzymes and aminopeptidases that will quickly 
metabolize compounds and peptide drugs.  In fact, the concentrations of 
degradation enzymes in the nasal epithelium are comparable to that found in the 
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liver (Sarkar, 1992) and serve as a potentially major roadblock to administration 
via this route.  A range of methods to maximize the transport of nasally applied 
compounds to the CNS is an area of burgeoning research (Patel et al., 2009), 
and many of the techniques used in the circumvention of the blood-brain barrier 
during systemic delivery are being applied with intranasal delivery.  For instance, 
the conjugation of the Tat-protein to FGF significantly increased concentrations 
of the factor in the brain compared to non-conjugated FGF, and increased the 
efficacy of the compound at the same dose-concentration (Lou et al., 2012).  
Liposomal encapsulation of intranasally delivered compounds seems to increase 
transport to the CNS (Migliore et al., 2010) by increasing paracellular transport 
and protecting the loaded compound from degradation.  The co-administration of 
short peptide sequences has been shown to enhance transport by saturating 
aminopeptidases in the epithelium (Sarkar, 1992).  Chitosan, a 
mucopolysaccharide, has also shown promise in increasing bioadhesion and 
enhancing absorption perhaps through the modulation of tight-junctions 
(Artursson et al., 1994; Dodane et al., 1999), leading to an increased 
bioavailability of nerve growth factor (NGF) by as much as 14-fold over the same 
concentration without chitosan (Vaka S. R. et al., 2009) and BDNF by 12-fold 
(Vaka S. et al., 2010).  However, bioavailability of cefotaxime, a cephalosporin 
antibiotic of 455 Daltons, was not found to be increased intranasally with chitosan 
compared to intravenous injection with chitosan (Manda et al., 2011).  Questions 
remain as to whether such enhancers result in greater biological efficacy than a 
simple aqueous solution formulated at an optimized concentration, pH and 
osmolarity (Illum, 2007).  The advantages of a simpler, saline solution include a 
more expedited FDA-approval process for clinical trials potentially with the need 
for fewer safety studies, and a more stable drug solution for longer life and 
versatility in storage conditions for improved patient compliance and outcomes. 
The low-cost and ease of administration of this route has the potential to 
open up a new range of brain-targeting treatments for neuropsychiatric disorders 
that would otherwise go untreated or be treated with poorly targeted compounds.  
With the advent of a greater understanding of neurotrophic factors, their 
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receptors and signaling cascades, and their role in development and cellular 
maintenance, a wide range of intracellular signaling processes and receptors are 
available for targeting through biopharmacological engineering.  One of the main 
issues that remain is the ability to effectively deliver these compounds to the 
regions of the brain sensitive to such therapies.  Intranasal administration may, 
with the right compound, be capable of transporting these new classes of drugs 
to the CNS. 
 
Goal 
To determine if the DNSP-11 peptide can be administered to the nasal 
cavity and be transported to the brain in sufficient quantity to produce protective 
effects from neurodegenerative diseases such as Parkinson’s disease. 
 
Study Outline 
 In order to test the hypothesis that intranasally administered DNSP-11 
enters the CNS and protects the nigrostriatal dopamine system from a 
unilaterally injected 6-hydroxydopamine lesion of the substantia nigra in Fischer 
344 rats, three endpoints for analysis were performed: histological, 
neurochemical, and behavioral.  In addition, some measures of the safety of the 
drug were recorded, and questions regarding the presence of the DNSP-11 
sequence as an endogenous peptide were addressed.  All studies and analyses 
were performed in a blinded, randomized controlled manner. 
 The aim of the histological endpoint was to quantify the number of tyrosine 
hydroxylase (TH) positive cells in the lesioned substantia nigra as a percentage 
of the unlesioned, contralateral substantia nigra.  Tyrosine hydroxylase positive 
striatal fiber density was also quantified by computerized threshold analysis as a 
percentage of the unlesioned hemisphere.  Tissue sections of 30 µm in thickness 
were immunoreacted with a monoclonal antibody against TH and visualized by 
nickel-enhanced DAB chromogen.  The presence of DNSP-11 in the CNS was 
also examined by quantification of an iodine-125 radiolabelled version of the 
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modified peptide sequence.  These studies provided information about the 
quantity of this neuronal population and their projections to the striatum, and this 
work comprises the whole of Chapter Three. 
 Neurochemical quantification was performed by two methods: whole 
striatal tissue neurochemical content, and functional release by striatal 
microdialysis.  Baseline, tonic release of dopamine in the striatum was collected 
by microdialysis probe and analyzed by HPLC-EC.  Potassium-evoked release of 
dopamine and outflow of dopamine by d-amphetamine were also studied during 
striatal microdialysis.  The whole striatum was excised post-mortem and its 
neurochemical content analyzed by HPLC-EC.  Acute effects of DNSP-11 on 
striatal dopamine release were also performed by reverse microdialysis.  These 
studies can be found in Chapter Four. 
 The unilateral 6-OHDA rodent lesion model of Parkinson’s disease 
produces a rotation behavior due to asymmetric motor output that can be 
accentuated by the injection of apomorphine or other compounds.  This provides 
an interesting quantification of possible protection from the motor symptoms of 
parkinsonism.  Animals were administered apomorphine and placed in a 
standardized rotation apparatus in which their rotations were unbiasedly 
quantified by computer.  In addition, to continuously measure changes in activity 
levels and body temperature as a quantification of treatment safety, animals were 
implanted with a wireless, battery free device that transmitted activity levels and 
body temperature data to a computer by induction field located under their 
homecage.  The animals’ body weight was also measured daily as a measure of 
rate of recovery from lesion induction.  These data are provided in Chapter Five. 
 Finally, it is hypothesized that the DNSP-11 sequence is endogenously 
processed from the pro-region of its parent protein, GDNF.  A custom, polyclonal 
antibody to DNSP-11 was acquired and differential immunoreactivity patterns in 
naïve Fischer 344 brain tissue was characterized both at post-natal day 10 and 
at 3 months of age.  Finally, tissue sections were homogenized and reacted for 
the DNSP-11 antigen in immunoprecipitation, and the eluent sequenced.  This 
study is contained within Chapter Six. 
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Figure 1.1 – Images of α-synuclein containing Lewy Bodies.   
Lewy Bodies, visualized here as dark brown intracellular inclusions, are protein 
aggregates located within neurons of the central nervous system, especially the 
substantia nigra and are characteristic of Parkinson’s disease and other 
disorders of the CNS.  Lewy Bodies typically are spherical in shape with a dense 
central core surrounded by small fibrils comprising a shell or corona.  Image from 
(Spillantini et al., 1997). 
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Figure 1.2 – Sectional anatomy of the human brain comparing parkinsonian and 
normal patients. 
Shown are the substantia nigra (A) dorsal to the cerebral peduncles in the 
midbrain, and locus ceruleus (B) located in the dorsal tegmental pontine 
brainstem.  Both the substantia nigra and locus ceruleus are catecholaminergic 
neurons and contain high concentrations of neuromelanin.  In each inset image, 
the left section shows an example of a normal human brain, and the right section 
is an example of a parkinsonian brain.  Notice the loss of the darkly colored 
nuclei in both sections, indicated by the red arrows.  (Images modified from: 
MedScape <http://emedicine.medscape.com/>; Rosenblum, W. I., VCU 
<http://www.pathology.vcu.edu>) 
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Figure 1.3 – The biosynthetic pathway of dopamine and norepinephrine from L-
tyrosine.  
This pathway is utilized by catecholaminergic neurons, such as those of the 
substantia nigra pars compacta and locus ceruleus.  (Image from Wikimedia: 
<http://en.wikipedia.org/wiki/File:Catecholamines_biosynthesis.svg>) 
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Figure 1.4 – Drawings from sagittal sections of the human brain showing the 
nuclei of the basal ganglia.   
The striatum is comprised of both the caudate nucleus dorsomedially and the 
putamen ventrolaterally, which are separated by the white matter tract known as 
the internal capsule.  The globus pallidus contains both internal (GPi) and 
external (GPe) segments.  The subthalamic nucleus (STN) is proximal to the 
substantia nigra (SN) of which the pars reticulata segment is innervated by the 
STN.  The substantia nigra pars compacta is the dopaminergic input to the 
striatum. (Images modified from Shuenke et al, Atlas of Anatomy, 2007, pp. 312-
313. Illustrated by Markus Voll). 
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    A – Circuit Diagram     B – Normal Brain      C – Parkinsonian Brain 
                    
Figure 1.5 – Simplified version of the basal ganglia circuitry.   
Arrow color indicates the type of projection.  Blue is dopaminergic projections, 
which can either be stimulatory of the D1R “direct” pathway or inhibitory of the 
D2R “indirect” pathway.  Red is inhibitory, GABAergic projections, for example 
from the striatum, the GPe, and GPi.  Green is excitatory, glutamatergic 
projections, for instance from the STN, VA, and motor cortex.  Note that this 
circuit diagram does not represent all of the known connections, 
interconnections, or nuclei of this pathway, but it does serve to illustrate the 
functional roles of the direct and indirect pathways.  A) The first illustration shows 
the complete connections of this simplified circuit diagram.  B) The second 
illustrates an example of a normally functioning individual during motor output, 
while C) shows the balance in the pathways when the putamen is not receiving 
dopaminergic input from the substantia nigra.  (GPi, globus pallidus internal 
segment; GPe, external segment;  STN, subthalamic nucleus; VA, ventral 
anterior nucleus of the thalamus; SNc, substantia nigra pars compacta.)   
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Figure 1.6 – The immature or prepro-form of GDNF. 
Represented here in single letter amino acid sequence and block diagram form is 
the location of the DNSP-11 sequence within the pro-region of GDNF as 
determined by in silico examination of purported dibasic peptidase cleavage sites 
(Bradley et al., 2010), including two other potentially cleaved “DNSP” sequences 
with identified biological activity (Kelps et al., 2011; Littrell et al., 2012), DNSP-5 
between the signal peptide and DNSP-11, and DNSP-17 within the mature 
GDNF sequence.  It is theorized that DNSP-11 is cleaved from proGDNF by a 
combination of enzymes including prohormone convertase, endopeptidases and 
caroxypeptidase H, followed by amidation by peptidylglycine amidating 
monooxygenase (PAM).  (Modified from Bradley 2010). 
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Figure 1.7 – Diagram of the olfactory epithelium. 
Olfactory epithelium at the top of the image contains the olfactory receptor 
neuron cell bodies which project as a nerve bundle into the lamina propria then 
through the foramenae of the cribriform plate to synapse in the glomeruli layer of 
the olfactory bulb.  Three possible means of transit from the nasal cavity to the 
brain exist: a) intracellular, b) paracellular, and c) transcellular transport as 
illustrated starting at the top of the diagram.  Intracellular transport through the 
projections of the olfactory epithelium could occur slowly by non-specific 
mechanisms.  A purported lack of tight junctions between the olfactory receptor 
neuron and the olfactory ensheathing cell surrounding the neuron facilitates 
extracellular pathways referred to here as paracellular and transcellular, resulting 
in access to the perivascular and perineural spaces. Modified from (Lochhead 
and Thorne, 2012). 
 
 
Copyright © James William Hendry Sonne  
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Chapter Two:  Materials and Methods 
Reagents 
All reagents used for surgical procedures were U.S. Pharmacopeia (USP) 
purity certified when available, or of the highest purity available if not regulated 
by the USP.  Reagents used for histology were procured from Fisher Scientific 
(Fisher Chemical, Fairlawn, NJ) and reagents for neurochemistry were obtained 
from Sigma Aldrich (St. Louis, MO), unless otherwise noted.  The 6-
hydroxydopamine was obtained from Sigma Aldrich at 99.9% purity. 
Animals 
Ethics Statement 
All procedures were conducted at the University of Kentucky, accredited 
by the Association for Assessment and Accreditation of Laboratory Animal Care 
International, and approved by Institutional Animal Care and Use Committee. 
Animal Care and Housing 
Three to four month old male Fischer 344 rats were used in this study, 
housed in an environmentally controlled vivarium and kept under a standard 12-
hr light/dark cycle and provided with food and water ad libitum. 
Surgical Procedures 
Prior to surgery, animals were visually assessed for normal activity, 
inquisitiveness, condition of hair coat, eating, drinking, evidence of defecation 
and urination in the animal’s homecage, appearance of eyes, breathing rate, gait, 
and bodyweight.  If any abnormal conditions were observed, the animal was not 
used and the Department of Laboratory Animal Research veterinary services 
were consulted. 
All surgical procedures were performed under aseptic conditions and 
sterile field, using ethylene-oxide or autoclave sterilized tools and devices.  The 
surgical incision site was scrubbed three times alternating between both 
isopropyl alcohol and betadine (iodine) disinfectant.  The anesthetic primarily 
used was isoflurane at 5% in an anesthetic chamber to ensure anesthetic depth, 
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then moving to a nose-cone, typically at 2-3% isoflurane, to maintain anesthetic 
plane.  However, when noted, urethane and pentobarbital anesthesia were also 
used.  Anesthetic depth was determined by toe-pinch or corneal reflex response.  
Incisions were closed with 4-0 vicryl sutures (Ethicon, Johnson & Johnson) 
placed in a simple, interrupted pattern approximately 2 to 4 mm apart.  Animals 
were monitored post-operatively until awake and ambulatory in a fresh cage and 
then returned to the vivarium.  Animals were monitored daily post-operatively for 
3 to 5 days for signs of discomfort or infection and observations noted in a post-
operative chart.  If signs of distress were observed, Department of Laboratory 
Animal Research veterinary services was consulted. 
Unilateral 6-OHDA lesion of the substantia nigra 
Animals were anesthetized with isoflurane and placed in a stereotactic 
frame.  A hole over the area of injection was created and a Hamilton syringe (26 
gauge, 10 µL, tip style #3) was inserted at the following coordinates (with respect 
to bregma): AP: -5.4 mm, ML: -2.2 mm, DV: -7.5 mm (from dural surface), TB: -
3.3 mm (Figure 2.1) (Paxinos and Watson, 2005).  A fresh solution of 6-hydroxy-
dopamine HCl (6-OHDA·HCl, 99.9% purity, 4.0 mg/mL in 0.9% saline with 0.02% 
ascorbic acid) was injected at a total volume of 2.0 µL delivered over a 2 minute 
period.  The syringe was removed 2 minutes following injection.  Lesion site was 
verified histologically post-mortem on a subset of animals.  (AP: anterioposterior; 
ML: mediolateral; DV: dorsoventral; TB: tooth bar.)  
Blinded intranasal administration 
Solutions of vehicle only, scrambled peptide, or DNSP-11 were prepared 
by Luke H. Bradley, Ph.D. and provided as coded vials randomly assigned to 
subjects.  Animals were anesthetized via isoflurane nose-cone and placed 
supine.  Coded solutions were administered in 12.5 µL boluses by micropipetter 
at the opening of each nostril and allowed to be naturally drawn into the nasal 
cavity by inhalation.  The administration was repeated after a 2 to 5 minute 
period to allow nasal clearance.  Administration of the solutions, endpoint 
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processes, quantification and analyses were performed by a researcher blind to 
the solution contents. 
Solution containing either DNSP-11, scrambled peptide, or vehicle only 
was administered intranasally five consecutive days a week for three weeks (two 
consecutive days of rest from administration for every 5 days of administration) 
by a researcher blind to the solutions.  Animals were administered as above, 
alternately administering 12.5 µL to each nostril with 2 to 5 minute intervals 
between administrations for a total of 50 µL of solution per animal per day 
distributed between both nostrils (Figure 2.2).  On the 21st day after lesion 
induction, after two days off-treatment, the animals were subjected to endpoint 
analysis. (Figure 2.3) 
Peptide Synthesis and Dilution 
As reported previously (Bradley et al., 2010), peptide synthesis and 
purification were performed by GenScript (Piscataway, NJ USA).  The following 
peptide validations, preparations, and dilutions, as described in this section, were 
all performed by the laboratory of Luke H. Bradley, Ph.D.  Peptides were verified 
as >98% purity upon receipt via reverse-phase HPLC, LC-MS, and amino acid 
sequencing; and to be stable at physiologically relevant conditions by in vitro 
assay.  DNSP-11 peptide (PPEAPAEDRSL-NH2) was diluted to 2 µg/µL, 6 µg/µL, 
or 20 µg/µL in normal saline (0.9% NaCl vehicle) and the researchers were blind 
to the solution contents.  Controls included saline vehicle only and a scrambled 
DNSP-11 peptide sequence (LPSPREDAEPA-NH2) used at the same 
concentrations.  For studies involving iodinated, radiolabelled DNSP-11 peptide, 
the sequence was modified to include a lysine residue (R9K), synthesized by 
AAPPTEC (Advanced Automated Peptide Protein Technologies, Louisville, KY) 
and contract iodinated by the Bolton-Hunter method to a specific activity of 50 
µCi/g of DNSP-11 (Perkin Elmer NEN, Waltham, MA) and verified to be 95% 
pure by HPLC.  The bioactivity of these peptides was confirmed by in vitro assay, 
and purity by TLC.  For a list of these peptide sequences, see Table 2.1 
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MiniMitter Automated Monitoring System 
MiniMitter E-Mitter (Philips Respironics, Bend, OR, USA) devices are 
wireless, implantable, battery-free devices that continuously records an animal’s 
activity levels and body temperature.   The animal’s home cage is then placed on 
top of a specialized induction-field pad (Figure 2.4) connected to a computer with 
specialized MiniMitter software that translates the data into “Activity Units” or 
“Counts” and temperature.  Activity units are an arbitrary unit calculated by a 
change in the signal strength of the E-Mitter transmitter in the induction field.  
Any change in signal is counted as an activity unit and the total number of these 
changes during the designated time interval is given for that data point.  These 
devices were used to determine the activity levels and body temperature of the 
animals in the study.   
Surgical implantation of the MiniMitter device was performed at the same 
time as lesion induction.  Up to 24 hours prior to surgical implantation, and daily 
for three days post-operatively, the animal received carprofen (5 mg/kg, s.c. or 
p.o.) analgesic.  The animals, anesthetized via isoflurane, were weighed and 
placed in the surgical prep area.  The hair covering the surgical site, between the 
scapulae on the back, was clipped and the site prepared with anesthetic scrubs.  
Ocular lubricant (“artificial tears”) was applied to the eyes.  A small medio-lateral 
incision was made and a subcutaneous pocket was created in the fascial plane 
for insertion of the ethylene-oxide sterilized MiniMitter device.   
Statistical analysis 
Unless otherwise stated, column analysis was performed using unpaired 
Student’s t test or one-way ANOVA and grouped analysis was performed using 
two-way ANOVA.  Multiple comparisons were corrected for by Bonferroni’s post-
hoc test.  Due to the observed protective effects from previous studies of DNSP-
11 (Bradley et al., 2010), Student’s t tests were one-tailed unless otherwise 
stated, with 95% confidence levels, α=0.05, β=0.80 with significance defined as 
P<0.05.  Error bars are mean ± SEM.  Statistical analyses were performed on 
GraphPad Prism 6.01. (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.)  
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Table 2.1 – Amino acid sequences of peptides administered in this study. 
Peptide Sequence 
Human DNSP-11 PPEAPAEDRSL-NH2 
Modified DNSP-11 for 125I PPEAPAEDKSL-NH2 
Scrambled peptide LPSPREDAEPA-NH2 
 
Three different synthetic peptides were administered in the present studies, 
including the human DNSP-11 sequence, a version of the DNSP-11 sequence 
modified to accept iodination (R9K), and a scrambled version of the DNSP-11 
sequence as a negative control.  All peptides were C-terminal amidated.   
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Figure 2.1 – Representation of the 6-OHDA lesion injection of the SN. 
The vertical black line represents the needle at its final position at the following 
coordinates (with respect to bregma): AP: -5.4 mm, ML: -2.2 mm, DV: -7.5 mm 
(from dural surface), TB: -3.3 mm. Modified from (Paxinos and Watson, 2005). 
(SNc, substantia nigra pars compact; SNr, substantia nigra pars reticulate; VTA, 
ventral tegmental area; cp, cerebral peduncle; III, root of optic nerve or cranial 
nerve III) 
 
  
SNr 
SNc 
VTA 
cp 
cerebral 
cortex 
III 
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Figure 2.2 – Illustration of intranasal administration in the rat. 
Intranasal administration was performed as follows.  Animals were anesthetized 
via isoflurane nose cone and laid supine.  Using a micropipetter, a bolus was 
ejected into the opening of the nostril, here shown is a 12.5 µL ejection first 
performed on the right nostril.  The animal was given 2 to 5 minutes for the 
solution to be cleared from the nasal cavity, and then a bolus was ejected into 
the opposite nostril, followed by a 2 to 5 minute clearance period.  This was 
repeated again for a total of 50 µL over approximately 10 minutes as shown here. 
  
2-5 min 2-5 min 2-5 min 2-5 min 
12.5 µL 12.5 µL 12.5 µL 12.5 µL =50 µL 
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Day -1 Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
Off Intranasal Intranasal Intranasal Intranasal Intranasal Off 
Rotation 6-OHDA      
       
Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 
Off Intranasal Intranasal Intranasal Intranasal Intranasal Off 
Rotation       
       
Day 13 Day 14 Day 15 Day 16 Day 17 Day 18 Day 19 
Off Intranasal Intranasal Intranasal Intranasal Intranasal Off 
Rotation       
       
Day 20 Day 21      
Off Off      
Rotation Endpoint      
 
Figure 2.3 – Study timeline, schedule of treatment, lesion induction, and 
analysis. 
Outlined above is the overall study timeline with the time of lesion induction 
defined as “Day 0”.  The day prior to lesion induction, animals underwent 
baseline rotation behavior testing.  The next morning, the animals received their 
first intranasal administration followed approximately 30 minutes later by 6-OHDA 
lesion induction of the substantia nigra (shown with red background).  The 
animals received intranasal treatment (shown with blue background) for five of 
seven days a week for three weeks (two days “off” treatment every seven), with 
weekly rotation behavior.  On Day 21, the animals were taken for endpoint 
analysis, either for histology or neurochemical studies (data collection points 
shown with orange background).  Animal body weight was recorded daily.
43 
 
           
Figure 2.4 – Example images of MiniMitter device and setup. 
The small E-Mitter probe, shown in (A), is the approximate size of an osmotic 
mini-pump and can be implanted in the back or abdomen.  The animal, with E-
Mitter implanted, is then placed in their homecage which is set atop an induction 
field pad, the black box shown in (B), which continuously monitors changes in the 
signal from the E-Mitter, and changes in temperature recorded by the E-Mitter 
thermistor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © James William Hendry Sonne 
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Chapter Three:  A study of the effects of intranasally administered DNSP-11 
on tyrosine hydroxylase positive dopaminergic neurons and their 
projections in a 6-hydroxydopamine lesion rat model of Parkinson’s 
disease 
 
Hypothesis:  Efficacious doses of DNSP-11 can be delivered intranasally to 
enter the CNS in quantities sufficient to protect tyrosine hydroxylase positive 
neurons from a moderate 6-hydroxydopamine lesion of the substantia nigra. 
 
Introduction 
In order to test the hypothesis, young adult male Fischer 344 rats were 
subjected to a unilateral 6-OHDA lesion directly to the substantia nigra following 
an initial intranasal treatment thirty minutes prior to lesion induction (see Chapter 
Two).  The animals were intranasally administered solutions, by a researcher 
blind to treatment, five of seven consecutive days a week for three weeks (see 
Figure 2.3).  On the 21st day the animals were euthanized by transcardiac 
perfusion for immunohistochemical analysis of tyrosine hydroxylase positive 
neurons of the substantia nigra and fibers of the striatum.  In a separate cohort of 
animals, a 125I-radiolabeled version of the DNSP-11 peptide was administered 
intranasally and thirty minutes after administration the animal was euthanized by 
transcardiac perfusion its brain was sectioned and quantified for signal by 
gamma counter. 
Tyrosine Hydroxylase Enzyme 
Tyrosine hydroxylase (TH) is the enzyme involved in the rate-limiting step 
in the dopamine synthetic pathway and is responsible for converting L-tyrosine to 
L-DOPA (see Figure 1.3).  The activity of the TH enzyme is dependent on 
phosphorylation of a number of serine sites, primarily serine-40 by the cAMP-
dependent protein kinase A (PKA) (Fitzpatrick, 1999).  The activity of TH is 
subject to feedback inhibition by the products of the enzyme, namely 
catecholamines including dopamine (Daubner et al., 1992).  Once the enzyme is 
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active, it uses diatomic oxygen (O2) and tetrahydrobiopterin (BH4) in conjunction 
with an active site iron atom to hydroxylate the tyrosine substrate. 
In the human, nine transcripts for TH have been identified, but only four of 
these isoforms are translated to functioning enzymes.  Of those four, only two are 
prevalent in the human brain and they differ by the number of phosphorylation 
sites present on the enzyme.  Transcriptional regulation is responsible for long-
term regulation of the TH enzyme.  Because TH is necessary for catecholamine 
synthesis, its presence in a neuron can be used as a marker for 
catecholaminergic cells such as the dopaminergic neurons of the substantia 
nigra. 
Aside from phosphorylation, evidence in the literature suggests that TH is 
regulated by enzymatic complexing.  It has been reported that the protein 14-3-3, 
after phosphorylation by CaMKII, complexes with TH to enhance its activity 
(Ichimura et al., 1987; Wang J. et al., 2009); while α-synuclein has been shown 
to bind to TH and decrease its activity through the dephosphorylation of serine-
40 and the increase in activity of protein posphatase 2A (Peng et al., 2005).   
While the quantification of tyrosine hydroxylase positive (TH+) cells in the 
substantia nigra has long been a key component of pre-clinical studies of 
potential therapies for Parkinson’s disease or dopaminergic neurodegeneration 
(Kearns and Gash, 1995; Kearns et al., 1997; Ai et al., 2003), it cannot be the 
only metric for efficacy due to its vast array of post-translational regulatory 
possibilities.  It does serve as a powerful molecular marker of neuronal 
phenotype and morphology.  For this reason, TH+ cell counts of the substantia 
nigra and the quantification of their fiber projections to the striatum have long 
been powerful endpoints as one element of the analysis of potential therapies. 
Materials and Methods 
Animals were dosed intranasally while supine under isoflurane anesthesia, 
for five of seven consecutive days a week (see Chapter Two) by a researcher 
blind to treatment.  The first intranasal dose was given approximately 30 minutes 
prior to unilateral 6-OHDA lesion induction (see Chapter Two).  On the 21st day 
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after lesion induction (see Figure 2.3) animals were euthanized for 
immunohistochemical analysis. 
Tissue preparation and immunohistochemical processing 
Animals were perfused transcardially with cold saline and 4% 
paraformaldehyde fixative, the brain or whole skull was immersed in fixative for 
24 to 48 hours, followed by submersion in 30% sucrose.  Tissue was then 
sectioned coronally (30 µm) and stored in cryoprotectant solution (30.0% 
sucrose, 30.0% ethylene glycol in 100 mM NaPB pH 7.2) at -20 °C until 
immunostaining procedure. 
Every 12th section underwent 10 mM sodium citrate buffered antigen 
retrieval (with 0.05% Tween 20) at 80 °C for 10 minutes, then blocked with 4% 
normal goat serum for 1 hour at room temperature.  The sections were then 
immunolabeled with a monoclonal anti-tyrosine hydroxylase antibody (1:1000, 
Chemicon Millipore, Temecula, CA USA) and incubated overnight at 4°C. The 
sections were repeatedly washed and then incubated with peroxidase-
conjugated secondary antibody (1:1000, Vector Labs, Burlingame, CA USA).  
Immunoreactivity was visualized with NiDAB chromogen.  This procedure is 
modified from one previously described (Ai et al., 2003). 
Substantia nigra TH+ cell counting 
Tyrosine hydroxylase positive cells of the substantia nigra were quantified 
in three 30 µm thick sections per animal according to the following criteria:  only 
TH+ cells with clear nuclei and lying lateral to the oculomotor nerve root were 
included in the quantification.  Three sections per animal were chosen in relation 
to the 6-OHDA injection site: the section containing the injection point (-5.4 mm 
with respect to bregma), the section 360 µm rostral to the injection site 
(approximately -5.0 mm) and the section 360 µm caudal to the injection site 
(approximately -5.8 mm).  Images were captured at 5x magnification and 
quantified by a researcher blind to treatment.  The contralateral unlesioned 
hemisphere was also quantified and the proportion of TH+ cells in the lesioned 
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versus the unlesioned hemispheres is shown.  A total of 18 animals were used 
for this analysis (Table 3.1). 
Striatal fiber density quantification 
Striatal fiber density measures were quantified using contrast threshold 
analysis software (BioQuant, Nashville, TN USA).  Again, three striatal sections 
were analyzed per animal.  The unlesioned hemispheres were standardized to 
approximately 90% TH+ striatal area and the lesioned hemispheres compared as 
a percentage of unlesioned hemispheres.  Quantification was performed by a 
researcher blind to treatment. 
Tracking of radiolabeled peptide to the CNS 
The DNSP-11 sequence was conservatively modified to contain a lysine 
residue (R9K, see Table 2.1), and this sequence was confirmed by previously 
defined in vitro bioassay in the laboratory of Luke H. Bradley, Ph.D. (Bradley et 
al., 2010) to produce similar biological effect as DNSP-11.  Modified DNSP-11 
was radiolabeled by contract (Perkin Elmer NEN, Boston, MA) with iodine-125 by 
the Bolton Hunter method.   
A total of 50 µCi (300 µg) was administered intranasally in a total of 50 µL 
as previously described.  Thirty minutes after the first intranasal dose was 
administered, a sample of CSF was removed by cisternal puncture, the animal 
was euthanized by thoracotomy and a blood sample was taken from the left 
ventricle.  Transcardiac perfusion with cold saline was performed followed by 
decapitation.  The brain was removed and 2 mm thick sections were serially 
collected using a brain mold.  Sample weight was determined and gamma 
counting was performed to quantify the amount of radioactivity present in the 
CNS.  A total of seven animals was used in this study (Table 3.2), four given 
radiolabelled I125-DNSP-11, three given saline only.  One of the four I125-DNSP-
11 treated animal was excluded from this group due to poor perfusion quality.  
This study was performed by Mallory J. Stenslik. 
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Results 
Scrambled DNSP-11 as a negative control 
Concerns existed that the constituent amino acids in the DNSP-11 
sequence may be cleaved by the numerous aminopeptidases and oxidative 
enzymes in the olfactory epithelium (Sarkar, 1992) to cross the blood-brain 
barrier via amino acid transporters, entering the CNS and producing a stimulatory 
effect on the dopamine system.  To control for this possible effect in protection 
bioassays, a scrambled version of the DNSP-11 sequence (6 µg/µL, see Table 
2.1) was administered intranasally along with DNSP-11 or saline vehicle only, all 
of which were assigned randomly and administered in a blinded manner.  
Scrambled peptide was then evaluated against the saline vehicle control treated 
animals for tyrosine-hydroxylase protection determined by TH+ positive 
substantia nigra neuronal cell counts.  It was observed that scrambled peptide 
and vehicle treated animals resulted in the same TH+ neuronal cell loss in the 
substantia nigra (P=0.88. Vehicle treated cell loss: 91.4% ±4.1%, n=6.  Scramble 
treated cell loss: 92.2% ±3.5%, n=6.).  Comparisons between Vehicle only and 
Scrambled peptide treated animals were performed for all measurements with no 
significant differences observed (P > 0.05).  As such, vehicle-only and scramble 
treated animals were combined as one negative control group. 
Cell counts of the substantia nigra 
In order to determine if intranasally administered DNSP-11 peptide could 
result in protection of tyrosine hydroxylase positive neurons and fibers, Fischer 
344 rats received the first intranasal treatment approximately 30 minutes prior to 
a unilateral 6-OHDA (4.0 mg/kg) lesion of the substantia nigra (see Chapter 
Two).  The animals were given intranasal treatment 5 days a week for 3 weeks, 
and euthanized by perfusion fixation on day 21 post-lesion.  The animals brains 
were removed and processed for immunohistochemical analysis of tyrosine 
hydroxylase (TH) reactivity compared with the unlesioned hemisphere.  When 
those animals treated intranasally with scrambled peptide or vehicle only were 
combined in one negative control group, animals treated intranasally with DNSP-
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11 exhibit significantly greater TH-positive neuronal cell bodies in the substantia 
nigra (Figure 3.1, P=0.0192, n=18).  Negative control treated animals exhibited a 
92.1% (±2.6%, n=12) TH+ nigral cell loss 21 days after 6-OHDA lesion, while 
DNSP-11 treated animals exhibited a 75.2% (±9.5%, n=6) cell loss.  Animals 
treated with DNSP-11, unlike negative control animals, closely resembled 
unlesioned substantia nigra tissue (Figure 3.2).  There were no statistically 
significant differences observed in the number of TH+ cell counts of the intact, 
unlesioned substantia nigra (data not shown, P=0.9223, n=18).  No statistical 
outliers by Grubb’s test were present, and the lesion site was histologically 
verified prior to analysis.  All procedures and analyses were performed by a 
researcher blind to the treatment group identities. 
Fiber density of the striatum 
In this same cohort, TH+ fiber density in the striatum was quantified by 
computerized threshold analysis.  Animals that received intranasal DNSP-11 
treatment exhibited significantly greater striatal densities compared to control 
treated animals (Figure 3.3, P=0.047, n=18).  DNSP-11 treated animals exhibited 
76.2% (±9.8%, n=6) striatal TH+ density loss, compared with 90.7% (±3.1%, 
n=12) loss in control treated animals.  Animals treated with DNSP-11, unlike 
negative control animals, more closely resembled unlesioned striatal tissue 
(Figure 3.4).  A linear regression of TH reactivity of nigral cell bodies to striatal 
fiber density resulted in a significantly non-zero slope ( 
Figure 3.5, m=0.716 ±0.158, P=0.0003, R2=0.561), indicating intra-animal TH+ 
immunoreactivity levels are reflected in both critical regions of the dopaminergic 
motor system.  No statistical outliers by Grubb’s test were present.  All 
procedures and analyses were performed by a researcher blind to the treatment 
group identities. 
Quantification of peptide by radiolabel 
Presence of the radiolabel was confirmed in the CNS 30 minutes after 
intranasal administration.  Mean radiolabel signal corresponded to approximately 
0.29% of the 300 µg administered to the nose. (Table 3.3)(Figure 3.6) 
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Discussion 
Overview and Interpretation 
These results support the hypothesis that intranasally administered 
DNSP-11 enters the CNS and protects TH+ neurons from the 6-OHDA toxin in 
the Fischer 344 male young adult rat.  This provides important data to support 
the overall hypothesis that DNSP-11 can be administered intranasally, enter the 
CNS and protect TH+ neurons from degeneration.    
Lesion accuracy and quality as a potential variable 
The design of this study relied on a concomitant delivery of the lesion-
inducing toxin (6-OHDA) immediately after delivery of a protective agent (DNSP-
11) against the toxin.  This design can elicit questions as to the causative 
variable in the quantity of cell loss observed as the endpoint.  However, because 
the treatments were performed in a manner blind to the treatment contents, this 
protects the results of the study from bias.  Lesion variability among the negative 
control groups was low (92.1% cell loss ±2.6%, n=12), indicating high precision 
of the standard operating procedure used for lesion induction among this cohort.  
Finally, a higher resolution technique for more precise quantification of TH+ cells 
of the substantia nigra, to include cell body size, may identify additional 
differences between groups. 
Permeabilization of the blood-brain barrier from 6-OHDA lesion 
It has been shown that a 6-OHDA lesion can transiently permeabilize the 
blood-brain barrier (Cooper et al., 1982), which may allow systemic delivery 
during the timeframe of this study.  It was not felt that this was a major concern, 
as an increased permeability of the blood-brain barrier has been described in 
Parkinson’s disease (Hunot and Hirsch, 2003; Kortekaas et al., 2005; Rite et al., 
2007), thus a degree of blood-brain barrier permeability may model the disease 
state.  Due to this observation in the literature, it was not a specific concern to 
determine whether or not protection resulting from intranasally administered 
DNSP-11 occurs through a direct transit along cranial nerve routes or through 
systemic vascular delivery.  However, studies of the radiolabeled DNSP-11 
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peptide (Figure 3.6) support the hypothesis that intranasal administration of this 
peptide may result in direct transit to the CNS through the olfactory system but 
does not rule out vascular delivery (see Figure 1.7 for a description of transport 
across the olfactory epithelium).  And although it is assumed that the peptide is 
excluded from the CNS by the blood-brain barrier, the possibility of the peptide’s 
active transport across the blood-brain barrier is not addressed in this study. 
Quantification of radiolabeled peptide 
The observed distribution of radioactivity after intranasal administration of 
the radiolabelled peptide supports the hypothesis of transit of the peptide from 
the nasal cavity to the brain.  Radioactivity was found throughout the brain rostro-
caudally at the thirty minute time point. 
Variability in the perfusion quality may affect the overall quantity of 
radiolabel found in the brain.  For this reason, it is hypothesized that quantities of 
the radiolabel within the vascular system contributed to the total quantity 
observed in the brain, increasing the level of noise.  In order to confirm the direct 
nose to brain route, future studies may be designed to compare the 
pharmacokinetics of intranasal and intravascular delivery using the radiolabelled 
peptide in a time-response study.  If intranasal administration results in a peak 
concentration in the brain prior to a peak observed after intravascular 
administration then this suggests a direct route from the nasal cavity.  In addition, 
such a time-response study would provide more precise data on the total quantity 
that enters the brain after a single administration.  Finally, to confirm that the 
intact DNSP-11 transits to the CNS, an immunoprecipitation for DNSP-11 after 
intranasal administration of the 125I-labeled peptide followed by quantification by 
gamma counting would be strong evidence to support the observed biological 
effects.  A highly sensitive, monoclonal antibody would benefit such a study.   
The present study, while not addressing these issues, does support the 
transport of intranasal DNSP-11 to the brain; however, the possibility remains 
that the peptide is being degraded within the nasal cavity or vasculature and that 
the constituent amino acids (of which the lysine residue is radiolabeled in this 
study) would be able to enter the CNS by the cationic amino acid transporter, 
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producing a false positive.  Taken in conjunction with the biological activity of the 
DNSP-11 peptide, the similarity of that effect to the intracranially injected DNSP-
11 peptide, and the lack of effect observed in the scrambled peptide treated 
animals, this suggests that the intact peptide is directly entering the CNS in 
biologically efficacious quantities.  Indeed, the preponderance of evidence in the 
literature indicates that this direct route into the CNS is sufficient for compounds 
as small as dopamine and as large as entire mesenchymal stem cells to enter 
the CNS.   
Finally, it is important to keep in mind the translational nature of this work.  
While intranasal delivery of DNSP-11 in rats is an important step, the ultimate 
goals are intranasal administration in non-human primates and eventually 
humans.  The percentage of transit to the CNS from the nasal cavity may be 
quite different between species.  Changes in formulation aimed at increasing 
intranasal delivery to the CNS in rats may not translate to improvements in 
primates.  While the quantification of radiolabeled DNSP-11 may be a 
satisfactory proof of concept experiment, it may be an ineffective assay for a 
translationally aimed study. 
Implications of post-transcriptional regulation of the tyrosine 
hydroxylase enzyme 
Although the hypothesis is supported and TH+ neurons and their fiber 
projections are higher in the animals treated with intranasal DNSP-11, because 
TH can be post-translationally regulated these results are insufficient to show 
efficacy for the treatment of Parkinson’s disease and the resultant behavioral or 
motor deficits of the disease.  These neurons may maintain their TH+ phenotype 
but may not produce or release dopamine in the striatum.  For this reason, an 
evaluation of dopamine content and its functional release in the striatum, 
including an evaluation of the animal’s behavior, must follow. 
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Table 3.1 – Animal groups for TH+ histological study 
 DNSP-11 Treated 
Vehicle-only 
Treated 
Scrambled 
Treated 
Numbers: 6 6 6 
 
A total of 18 young adult male Fischer 344 rats were used for the histological 
quantification of TH+ cells of the substantia nigra and fiber density of the 
striatum.  Due to similarities in response between the Vehicle and Scrambled 
peptide treated groups, these two groups were combined to one “Negative 
Control” group.  The DNSP-11 treated group received 300 µg in 50 µL per 
treatment.  No animals were excluded from this study. 
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Figure 3.1 – Percentage of intact TH+ cells of the substantia nigra of animals 21 
days after 6-OHDA lesion induction.   
Of animals with a 6-OHDA lesion of the substantia nigra, those that received 
intranasally administered DNSP-11 at 300 µg/day (75.2% cell loss ±9.5%, n=6) 
exhibited significantly more TH+ cells in the substantia nigra (*P=0.0192, 
t(16)=2.257) 21 days after lesion induction when contrasted with the cell counts of 
those that received negative control treatment (92.1% cell loss ±2.6%, n=12; 
either saline vehicle only (n=6), or a scrambled version of the peptide sequence 
(n=6)).  As predicted, animals treated with scrambled peptide or vehicle only 
were not significantly different from each other (P=0.806) and were grouped as 
one “Negative Control” group.  Numbers are represented as the percent of 
unlesioned hemisphere.  Analysis by t-test. 
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Figure 3.2 – Representative sections showing TH+ immunoreactivity of the 
substantia nigra in treated and negative control animals 21 days after 6-OHDA 
lesion induction. 
Images contrast enhanced for clarity.  Measurement bar represents 200 µm. 
 
DNSP-11 
Treated 
Negative Control 
Treated 
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Figure 3.3 – Percentage of intact TH+ fiber density in the striatum of animals 21 
days after 6-OHDA lesion induction.  
Of animals with a 6-OHDA lesion of the substantia nigra, those that received 
intranasally administered DNSP-11 at 300 µg/day (76.2% density loss ±9.8%, 
n=6) exhibited significantly greater TH+ striatal fiber density (*P=0.0468, 
t(16)=1.782) 21 days after lesion induction when contrasted with the fiber density 
of those that received negative control treatment (90.7% density loss ±3.1%, 
n=12; either saline vehicle only (n=6), or a scrambled version of the peptide 
sequence (n=6)). As predicted, animals treated with scrambled peptide or vehicle 
only were not significantly different from each other (P=0.654) and were grouped 
as one “Negative Control” group.  Numbers are represented as the percent of 
unlesioned hemisphere.  Analysis by t-test. 
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Figure 3.4 – Representative sections showing TH+ immunoreactivity of the 
striatum in treated and negative control animals 21 days after 6-OHDA lesion 
induction. 
Images contrast enhanced for clarity.  Measurement bar represents 500 µm. 
DNSP-11 
Treated 
Negative Control 
Treated 
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Figure 3.5 – Correlation of TH+ nigral cell counts and striatal fiber density in 6-
OHDA lesioned animals. 
Animals that exhibited the greatest number of remaining TH+ cells in the 
substantia nigra also tended to have the greatest TH+ striatal fiber density, as 
illustrated by the significantly non-zero (P=0.0003, F(1,16)=20.45) linear regression 
slope (m=0.716).  Dotted curves indicated 95% confidence interval. 
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Table 3.2 – Animal groups for radiolabel tracking study. 
 Intranasal  
I125-DNSP-11 
Intranasal  
Saline 
Perfused with: Normal saline Normal saline 
CSF collected? Cisternal puncture Cisternal puncture 
Numbers: 4 3 
 
To determine the quantity of radioactivity in the CNS, blood, and CSF after 
intranasal administration, three groups of animals were used: four animals 
received intranasal I125-DNSP-11 and three animals received intranasal saline 
only.  One I125-DNSP-11 treated animal was excluded from this group due to 
poor perfusion quality.  This study was performed by Mallory J. Stenslik.  
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Table 3.3 – Quantification of radioactivity in the CNS after administration of I125 
labeled, modified DNSP-11 peptide. 
 Intranasal  
I125-DNSP-11 
(ng/mg ± SEM) 
Blood 1.46+0.18 
CSF 0.22+0.047 
Olfactory Bulb 0.086+0.005 
Section 1 0.051+0.011 
Section 2 0.054+0.007 
Section 3 0.027+0.023 
Section 4 0.057+0.011 
Section 5 0.061+0.008 
Section 6 0.059+0.011 
Section 7 0.059+0.006 
Section 8 0.057+0.003 
Section 9 0.058+0.010 
Section 10 0.064+0.013 
Section 11 0.080+0.002 
 
Tabular quantification of radioactivity (calculated nanograms of 125I-DNSP-11 per 
milligram of tissue).  Brain tissue was sectioned in 2 mm thick serial coronal 
sections using a rat brain mold.  Animals treated with radiolabeled DNSP-11 
(n=3) produced significant signal, while control animals treated with normal saline 
(n=3) were observed to have CPM values at or below background levels (<100 
CPM).  This study was performed by Mallory J. Stenslik. 
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Figure 3.6 – Normalized DNSP-11 Concentrations (ng/mg) at 30 Minutes in 
Blood, CSF and Brain.  
Calculated concentrations of DNSP-11 after administration of a radiolabeled 
version of the peptide support the hypothesis that DNSP-11 enters the CNS after 
intranasal administration.  Male Fischer 344 rats (n=3 per group) were either 
given a total bilateral dose (50 µCi/300 µg) of 125I-labeled DNSP-11 in vehicle (50 
µL of normal saline) or vehicle only.  At 30 minutes post administration, aortic 
blood (Blood) and cerebrospinal fluid (CSF) were taken. The animals were 
euthanized, perfused with 200 mL of normal saline and serial sections of the 
animals’ brains were removed rostro-caudally in 2 mm thick sections (OB: 
olfactory bulb, 1-11: brain sections). The percentage of 125I-labeled-DNSP-11 
found in blood, CSF and total brain were 0.27%, 0.0084% and 0.29% 
respectively.  Animals treated with normal saline were found to have CPM values 
below background levels (100 CPM).  This study was performed by Mallory J. 
Stenslik. 
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Chapter Four:  A study of the effects of DNSP-11 on monoamine 
neurotransmitter tissue content and functional dopamine release in normal 
and 6-hydroxydopamine lesioned rats 
 
Hypothesis: Efficacious doses of DNSP-11 can be delivered intranasally to 
modulate dopamine tissue content and metabolites in normal rats and to protect 
dopamine tissue content and functional release from a moderate 6-
hydroxydopamine lesion of the substantia nigra. 
 
Introduction 
In order to test the hypothesis, normal unlesioned young adult male 
Fischer 344 rats were intranasally administered a range of doses of DNSP-11 for 
five of seven consecutive days a week for three weeks (Chapter Two). On the 
18th day, approximately 30 minutes following the final intranasal administration, 
animals were euthanized and the olfactory bulb, striatum, and substantia nigra 
were removed for analysis of whole tissue neurochemical content.   
Then, a separate cohort of young adult male Fischer 344 rats was 
subjected to a unilateral 6-OHDA lesion of the substantia nigra directly (see 
Chapter Two) following an initial intranasal protective treatment 30 minutes prior 
to lesion induction.  The animals were intranasally administered DNSP-11, a 
scrambled version of the peptide, or vehicle only five consecutive days a week 
for three weeks (see Figure 2.3).  On the 21st day the animals were subjected to 
striatal microdialysis under urethane anesthesia to measure baseline, K+ and d-
amphetamine evoked release of dopamine, then euthanized and a 2 mm thick 
section of the striatum was collected at the level of the optic chiasm for whole 
tissue neurochemical content analysis.   
Finally, unlesioned rats with no prior treatment were subjected to 
microdialysis during which potassium-evoked release of dopamine was initiated, 
followed by perfusion with a solution of DNSP-11 through the microdialysis 
probe.  Then a second potassium-evoked release of dopamine was initiated to 
determine intra-animal changes after DNSP-11 perfusion.  
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Increases in dopamine tissue content ameliorate parkinsonian 
symptoms 
The loss of dopamine in the striatum of both humans and in animal 
models of Parkinson’s disease is the hallmark sign correlated to motor function 
deficit.  It has been observed that a loss of 80% of striatal dopamine content 
corresponds to the onset of motor symptoms (Gibb and Lees, 1991) as a result 
of an approximate 60% loss of dopaminergic neurons (Braak et al., 2006).  The 
biosynthesis of dopamine occurs in the cytoplasm of tyrosine hydroxylase 
positive neurons from the precursor L-DOPA, so an elevated presence of TH+ 
nigral neurons and their striatal fibers may allow for the production of elevated 
dopamine content in the target striatum.  For this reason, the determination of 
dopamine content in the putamen of the striatum has been an important endpoint 
in studies of Parkinson’s disease treatment models. 
Contrasting neurochemical content and functional release 
Dopamine content on its own is only a snap-shot of the absolute quantity 
of dopamine present, and does not reveal functional characteristics regarding the 
release and metabolism of dopamine.  The use of an intra-striatal microdialysis 
probe (CMA 11, 6000 MW cut-off), allows for the collection of dopamine and its 
metabolites from the interstitial space.  By simultaneously perfusing through the 
probe solutions designed to stimulate the release of dopamine, the functional 
characteristics of the circuitry may be elucidated.  For instance, perfusion with a 
100 mM K+ solution in artificial cerebrospinal fluid will induce a change in the 
ionic membrane potential and the synaptic release of dopamine by a mechanism 
dependent on intracellular Ca2+ stores similar to physiological release.  Also, d-
amphetamine (d-amp) increases extracellular dopamine by increasing the net 
efflux of dopamine through the dopamine transporter, which can provide 
information about total intracellular dopamine and the function of the dopamine 
transporter.  d-Amphetamine acts through a variety of mechanisms.  One such 
mechanism is by acting as a substrate for the dopamine transporter (DAT) 
effectively inhibiting the reuptake of extracellular dopamine by binding to the 
normal “outward-facing” or “inward-flowing” conformity of DAT thus competitively 
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blocking the influx of extracellular dopamine in a calcium-independent manner 
(Rothman et al., 2012).  Furthermore, d-amphetamine forces dopamine out of 
synaptic vesicles by altering ionic gradients across lipid membranes (Tsai et al., 
2000).  These intracellular ionic changes have also been shown to alter the 
conformity of the dopamine transporter to its inward-facing, outward-flowing 
conformity (Zhen et al., 2005) effectively reversing its flow to cause the efflux, or 
carrier-mediate release, of cytoplasmic dopamine (Liang et al., 2009; Steinkellner 
et al., 2012).  Data from studies of the functional release of dopamine, in 
conjunction with tissue dopamine content, can provide information on the 
functioning of the circuitry in ways that dopamine content alone cannot provide.  
Materials and Methods 
Dose response study in normal animals 
In order to determine the appropriate intranasal dose required to elicit a 
biological response, 100 µg, 300 µg, 1000 µg of DNSP-11, or vehicle only was 
administered intranasally using the administration protocol described in Chapter 
Two.  In short, animals were administered intranasal DNSP-11 or vehicle (Table 
4.1) by a researcher blind to treatment for five of seven consecutive days a week 
while under isoflurane anesthesia and laid supine.  With the day of the first 
administration defined as day 0, animals were euthanized by isoflurane overdose 
on the 18th day immediately following intranasal administration, their brains 
removed and the neurochemical tissue content of the olfactory bulb, striatum, 
and substantia nigra were investigated, as described below.   
Neurochemical protection studies in lesioned animals 
A target dose of 300 µg DNSP-11 was administered intranasally (using the 
same regimen as in Chapter Three and as described by Figure 2.3) in order to 
determine the protective effects of this dose on dopamine neurochemical tissue 
content and functional release of dopamine by striatal microdialysis. 
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Tissue preparation for neurochemical quantification 
In order to acquire samples of brain tissue, animals were overdosed with 
isoflurane and euthanized by decapitation.  The brain was removed, submerged 
in ice-cold saline, and then a 2 mm section of the whole striatum was removed at 
the level of the optic chiasm.  The sections were weighed, flash-frozen in dry ice 
and stored at approximately -74 °C.  Immediately prior to analysis by HPLC-EC, 
tissue samples were sonicated in 300 μl of cold 0.1 M perchloric acid containing 
dihydroxybenzylamine as an internal standard.  The samples were centrifuged 
for 5 min at 12,000 g and the supernatant transferred to 0.22 μm pore size 
Millipore Ultrafree centrifugal filters and spun at 12,000 g for 1 min. The filtrate 
was diluted with HPLC mobile phase and 50 μL injected onto the HPLC column. 
For dialysis samples, 20 μL of the dialysate was injected directly onto the 
column. 
Neurochemical quantification by HPLC-EC 
All neurochemical assays were performed by the laboratory of Wayne A. 
Cass, Ph.D. as previously described (Cass et al., 2003).  The HPLC system 
consisted of a Beckman Model 118 pump, a Beckman Model 507 autoinjector 
and an ESA Model 5200A Coulochem II electrochemical detector with a Model 
5011 dual-detector analytical cell (detector 1 set at +350 mV and detector 2 set 
at −300 mV). An ESA Hypersil ODS 3 μm particle C18 column (80Χ4.6 mm) was 
used for separations. Flow rate was 1.4 mL/min and the mobile phase was a pH 
4.1, 0.17 M citrate–acetate buffer (containing 5 mg/L EDTA, 70–80 mg/L 
octanesulfonic acid, and 7–8% methanol).  Chromatograms were recorded from 
both detectors using two dual-channel strip chart recorders.  Retention times of 
standards were used to identify peaks, and peak heights were used to calculate 
recovery of internal standard and amount of DA and metabolites. 
Striatal microdialysis 
The microdialysis technique allows for collection of extracellular 
compounds, especially monoamine neurotransmitters of interest in this study, by 
passive diffusion across the semipermeable probe membrane.  Microdialysis is 
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performed as a non-recovery surgery in this study.  Prior to in vivo microdialysis, 
probes were prepared by perfusion with 70% ethanol at 3 µL/min for 
approximately 20 minutes followed by reverse-osmosis water at 0.2 µL/min until 
in vitro probe recovery collection was performed.  Probes were then submerged 
in a solution containing known quantities of the analytes of interest (see p. 68) 
and perfused with artificial cerebrospinal fluid (see p. 68).    The animals were 
anesthetized with urethane (1.25 g/kg in 0.9% NaCl, i.p.) and placed in a 
stereotactic frame.  A rostro-caudal incision was made in the skin above the 
calvarium and a craniotomy was performed allowing the microdialysis probe 
(CMA 11 probe with 4 mm Cuprophane membrane length and 6000 Da MW cut-
off. CMA Harvard Apparatus Co., Kista, SE) to be placed in the whole striatum 
using stereotactic coordinates with respect to bregma: AP: +1.5 mm, ML: -2.3 
mm, DV: -8.0 mm (from dural surface), TB: -3.3 mm (Figure 4.1).  The probe tract 
was visualized post-mortem.  Artificial cerebrospinal fluid (aCSF) was then 
perfused at a rate of 1 µL/min and the probe was submerged in a standard 
solution containing known concentrations of the analytes of interest and a 20 min 
(20 µL) sample was collected for determination of probe recovery.  Then the 
probe was placed in the striatum using the above coordinates and samples 
collected after each 20 min period (totaling 20 µL per sample).  Six samples (0-
120 minutes) were collected and then the perfusate solution was switched to a 
100 mM potassium (K+) aCSF solution using a CMA 110 liquid switch for the 
seventh sample.  The seventh sample was collected over a 20 minute period and 
then perfusate solution was switched back to aCSF for the collection of the next 
four samples (140-220 minutes).  After the eleventh sample was collected, the 
perfusate was switched to a d-amphetamine containing aCSF solution.  Sample 
12 was collected over a 20 minute period and the perfusate switched back to 
aCSF for the following five samples (240-340 minutes).  The animals were then 
euthanized via anesthetic overdose and their brains removed for determination of 
neurochemical tissue content.  Sections of the substantia nigra were retained 
and submersion fixed, and a subset was processed histologically for TH 
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immunoreactivity to confirm lesion induction.  Solutions for microdialysis 
perfusion were prepared as described below. 
Solutions for microdialysis 
Microdialysis perfusates include three separate solutions: artificial 
cerebrospinal fluid (or aCSF, 124 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM 
MgCl2, 1 mM NaH2PO4, 25 mM NaHCO3, 5.9 mM d-glucose), 100 mM K+ aCSF 
(26 mM NaCl, 100 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM NaH2PO4, 25 mM 
NaHCO3, 5.9 mM d-glucose), and 250 µM d-amphetamine aCSF (250 µM d-
amphetamine sulfate, 124 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM 
NaH2PO4, 25 mM NaHCO3, 5.9 mM d-glucose), and all were pH adjusted with 
sulfuric acid and/or sodium hydroxide to within the 7.2-7.4 range.   
A standard solution of analytes for probe recovery contained the following 
concentrations (M) of neurochemicals: 2 x 10-7 norepinephrine (NE), 1 x 10-7 3,4-
dihydroxyphenylacetic acid (DOPAC), 2 x 10-7 dopamine (DA), 1 x 10-7 
homovanillic acid (HVA),  2 x 10-7 serotonin (5-hydroxytryptamine, 5-HT), 4 x 10-7 
5-hydroxyindoleacetic acid (5-HIAA).   
Perfusion of DNSP-11 through microdialysis probe 
In order to determine the percentage of DNSP-11 that perfuses through 
the CMA 11, 6000 Da MW cut-off, microdialysis probe, probes were submerged 
in solutions containing a range of concentrations of DNSP-11 between 0.1 µM 
and 1000 µM in aCSF that was kept at approximately 37°C via water bath. 
Probes were perfused as described above, with aCSF at 1 µL/min, and samples 
were collected every 20 minutes.  The concentration of DNSP-11 was quantified 
by enzyme-linked immunosorbent assay (ELISA).  
Enzyme-linked immunosorbent assay  
A 1:1 serial dilution of the DNSP-11 peptide provided a detection range of 
5 ng/mL to 2000 ng/mL.  Sample was placed in wells with sodium 
carbonate/bicarbonate coating buffer (pH 9.6) overnight at 4°C, followed by 
blocking (0.1% purified BSA in PBS) at room temperature for 1 hour.  The 
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custom, polyclonal antibody to DNSP-11 (1:2000, α-Diagnostic, San Antonio, 
Texas USA) was added and allowed to incubate for 2 hours at room temperature, 
followed by a 1 hour incubation at room temperature with secondary, peroxidase-
labeled antibody (1:10,000).  The chromogen (R&D Systems, Reagent Kit 
DY999) was allowed to develop for 20 minutes at room temperature at which 
time the reaction was quenched (R&D Systems, Stop Solution DY994).  The 
optical density of the wells was recorded at 450 nm immediately after quenching. 
Acute perfusion of DNSP-11 during microdialysis 
In order to determine possible acute effects of DNSP-11 on the release of 
dopamine, a 50 µM DNSP-11 solution in aCSF was perfused through the CMA 
11 microdialysis probe.  Microdialysis was performed as above with 
modifications.  The probe was perfused with aCSF for the 1st through 5th 20 
minute samples, then the perfusate was switched to the 100 mM K+ aCSF 
solution for the 6th sample collection.  For the 7th through 9th sample collections, 
the perfusate was switched back to aCSF; then the perfusate was switched to an 
aCSF solution or a solution of 50 µM DNSP-11 in aCSF which was perfused for 
the 10th to 14th samples.  For the 15th sample the perfusate was switched back to 
the 100 mM K+ aCSF, followed by perfusion with aCSF for the 16th through 18th 
samples.  A total of 8 animals were used in this study, four controls and four 
DNSP-11.  Two animals in the DNSP-11 group were excluded due to non-
detectable baselines. 
Results 
Dose response in normal animals 
Normal, unlesioned animals given DNSP-11 intranasally for five of seven 
days a week for three weeks showed significant changes in monoamine 
neurochemicals at different doses (Table 4.2).  While dopamine levels 
significantly decreased at 100 and 1000 µg doses, DOPAC significantly 
increased at 300 µg (Figure 4.2).  This resulted in a significantly higher dopamine 
turnover (here defined as the ratio of all dopamine metabolites (HVA+DOPAC) to 
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dopamine) in animals that received 300 µg per treatment of DNSP-11 (Figure 
4.3, **P=0.0014, 24.3% increase).   
Significant changes the monoamine in the substantia nigra were also 
observed (Table 4.3).  Both DOPAC and HVA were significantly elevated in the 
animals that received 300 mg of DNSP-11 per treatment (Figure 4.4).  Dopamine 
turnover in the substantia nigra of these animals was also significantly elevated 
at this dose (Figure 4.5, ****P<0.0001, 33.7%, n=12), and at the 1000 µg per 
treatment dose (31.6% increase, n=12).  Also of note, the level of serotonin in the 
substantia nigra of animals given 1000 µg per treatment was significantly 
decreased (Figure 4.6, ***P=0.0003, 31.3% decrease, n=12) with a significant 
increase in serotonin turnover (Figure 4.7, ***P=0.0006, 21. 3% increase, n=12).  
Finally, in the olfactory bulb (Table 4.4), dopamine levels were significantly 
affected by DNSP-11 treatment, but there was no observed effect on dopamine 
metabolites (Figure 4.8) and turnover was not significantly affected (Figure 4.9).  
Whole striatum neurochemical content in lesioned animals 
Of the lesioned animals (Table 4.5) treated with DNSP-11, scrambled 
peptide, or vehicle-only, no changes to striatal monoamine neurochemical tissue 
content was observed (Table 4.6).  when comparing the negative control treated 
animals and the DNSP-11 treated animals (Figure 4.10, P=0.3727).  The 
unlesioned hemispheres also were not significantly different between groups 
(P=0.8437).  However, the animals in this study were present in two distinct 
populations within each group: those with a partial lesion of striatal dopamine 
content, and those with a severe lesion (<1000 ng/g DA, see Figure 4.10).  
These populations were separated for further analysis of the effects of intranasal 
DNSP-11 treatment. 
When analyzing only the partially lesioned animals, a significant difference was 
observed with respect to treatment.  Firstly, animals treated with vehicle only or 
scrambled peptide were not significantly different from each other (P=0.7905, see 
Table 4.7), as predicted, and were combined as one “Negative Controls” group.  
When comparing DNSP-11 and negative control treated animals, the effect of 
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treatment was significant, and the DNSP-11 treated animals contained 56.4% 
more striatal dopamine content than the negative control animals (Figure 4.11. 
###P=0.0006, DNSP-11: 10037 ± 1672 ng/g DA; Negative Controls: 6417 ± 835.6 
ng/g DA).  This effect in the DNSP-11 treated animals resulted in dopamine 
content in the lesioned hemisphere that was not significantly different from the 
unlesioned hemispheres (P=0.6017).  Also of note, the unlesioned hemispheres 
of DNSP-11 treated animals contains significantly greater dopamine by 18.2% 
than that of the unlesioned hemispheres of negative control treated animals 
(Figure 4.11, P=0.0301. DNSP-11 unlesioned hemispheres: 12101 ± 783.9; 
Negative Controls, unlesioned hemispheres: 10235 ± 522.9).  However, in the 
severely lesioned animals, there was no significant difference in monoamine 
neurotransmitter levels (Table 4.8) between treatment groups (Figure 4.12). 
Functional neurochemical release by microdialysis in lesioned 
animals 
Of the animals subjected to striatal microdialysis (Table 4.9), significance 
changes with respect to potassium-evoked dopamine overflow and DOPAC 
levels were observed (Table 4.10).   It was observed that treatment with DNSP-
11 resulted in a significant decrease in the potassium-evoked overflow of 
dopamine (****K+ P<0.0001, 45.8% less than the combined negative controls. 
Figure 4.13).  The vehicle and scrambled peptide treated groups were not 
significantly different (P=0.9573).  However, baseline dopamine and metabolite 
overflows were not significantly different between the negative control treated 
and DNSP-11 treated groups (Figure 4.13), nor were baseline dopamine 
metabolite concentrations (Figure 4.14).  The effect of decreased evoked 
dopamine overflow was driven primarily by animals determined to be in the 
severely lesioned subgroup (<1000 ng/g striatal dopamine: DNSP-11 n=3, 
Vehicle n=4, Scrambled n=1).  When those severely lesioned animals were 
removed from the analysis, no significant differences between groups of partially 
lesioned animals was observed (P=0.9929, Figure 4.15).   
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Perfusion of DNSP-11 through microdialysis probe in vitro 
By comparing the quantity of DNSP-11 collected during microdialysis to a 
sample of the quantity in the vial in which the probe was submerged, it was 
determined that an average of 1.6% ± 0.66 DNSP-11 is recovered by the 
microdialysis probe in vitro at 37°C.  It was determined that 50 µM concentration 
of DNSP-11 in aCSF solution would result in approximately 0.8 µM perfused in 
the brain every 20 minute sampling period.  This concentration is within an order 
of magnitude of the concentration in the brain after intranasal administration of 
300 µg of DNSP-11 and after intracranial injection of 30 µg of DNSP-11, which is 
known to produce biological effects at the two-week time point (Littrell, 2011).  
Acute effects of DNSP-11 on potassium evoked release of dopamine 
After perfusion of 50 µM DNSP-11 in aCSF through the microdialysis 
probe for 100 minutes, dopamine overflow during potassium-evoked release was 
significantly lower than the normal potassium-evoked release recorded in the 
same animals prior to infusion with DNSP-11 (Figure 4.16; Decrease of 40.8%, 
****P<0.0001).  No significant differences in baseline dopamine, DOPAC (Figure 
4.17) or HVA (Figure 4.18) levels were observed. 
Discussion 
Overview and interpretation 
These studies provide data on the possible long-term and immediate 
effects of DNSP-11, in both normal and lesioned animals, while providing 
important dosing information for future studies.  The dose response study in 
normal animals resulted in observed changes in monoamine neurochemical 
levels of the striatum and substantia nigra, with especially strong changes to 
dopamine metabolism in the substantia nigra.  Due to these results, the 300 µg 
dose became the focus for protection studies of intranasal DNSP-11 in 6-OHDA 
lesioned animals.   
When considering all of the 6-OHDA lesioned animals in the protection 
study, treatment with DNSP-11 did not have an effect on striatal dopamine 
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content; however, due to variability of the lesion within this cohort the animals 
were present in two subgroups: those with severe lesions (<1000 ng/g striatal 
DA), and those with partial lesions.  Of the animals with partial lesions, those that 
were treated with DNSP-11 had significantly higher levels of striatal dopamine 
(Figure 4.11).  Indeed, the partially lesioned animals that received DNSP-11 
treatment possessed striatal dopamine levels not significantly different from their 
unlesioned hemispheres.  It is hypothesized that natural and uncontrollable 
variations in the 6-OHDA lesion severity resulted in a subgroup of severely 
lesioned animals that could not be rescued by DNSP-11 treatment at the dose 
provided.  Furthermore, the significant, negative effects observed in the 
microdialysis studies were driven primarily by the three severely lesioned animals 
of the DNSP-11 group.  This variability may be overcome in restoration studies in 
which animals can be prescreened for lesion severity.  In addition, due to the 
inherent variability of intranasal delivery, reduction of lesion variability becomes 
important.  As such, other toxic lesion or genetic models of Parkinson’s disease 
may prove to be better models to quantify the effects of intranasal treatment with 
DNSP-11. 
Dose-response curve 
The dose response in normal, unlesioned animals shows an increase in 
striatal dopamine turnover at the 300 µg per day dose, but no significant 
difference from vehicle-only treated controls at the 1000 µg per day dose, 
suggesting a possible bimodal response curve.  When considering the effect of 
DNSP-11 on neurochemical content aside from dopamine it may be 
hypothesized that this bimodal response was due to regulatory or compensatory 
mechanisms.  At the 1000 µg dose, serotonin content in the nigra was 
significantly lower (Figure 4.6) than the vehicle treated animals while serotonin 
turnover was significantly higher (Figure 4.7).  This may indicate a regulatory or 
compensatory mechanism, or it may indicate differential efficacy at a range of 
concentrations on other monoamine systems compared to the dopamine system. 
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The exact roles of serotonin on the dopaminergic motor system are 
complex, but it is observed that these and other monoamine systems are subject 
to profound loss in patients suffering from Parkinson’s disease (Scatton et al., 
1983; Miyawaki et al., 1997).  In fact, in many patients, the symptoms of mood 
disorder and autonomic dysfunction precede the motor signs of Parkinson’s 
disease (Kummer and Teixeira, 2009; Lohle et al., 2009).  Outstanding questions 
remain in the literature surrounding the effects of serotonin interaction in the 
dopaminergic system, but it has been shown that 5-HT receptor subtypes 
differentially affect the dopaminergic system, some antagonizing dopamine and 
others agonizing dopamine release in the striatum (Lucas et al., 2000a; Lucas et 
al., 2000b; Lucas and Spampinato, 2000; Di Matteo et al., 2008).   
While norepinephrine levels were not significantly altered with DNSP-11 
treatment, levels of the metabolites of norepinephrine were not measured.  
Furthermore, small changes in neurochemical levels may have appreciable 
regulatory impacts.  Similar to serotonin, the effects of changes in NE levels 
remain to be fully described, but it is known that lesions of the locus ceruleus 
increase the pathology and behavior deficits in Parkinson’s disease animal 
models (Mavridis et al., 1991; Srinivasan and Schmidt, 2003) suggesting that NE 
is sufficient, at some stages of the disease, to attenuate the behavioral output 
and neuronal loss associated with the disease.  The locus ceruleus directly 
innervates the SN and striatum, stimulating burst firing of the dopaminergic 
system (Grenhoff and Svensson, 1993).  However, like the serotonin receptors, 
norepinephrine is bound by a multitude of receptors, all with different functions 
and localizations, complicating the explanation of circuit interactions (Hein et al., 
1999).  Norepinephrinergic projections in the striatum have been shown to 
modulate dopamine turnover by the α2CAR NE receptor (Sallinen et al., 1997), 
and may do so indirectly by modulating glia and astrocyte activity by the whole 
range of membrane bound NE receptor families (Mori et al., 2002).  Furthermore, 
the α2CAR norepinephrine receptors in the striatum are known to be sensitive to 
dopamine at low synaptic concentrations (Hein et al., 1999; Zhang W. et al., 
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1999) while not being activated by apomorphine (Fox et al., 2001), indicating 
complex cross-sensitivities to these various neurotransmitters.   
As such, the dose response to DNSP-11 may be best described under the 
hypothesis of differential effects to the monoamine systems both pre- and post-
synaptically.  Such effects may be elucidated by primary cell culture studies or by 
highly localized analysis in animal models, but are beyond the scope of the 
present study.  Due to the powerful effect on the striatal dopamine system and 
the relative paucity of changes to other systems and anatomical regions at the 
300 µg per treatment dose, it was determined that the protection studies should 
focus on this concentration of administered DNSP-11.   
The use of isoflurane anesthesia in this study may in itself alter 
neurochemical production, however no significant correlation between duration of 
isoflurane anesthesia and striatal dopamine turnover was found (m=0.0004, 
R2=0.4, P=0.0959, data not shown).  Furthermore, the anesthetic used during 
intranasal administration may alter respiration and blood-flow, changing the 
dynamic of intranasal delivery.  Indeed, reports differ on the use of anesthesia in 
rodent models of intranasal delivery.  Some suggest that isoflurane anesthesia 
adversely affects intranasal delivery by drying the nasal mucosa, while other 
reports indicate anesthetics may open the blood-brain barrier (Tetrault et al., 
2008).  However, these effects appear to be minimal in scope.   Ideally, future 
studies would move to self-administration, which is feasible in non-human 
primate models. 
Effects of intranasal DNSP-11 in 6-OHDA lesioned animals 
While DNSP-11 produced effects on the monoamine systems in the normal, 
unlesioned animal, the protective effects of DNSP-11 on dopamine 
neurochemical content were only observed in a subset of animals with partial 
lesions (Figure 4.11).  Lesion variability among this cohort resulted in a subgroup 
of severely lesioned animals (Figure 4.12) upon which DNSP-11 was insufficient, 
at the dose given, to produce the same protective effect seen in the partially 
lesioned subgroup of animals.   
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It is important to note the differences between the location of lesion 
induction and the location of the measurements of both neurochemical content 
and functional release by microdialysis. In contrast with previous DNSP-11 
studies (Bradley et al., 2010) which utilized a severe lesion of the medial 
forebrain bundle (MFB) and neurochemical content analysis targeted specifically 
to the dorsolateral rat striatum, the present study used a lesion of the substantia 
nigra and analysis of the whole striatum.  A targeted analysis of the dorsolateral 
striatum, or the use of other models including the MFB lesion model, may result 
in reduced noise and variability.  In addition, the repeated intranasal dosing 
regimen in which the animals were off-treatment for the two days prior to 
neurochemical endpoint may have created unintended consequences.  The 
intent of this timeline was to emphasize long-term protective effects of DNSP-11 
treatment; however, this may also have introduced a negative rebound or a 
“wash-out” effect due to being off of treatment, perhaps complicating the 
neurochemical data.   
The effects of DNSP-11 on functional neurochemistry, as collected by 
microdialysis, most closely resemble the data obtained from aged Fischer 344 
rats administered DNSP-11 in a single intracranial injection (Fuqua, 2010), in 
which potassium-evoked and baseline release of dopamine were found to be 
significantly decreased in DNSP-11 treated animals.  In the present study, the 
DNSP-11 treated animals exhibited a significant decrease in potassium evoked 
dopamine (Figure 4.13) and a non-significant trend toward decreased baseline 
levels of dopamine and its metabolites, while d-amphetamine evoked release 
was unchanged.  This decrease was driven primarily by the small (n=3 DNSP-11 
treated) subgroup of severely lesioned animals suggesting these changes may 
be occurring only in the severely depleted striatum or may be a statistical artifact.  
If this effect is confirmed, one hypothesis is that DNSP-11 may have pleiotropic 
effects aside from long-term protection against neurotoxic lesions, all while not 
affecting dopamine content or d-amphetamine evoked release of dopamine.  The 
decrease specifically in potassium-evoked, calcium-dependent release may 
indicate that DNSP-11 affected dopamine release pre-synaptically through a 
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calcium-dependent mechanism.  Other possibilities include post-synaptic 
sensitization or an increase in auto-inhibition of the pre-synaptic neuron.  Indeed, 
5-HT has been shown to increase auto-inhibition of the substantia nigra and VTA 
by DA (Olijslagers et al., 2004).  This may be an important area for future studies 
of long and short term effects of DNSP-11.   
Acute versus long-term effects of DNSP-11 
It was observed in the protection studies that a subgroup of severely 
lesioned animals exhibited greatly reduced potassium-evoked, calcium-
dependent release of dopamine after three weeks of intranasal DNSP-11 
treatment, and this led to questions about possible pleiotropic effects of DNSP-
11.  Here, naïve animals were taken for striatal microdialysis, during which they 
were perfused with a 50 µM solution of DNSP-11 in aCSF, or aCSF-only without 
peptide, through the microdialysis probe.  Potassium-evoked dopamine release 
was performed before and after the perfusion of DNSP-11 or aCSF-only, and 
was found to be decreased after perfusion with DNSP-11 and significantly lower 
than in aCSF-only perfused animals.  Data from this study supports the 
hypothesis that DNSP-11 has acute effects on calcium-dependent, potassium-
evoked dopamine release within two hours of introduction to the striatum via 
microdialysis probe.  Additionally, no significant intra-animal variability in 
potassium-evoked DA release was observed in the control animals, indicating the 
analysis of the second potassium-evoked release as a percentage of the first 
potassium-evoked release is valid.  This finding of the equality of multiple 
potassium-evoked releases is consistent with one report of microdialysis in 
awake animals (Ripley et al., 1997) but contradicts another in anesthetized 
animals (Kametani et al., 1995). 
 In summary, while DNSP-11 significantly affected the ratio of dopamine to 
its metabolites in the striatum and substantia nigra of normal animals, the dose of 
DNSP-11 provided to lesioned animals may be insufficient to protect against a 
severe, acute toxic loss of neurons in a subset of animals.  The data supports the 
overall hypothesis that intranasal DNSP-11 produces biological effects on the 
central nervous system. 
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Figure 4.1 – Representative placement of the microdialysis probe in the striatum. 
The vertical black line with blue end represents the CMA 11 microdialysis probe 
with 4 mm long 6,000 MW cut-off membrane at its final position at the following 
coordinates (with respect to bregma): AP: +1.5 mm, ML: -2.3 mm, DV: -8.0 mm 
(from dural surface), TB: -3.3 mm. Modified from (Paxinos and Watson, 2005). 
(ac, anterior commissure; cc, corpus callosum; LV, lateral ventricle.) 
  
cerebral 
cortex 
caudate-
putamen 
of 
striatum 
cc 
LV 
ac 
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Table 4.1 – Animal groups for dose response study in normal, unlesioned rats. 
 Vehicle 0 µg 
DNSP-11 
100 µg 
DNSP-11 
300 µg 
DNSP-11 
1000 µg 
Numbers: 9 6 6 6 
 
A total of 27 animals were used in this study.  For every 6 animals in each dosing 
group, 3 animals were concomitantly administered and evaluated vehicle only (0 
µg), and the neurochemical content of the DNSP-11 administered animals were 
compared as a percentage of the concomitantly administered vehicle only 
animals.  Due to the bilateral treatment, each hemisphere was used as an 
independent data point.  No animals were excluded from this study.  Treatment 
was performed in a blinded manner. 
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Table 4.2 – Striatal neurochemical levels in normal rats given a range of 
intranasal doses of DNSP-11. 
 Treatment  
 
Treatment 
Statistics 
 
 0 µg DNSP-11 
per day 
(Vehicle only) 
100 µg DNSP-
11 
per day 
300 µg DNSP-
11 
per day 
1000 µg DNSP-
11 
per day 
DA 
(ng/g) 
 12427 
± 1693 
   9043 
± 3496 
t(50)=3.695 
 11923 
± 2213 
t(50)=0.5494 
   9910 
± 2428 
t(50)=2.748 
P=0.0006 
## 
F(3,50)=5.913
 
DOPAC 
(ng/g) 
 1919 
± 400 
 1257 
± 425 
t(50)=3.722 
 2422 
± 635 
t(50)=2.820 
 1574 
± 455 
t(50)=1.938 
P=0.0001 
#### 
F(3,50)=13.21
 
HVA 
(ng/g) 
   832 
± 254 
   570 
± 192 
t(50)=3.515 
   843 
± 154 
t(50)=0.1406 
   658 
± 147 
t(50)=2.366 
P=0.0016 
## 
F(3,50)=5.916
 
(HVA+DOPAC)
/DA 
   0.221 
± 0.032 
   0.215 
± 0.051 
t(50)= 0.3571 
   0.274 
± 0.040 
t(50)= 3.709 
   0.227 
± 0.032 
t(50)= 0.4492 
P=0.0014 
## 
F(3,50)=6.042
 
5-HT 
(ng/g) 
   576 
± 104 
   625 
± 110 
t(50)=1.317 
 555 
± 94 
t(50)=0.5423 
 582 
± 93 
t(50)=0.1594 
P=0.3859 
 
F(3,50)=1.033 
5-HIAA 
(ng/g) 
   653 
± 126 
 605 
± 74 
t(50)=1.364 
 739 
± 61 
t(50)=2.474 
 640 
± 78 
t(50)=0.3618 
P=0.0077 
## 
F(3,50)=4.436
 
(5-HIAA/5-HT) 
 
   1.14 
± 0.17 
   0.980 
± 0.099 
t(50)=3.028 
   1.35 
± 0.17 
t(50)=3.869 
   1.11 
± 0.10 
t(50)=0.6256 
P<0.0001 
#### 
F(3,50)=13.62
 
NE 
(ng/g) 
 100 
± 31 
 139 
± 83 
t(50)=2.064 
   92 
± 28 
t(50)=0.3348 
   99 
± 50 
t(50)=0.06490 
P=0.1135 
 
F(3,50)=2.089 
n = 
(hemispheres) 
18 12 12 12 
 
Animals treated intranasally with DNSP-11 exhibited significant changes in the 
levels of striatal dopamine and its metabolites.  (Values are displayed as “analyte 
mean ng/g of analyte ± standard deviation”.  Analysis by one-way ANOVA with 
Bonferroni’s post hoc test. With respect to 0 µg vehicle-only treated group, 
*P<0.05; **P<0.01; ***P<0.001.) 
  
** * 
** 
** 
** * 
*** * 
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Figure 4.2 – Striatal dopamine and metabolites in normal rats given intranasal 
DNSP-11. 
A significant decrease in dopamine content was observed in the 100 µg/day and 
1000 µg/day treated groups, DOPAC was significantly different at the 100 µg/day 
and 300 µg/day groups, and HVA was significantly decreased in the 100 µg/day. 
(DA: ##Treatment P=0.0016; DOPAC: ####Treatment P=0.0001; HVA: ##Treatment 
P=0.0016 by one-way ANOVA.  0 µg, n=18 hemispheres; 100 µg, n=12 
hemispheres; 300 µg, n=12 hemispheres; 1000 µg, n=12 hemispheres.  Analysis 
by one-way ANOVA with Bonferroni’s post hoc test. With respect to 0 µg vehicle-
only treated group, *P<0.05; **P<0.01.  Error bars displayed as SEM.)  
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Figure 4.3 – Striatal total dopamine turnover in normal rats given intranasal 
DNSP-11. 
A significant increase in total dopamine turnover was observed in the striatum of 
normal rats treated with 300 µg/day DNSP-11 for five of seven days a week for 
three weeks.  (##Treatment, P=0.0014. 0 µg, n=18 hemispheres; 100 µg, n=12 
hemispheres; 300 µg, n=12 hemispheres; 1000 µg, n=12 hemispheres. Analysis 
by one-way ANOVA with Bonferroni’s post hoc test.  **P<0.01 with respect to 0 
µg vehicle-only treated group.  Error bars displayed as SEM.) 
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Table 4.3 – Nigral neurochemical levels in normal rats given a range of 
intranasal doses of DNSP-11. 
 Treatment  
 
Treatment 
Statistics 
 
 0 µg DNSP-11 
per day 
(Vehicle only) 
100 µg DNSP-
11 
per day 
300 µg DNSP-
11 
per day 
1000 µg DNSP-
11 
per day 
DA 
(ng/g) 
   620 
± 250 
   481 
± 203 
t(50)=1.749 
   815 
± 204 
t(50)=2.439 
   416 
± 173 
t(50)=2.559 
P=0.0002 
#### 
F(3,50)=8.201
 
DOPAC 
(ng/g) 
   151 
±   69 
   103 
±   50 
t(50)=1.977 
   269 
±   72 
t(50)=4.872 
   124 
±   66 
t(50)=1.099 
P<0.0001 
#### 
F(3,50)=15.63 
HVA 
(ng/g) 
   55 
± 18 
   37 
± 17 
t(50)=3.057 
   81 
± 18 
t(50)=4.198 
   51 
± 11 
t(50)=0.7712 
P<0.0001 
#### 
F(3,50)=15.30 
(HVA+DOPAC)
/DA 
   0.332 
± 0.047 
   0.289 
± 0.066 
t(50)=1.340 
   0.443 
± 0.119 
t(50)=3.556 
   0.436 
± 0.103 
t(50)=3.331 
P<0.0001 
#### 
F(3,50)=13.17 
5-HT 
(ng/g) 
   882 
± 252 
   767 
± 161 
t(50)=1.637 
   928 
± 107 
t(50)=0.6653 
   606 
± 158 
t(50)=3.940 
P=0.0003 
### 
F(3,50)=7.380 
5-HIAA 
(ng/g) 
   685 
± 152 
   572 
± 109 
t(50)=2.606 
 812 
± 78 
t(50)=2.898 
 582 
± 95 
t(50)=2.375 
P<0.0001 
#### 
F(3,50)=11.04 
(5-HIAA/5-HT) 
 
   0.796 
± 0.105 
   0.757 
± 0.135 
t(50)=0.6823 
   0.882 
± 0.099 
t(50)=1.508 
   1.011 
± 0.249 
t(50)=3.763 
P=0.0006 
### 
F(3,50)=6.789 
NE 
(ng/g) 
 303 
± 75 
 293 
± 86 
t(50)= 0.2434 
 299 
± 82 
t(50)= 0.1009 
   334 
± 191 
t(50)= 0.7191 
P=0.8191 
 
F(3,50)=0.3085 
n = 
(hemispheres) 
18 12 12 12 
 
Animals treated intranasally with DNSP-11 exhibited significant changes in the 
levels of nigral dopamine and its metabolites.  Significance is shown with respect 
to the 0 µg vehicle-only treated group.  (Values are displayed as “analyte mean 
ng/g ± standard deviation”.  Analyses by one-way ANOVA with Bonferroni’s post 
hoc test.  With respect to 0 µg vehicle-only treated group, *P<0.05; **P<0.01; 
***P<0.001; ****P<0.0001.) 
  
* 
**** 
* *** 
** ** 
*** 
* * 
** 
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Figure 4.4 – Nigral dopamine and metabolites in normal rats given intranasal 
DNSP-11. 
A significant change in the levels of dopamine and its metabolites were observed 
in the substantia nigra after treatment with intranasal DNSP-11.  (DA: 
###Treatment P=0.0002; DOPAC: ####Treatment P<0.0001; HVA: ####Treatment 
P<0.0001.  0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres; 300 µg, n=12 
hemispheres; 1000 µg, n=12 hemispheres. Analyses by one-way ANOVA with 
Bonferroni’s post hoc test. With respect to 0 µg vehicle-only treated group, 
*P<0.05; ***P<0.001; ****P<0.0001.  Error bars displayed as SEM.) 
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Figure 4.5 – Nigral total dopamine turnover in normal rats given intranasal 
DNSP-11. 
The ratio of HVA+DOPAC to DA was significantly different between vehicle only 
and DNSP-11 treated groups (####Treatment P<0.0001; 0 µg, n=18 hemispheres. 
100 µg, n=12 hemispheres; **300 µg, P<0.01, n=12 hemispheres; **1000 µg, 
P<0.01, n=12 hemispheres. Analysis by one-way ANOVA with Bonferroni’s post 
hoc test.  Significance is shown with respect to 0 µg vehicle-only treated group.  
Error bars displayed as SEM.) 
 
  
85 
 
 
Figure 4.6 – Serotonin levels in the substantia nigra of normal rats given 
intranasal DNSP-11. 
Serotonin levels were significantly decreased in animals treated intranasally with 
DNSP-11 for three weeks when compared with concomitant vehicle-only 
negative control animals. (###Treatment P=0.0003; **1000 µg, P<0.01, n=12 
hemispheres; 0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres; 300 µg, n=12 
hemispheres. Analysis by one-way ANOVA with Bonferroni’s post hoc test. 
Significance is shown with respect to 0 µg vehicle-only treated group.  Error bars 
displayed as SEM.) 
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Figure 4.7 – Serotonin turnover in the substantia nigra of normal rats treated with 
DNSP-11. 
Serotonin turnover was significantly elevated in animals treated intranasally with 
DNSP-11 for three weeks when compared with concomitant vehicle-only 
negative control animals. (###Treatment P=0.0006; **1000 µg, P<0.01, n=12 
hemispheres; 0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres; 300 µg, n=12 
hemispheres. Analysis by one-way ANOVA with Bonferroni’s post hoc test. 
Significance is shown with respect to 0 µg vehicle-only treated group.  Error bars 
displayed as SEM.) 
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Table 4.4 – Neurochemical levels in the olfactory bulb of normal rats given a 
range of intranasal doses of DNSP-11. 
 Treatment  
 
Treatment 
Statistics 
 
 0 µg DNSP-11 
per day 
(Vehicle only) 
100 µg DNSP-
11 
per day 
300 µg DNSP-
11 
per day 
1000 µg DNSP-
11 
per day 
DA 
(ng/g) 
   30 
± 14 
 16 
± 7 
t(50)=3.426 
 38 
± 5 
t(50)=1.865 
   43 
± 13 
t(50)=3.223 
P<0.0001 
#### 
F(3,50)=13.88 
DOPAC 
(ng/g) 
 15 
± 5 
 16 
± 7 
t(50)=0.5192 
 15 
± 4 
t(50)=0.02533 
 14 
± 7 
t(50)=0.3166 
P=0.8963 
 
F(3,50)=0.1994 
HVA 
(ng/g) 
   46 
± 12 
   42 
± 13 
t(50)=0.7615 
   39 
± 12 
t(50)=1.316 
   38 
± 16 
t(50)=1.534 
P=0.4091 
 
F(3,50)=0.9813 
(HVA+DOPAC)
/DA 
   1.63 
± 0.51 
   1.42 
± 0.32 
t(50)=1.331 
   1.42 
± 0.36 
t(50)=1.308 
   1.20 
± 0.39 
t(50)=2.743 
P=0.0671 
 
F(3,50)=2.538 
5-HT 
(ng/g) 
 176 
± 34 
 207 
± 49 
t(50)=1.152 
   219 
± 105 
t(50)=1.605 
 210 
± 88 
t(50)=1.287 
P=0.3703 
 
F(3,50)=1.070 
5-HIAA 
(ng/g) 
 133 
± 21 
 141 
± 25 
t(50)=0.6271 
 157 
± 40 
t(50)=1.830 
 148 
± 50 
t(50)=1.131 
P=0.3194 
 
F(3,50)=1.200 
(5-HIAA/5-HT) 
 
   0.771 
± 0.138 
   0.699 
± 0.144 
t(50)=1.313 
   0.779 
± 0.175 
t(50)=0.1541 
   0.724 
± 0.130 
t(50)=0.8603 
P=0.4583 
 
F(3,50)=0.8791 
NE 
(ng/g) 
 183 
± 62 
 204 
± 39 
t(50)=1.145 
 209 
± 34 
t(50)=1.376 
 121 
± 51 
t(50)=3.371 
P=0.0002 
### 
F(3,50)=8.005 
n = 
(hemispheres) 
18 12 12 12 
 
Animals treated intranasally with DNSP-11 exhibited significant changes in the 
levels of some neurochemicals in the olfactory bulb.  Significance is shown with 
respect to the 0 µg vehicle-only treated group.  (Values are displayed as “analyte 
mean ng/g ± standard deviation”.  Analyses by one-way ANOVA with 
Bonferroni’s post hoc test. With respect to 0 µg vehicle-only treated group, 
*P<0.05; **P<0.01.) 
  
** ** 
* 
** 
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Figure 4.8 – Olfactory bulb dopamine and metabolites in normal rats given 
intranasal DNSP-11. 
Significant differences in the levels of dopamine were observed in the olfactory 
bulb of normal rats given intranasal DNSP-11 daily for three weeks.  (Dopamine: 
####Treatment P<0.0001. 0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres; 
300 µg, n=12 hemispheres; 1000 µg, n=12 hemispheres. Analyses by one-way 
ANOVA with Bonferroni’s post hoc test. With respect to 0 µg vehicle-only treated 
group, *P<0.05; **P<0.01.  Error bars displayed as SEM.) 
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Figure 4.9 – Olfactory bulb total dopamine turnover in normal rats given 
intranasal DNSP-11. 
Total dopamine turnover in the olfactory bulb was not significantly different 
between groups. (Overall treatment P=0.0671; *1000 µg P=0.0253, n=12 
hemispheres 0 µg, n=18 hemispheres; 100 µg, n=12 hemispheres; 300 µg, n=12 
hemispheres. Analyses by one-way ANOVA with Bonferroni’s post hoc test. 
Shown as mean ± SEM.) 
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Table 4.5 – Animal groups for neurochemical content study in 6-OHDA lesioned 
animals. 
 Vehicle-only Treated 
Scrambled 
Treated 
DNSP-11 
Treated 
Numbers 12 9 14 
 
Scrambled and vehicle (saline only) were combined into one group for analysis 
due to similarities in response.  The DNSP-11 and Scrambled peptide treated 
groups received 300 µg in 50 µL per treatment of each compound respectively.  
Due to similarities in response, vehicle-only and scrambled peptide treated 
groups were combined into one “Negative Control” group.  Of the animals above, 
one DNSP-11 treated and one scrambled treated animal were excluded due to 
complications during endpoint collection.  Three animals not included in the 
above numbers died due to anesthetic complications during the lesion induction 
surgery: two were in the DNSP-11 group and one was in the scrambled treated 
group. Treatment was performed in a blinded manner. 
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Table 4.6 – Striatal neurochemical content of 6-OHDA lesioned animals. 
  Treatment One-way 
ANOVA 
Treatment 
Statistics 
  Vehicle Only Scrambled 
Peptide 
DNSP-11 Peptide 
 
Le
si
on
ed
 h
em
is
ph
er
e 
DA 
(ng/g) 
   3738 
± 3577 
   5022 
± 4391 
   4795 
± 5701 
P=0.7953 
DOPAC 
(ng/g) 
   677 
± 552 
 1062 
± 790 
   831 
± 852 
P=0.5073 
HVA 
(ng/g) 
   433 
± 390 
   453 
± 446 
   452 
± 555 
P=0.9936 
(HVA+DOPAC)/DA 
 
   0.527 
± 0.456 
   0.421 
± 0.262 
   0.394 
± 0.158 
P=0.5669 
5-HT 
(ng/g) 
   613 
± 182 
   640 
± 120 
   660 
± 137 
P=0.7392 
 
5-HIAA 
(ng/g) 
 1198 
± 209 
 1174 
± 286 
 1267 
± 246 
P=0.6286 
(5-HIAA/5-HT) 
 
   2.10 
± 0.66 
   1.83 
± 0.26 
   1.91 
± 0.38 
P=0.4243 
 
NE 
(ng/g) 
   75 
± 65 
   92 
± 49 
   79 
± 57 
P=0.7923 
 
In
ta
ct
 h
em
is
ph
er
e 
DA 
(ng/g) 
 10621 
± 1847 
   9772 
± 1829 
 11252 
± 2062 
P=0.2263 
DOPAC 
(ng/g) 
 1777 
± 474 
 1591 
± 333 
 1771 
± 409 
P=0.5344 
HVA 
(ng/g) 
   880 
± 201 
   779 
± 166 
   822 
± 231 
P=0.5489 
(HVA+DOPAC)/DA 
 
   0.258 
± 0.047 
   0.247 
± 0.049 
   0.233 
± 0.049 
P=0.4656 
5-HT 
(ng/g) 
   650 
± 152 
   671 
± 126 
   677 
± 106 
P=0.8611 
5-HIAA 
(ng/g) 
 1154 
± 225 
 1109 
± 245 
 1125 
± 183 
P=0.8855 
(5-HIAA/5-HT) 
 
   1.84 
± 0.45 
   1.66 
± 0.24 
   1.67 
± 0.28 
P=0.3687 
 
NE 
(ng/g) 
 143 
± 34 
 150 
± 42 
 145 
± 36 
P=0.8971 
 
 n = 12 8 13 
The striatal neurochemical profile of rats subjected to a 6-OHDA lesion is 
provided above.  While this data represents the mean values (± standard 
deviation) of the animals in each group, the animals were present in two distinct 
populations within these groups: those with severe lesions and those with partial 
lesions.  These populations were separated for further analysis below.  
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Figure 4.10 – Striatal dopamine content in lesioned animals after 21 days with 
intranasal treatment. 
Striatal dopamine content in the lesioned hemisphere was not significantly higher 
in animals given DNSP-11 compared with vehicle-only and scrambled-peptide 
treated animals (P=0.3727, t-test).  Note the severely lesioned population in both 
the DNSP-11 and Negative Control treated groups below 1000 ng/g DA.  As 
predicted, the lesioned hemispheres of Vehicle only and Scrambled peptide 
treated animals were not significantly different (P=0.4815) and were combined as 
one “Negative Control” group. Dopamine content was also not significantly 
different in the intact hemispheres (P=0.8437, two-tailed t-test). (DNSP-11, n=13; 
Negative Controls: Vehicle-only, n=11, Scrambled n=9.) (One vehicle-only, intact 
hemisphere data point is outside the plot at 35877 ng/g DA and was found to be 
a significant outlier by Grubb’s test.  Displayed as mean ± SEM.) 
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Table 4.7 – Striatal neurochemical content of partially lesioned animals. 
  Treatment One-way 
ANOVA 
Treatment 
Statistics 
  Vehicle Only Scrambled 
Peptide 
DNSP-11 Peptide 
 
Le
si
on
ed
 h
em
is
ph
er
e 
DA 
(ng/g) 
   6198 
± 2539 
   6673 
± 3728 
   10037 
± 4095 
P=0.1354 
DOPAC 
(ng/g) 
 1083 
± 305 
 1350 
± 629 
 1651 
± 488 
P=0.1470 
HVA 
(ng/g) 
   714 
± 236 
   604 
± 411 
   953 
± 419 
P=0.1579 
(HVA+DOPAC)/DA 
 
   0.308 
± 0.073 
   0.284 
± 0.049 
   0.276 
± 0.073 
P=0.6677 
5-HT 
(ng/g) 
   697 
± 174 
   641 
± 132 
   658 
± 132 
P=0.7771 
 
5-HIAA 
(ng/g) 
 1266 
± 251 
 1162 
± 328 
 1287 
± 260 
P=0.6908 
(5-HIAA/5-HT) 
 
   1.91 
± 0.57 
   1.80 
± 0.23 
   1.99 
± 0.40 
P=0.7176 
 
NE 
(ng/g) 
 116 
± 53 
 113 
± 29 
 122 
± 37 
P=0.9237 
 
In
ta
ct
 h
em
is
ph
er
e 
DA 
(ng/g) 
 10090 
± 1913 
   9959 
± 2042 
 1210 
± 1920 
P=0.1311 
DOPAC 
(ng/g) 
 1629 
± 504 
 1644 
± 340 
 1845 
± 321 
P=0.5766 
HVA 
(ng/g) 
   919 
± 163 
   813 
± 175 
   993 
± 136 
P=0.1537 
(HVA+DOPAC)/DA 
 
   0.268 
± 0.060 
   0.253 
± 0.054 
   0.238 
± 0.038 
P=0.6165 
5-HT 
(ng/g) 
   687 
± 185 
   689 
± 139 
   660 
± 108 
P=0.9304 
5-HIAA 
(ng/g) 
 1193 
± 281 
 1134 
± 275 
 1155 
± 237 
P=0.9144 
(5-HIAA/5-HT) 
 
   1.82 
± 0.50 
   1.66 
± 0.27 
   1.77 
± 0.31 
P=0.7156 
 
NE 
(ng/g) 
 146 
± 41 
 161 
± 40 
 143 
± 40 
P=0.6671 
 
 n = 7 7 6 
As predicted, Vehicle only and Scrambled peptide treated animals were not 
significantly different with regards to dopamine (P=0.7905, two-tailed t-test) and 
were combined as one “Negative Controls” group for further analysis below. 
Analysis by one-way ANOVA with Bonferroni’s post hoc.  Values are mean ± SD. 
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Figure 4.11 – Striatal dopamine content in partially lesioned animals after 21 
days with intranasal treatment. 
Among the animals with a partial lesion, those animals treated with intranasal 
DNSP-11 exhibited significantly greater dopamine content in the lesioned 
hemisphere when compared with animals treated with Vehicle only or Scrambled 
peptide (Overall effect of treatment ###P<0.0006, F(3,33)=7.481. Lesioned 
hemispheres *P=0.0343, t(33)=2.679).  The lesioned hemispheres of the DNSP-11 
treated animals was not significantly different than their unlesioned hemispheres 
(P=0.6017, t(33)=0.1448).  Analysis by one-way ANOVA with Bonferroni’s post 
hoc test.  As predicted, the lesioned hemispheres of the Vehicle only and 
Scrambled peptide treated animals were not significantly different (P=0.7905 by 
two-tailed t-test) and were combined as one “Negative Control” group.  The intact 
hemispheres were significantly different between groups (∗P=0.0301 by t-test, 
t(16)=2.022).  Displayed as mean ± SEM. 
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Table 4.8 – Striatal neurochemical content of severely lesioned animals. 
  Treatment One-way 
ANOVA 
Treatment 
Statistics 
  Vehicle Only Scrambled 
Peptide 
DNSP-11 Peptide 
 
Le
si
on
ed
 h
em
is
ph
er
e 
DA 
(ng/g) 
   293 
± 279 
   67 
± 41 
 302 
± 96 
P=0.2939 
DOPAC 
(ng/g) 
 109 
± 84 
   54 
± 26 
 128 
± 70 
P=0.4681 
HVA 
(ng/g) 
   39 
± 60 
   0 
± 0 
   26 
± 28 
P=0.5316 
(HVA+DOPAC)/DA 
 
   0.832 
± 0.602 
   0.835 
± 0.107 
   0.495 
± 0.142 
P=0.2876 
5-HT 
(ng/g) 
   495 
± 124 
   635 
± 104 
   661 
± 151 
P=0.1565 
 
5-HIAA 
(ng/g) 
1102 
±  79 
1217 
±  67 
 1174 
± 124 
P=0.3704 
(5-HIAA/5-HT) 
 
   2.36 
± 0.74 
   1.95 
± 0.42 
   1.84 
± 0.38 
P=0.2958 
 
NE 
(ng/g) 
   18 
± 21 
 19 
± 1 
   42 
± 43 
P=0.4608 
 
In
ta
ct
 h
em
is
ph
er
e 
DA 
(ng/g) 
 11258 
± 1739 
 9118 
± 802 
 10524 
± 2024 
P=0.4085 
DOPAC 
(ng/g) 
 1984 
± 382 
 1406 
± 327 
 1708 
± 488 
P=0.2994 
HVA 
(ng/g) 
   791 
± 236 
 661 
± 22 
   675 
± 192 
P=0.5798 
(HVA+DOPAC)/DA 
 
   0.246 
± 0.028 
   0.226 
± 0.018 
   0.229 
± 0.059 
P=0.7990 
5-HT 
(ng/g) 
 598 
± 81 
607 
±  2 
   692 
± 111 
P=0.2434 
5-HIAA 
(ng/g) 
 1098 
± 120 
1021 
±  89 
 1083 
± 145 
P=0.7835 
(5-HIAA/5-HT) 
 
   1.87 
± 0.41 
   1.68 
± 0.15 
   1.59 
± 0.24 
P=0.3262 
 
NE 
(ng/g) 
 139 
± 27 
 112 
± 24 
 147 
± 34 
P=0.3990 
 
 n = 5 2 7 
As predicted, Vehicle only and Scrambled peptide treated animals were not 
significantly different (P=0.3300, two-tailed t-test) and were combined as one 
“Negative Control” group for further analysis.  Analysis by one-way ANOVA with 
Bonferroni’s post hoc.  Values are mean ± SD.  
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Figure 4.12 – Striatal dopamine content in severely lesioned animals after 21 
days with intranasal treatment. 
The lesioned hemispheres of animals that exhibited a severe lesion of striatal 
dopamine (<1000 ng/g DA, see Figure 4.10) were not significantly different 
between groups (P=0.2427, t-test).  As predicted, Vehicle only and Scrambled 
peptide treated animals were not significantly different (P=0.3300, two-tailed t-
test) and were combined as one “Negative Control” group.  Analysis by one-way 
ANOVA with Bonferroni’s post hoc test.  Displayed as mean ± SEM. 
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Table 4.9 – Animal groups for functional neurochemical study in 6-OHDA 
lesioned animals. 
 Vehicle-only Treated 
Scrambled 
Treated 
DNSP-11 
Treated 
Numbers: 12 10 14 
 
Scrambled and vehicle treated animals were combined into one group for 
analysis due to similarities in response. The DNSP-11 and scrambled treated 
group received 300 µg in 50 µL per treatment of each compound respectively.  
Due to similarities in response (Chapter Three), vehicle-only and scrambled 
peptide treated groups were combined into one “Negative Control” group.  Of the 
DNSP-11 treated animals, one was excluded due to complications during 
microdialysis resulting in premature death and one was excluded due to a bad 
microdialysis probe or poor collection.  Two vehicle treated animals were 
excluded due to a bad microdialysis probes or poor collection.  Two scrambled 
treated animals were excluded due to bad microdialysis probes or poor 
collection.  Three animals not included in the above numbers died due to 
anesthetic complications during the lesion induction surgery: two were in the 
DNSP-11 group and one was in the scrambled treated group. Treatment was 
performed in a blinded manner. 
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Table 4.10 – Neurochemical concentrations of microdialysis collected samples. 
Perfusate 
solution 
and 
Sample # 
Analyte Vehicle Only 
group  
[nM] 
Scrambled 
Peptide group 
[nM] 
DNSP-11 
Peptide group 
[nM] 
aCSF 
Samples 
4 - 6 
(Baseline) 
DA 7.79 ± 4.00 5.61 ± 5.49 4.88 ± 3.32 
 
DOPAC 2360 ± 1276 2052 ± 1447 1328 ± 873 
 
HVA 1504 ± 826 1394 ± 882 1673 ± 2139 
 
100 mM K+ 
Sample 7 
DA    413 
± 189 
   331 
± 283 
   191 
± 184 
 
250 µM  
d-Amp 
Sample 11 
DA    335 
± 163 
   408 
± 230 
   288 
± 200 
 
Neurochemical concentrations collected during microdialysis were significantly 
affected by treatment with DNSP-11.  Significantly lower potassium (K+) evoked 
release of dopamine was observed in animals treated intranasally with DNSP-11 
daily for three weeks following 6-OHDA lesion induction of the substantia nigra 
compared with negative control treated animals.  The overall effect of treatment 
on dopamine was significant (#P=0.0184, F(2,436)=5.073), the effect of treatment 
on 100 mM K+ evoked DA was significant (****P<0.0001, t(436)=6.838 with 
respect to vehicle; $$$P=0.0001, t(436)=4.149 with respect to scrambled). Effect of 
treatment on 250 µM d-Amp evoked DA was significant ($$P=0.0026, t(436)=3.334 
with respect to scrambled).  Overall effect of treatment on DOPAC was 
significant (####P<0.0001), but no significant difference in baseline, K+ evoked, or 
d-amp evoked DOPAC levels were observed.  Overall effect of treatment on HVA 
was not significant (P=0.4251).  As predicted, no significant difference in 
dopamine was observed between scrambled and vehicle treated groups (overall 
effect of treatment: P=0.7244). Analysis by two-way ANOVA with Bonferroni’s 
post hoc test.  Values shown are “mean nM of analyte ± SD.” 
**** $$$ 
$$ 
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Figure 4.13 – Functional release of dopamine collected by microdialysis in the 
striatum of lesioned animals. 
Significantly lower potassium (K+) evoked release of dopamine was observed in 
animals treated intranasally with DNSP-11 daily for three weeks following 6-
OHDA lesion induction of the substantia nigra compared with negative control 
treated animals. No changes in baseline dopamine release were observed. 
(#Treatment P=0.0184, F(2,436)=5.073. ****K+ P<0.0001, t(436)=6.838 with 
respect to Vehicle, $$$K+ P=0.0001, t(436)=4.149 with respect to Scrambled. 
$$d-amp P=0.0026, t(436)=3.334 with respect to Scrambled.)  DNSP-11 group, 
n=12. Negative controls: vehicle-only treated, n=10; scrambled-sequence treated 
n=8. Analysis by two-way ANOVA with Bonferroni’s post hoc test.  These 
observed effects were driven by severely lesioned animals of striatal dopamine 
(<1000 ng/g DA striatal tissue content, see Figure 4.10).  In animals with only a 
partial lesion, no significant differences between groups were observed with 
regards to striatal microdialysis (see Figure 4.15).  Data points are mean nM ± 
SEM.  
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Figure 4.14 – Baseline dopamine release and metabolites in the lesioned 
striatum collected by microdialysis. 
Baseline levels of dopamine and its metabolites, as determined by microdialysis, 
were not significantly different between groups.  For each data point, the levels of 
each compound were averaged over the fourth through sixth samples.  
Dopamine P=0.1926, t(27)=1.336; DOPAC P=0.0552, t(27)=2.004; HVA P=0.2841, 
t(26)=1.094.  (DNSP-11, n=12. Negative controls: vehicle-only treated, n=10, 
scrambled-sequence treated n=8.)  The HVA concentration from one animal (at 
8088 nM) was found to be a significant outlier by Grubb’s test and was removed.  
Analyses by two-tailed t-test.  Displayed as mean ± SEM. 
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Figure 4.15 – Functional release of dopamine collected by microdialysis in the 
striatum of animals that exhibited a partial lesion. 
Of the animals that exhibited only a partial lesion of the striatum, as defined in by 
a striatal dopamine content of under 1000 ng/g (see Figure 4.10), there was no 
statistically significant difference of functional dopamine release between groups 
(P=0.9929 with respect to overall treatment effect).  DNSP-11 group, n=4. 
Negative controls: vehicle-only treated, n=6; scrambled-sequence treated n=7.  
Analysis by repeated measures two-way ANOVA with Bonferroni’s post hoc test. 
Data points are mean nM ± SEM. 
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Figure 4.16 – Acute effects of DNSP-11 during microdialysis infusion on 
dopamine overflow. 
Naïve 3 month old Fischer 344 male rats were challenged with a 100 mM K+ 
aCSF solution and allowed to time to return to baseline.  After infusion with 
DNSP-11 during samples 10-14, K+ evoked release of dopamine was decreased 
by 40.8% from previous K+ evoked release (Figure 4.16A: F(1,4)=2.112 ****K+, 
P<0.0001, t(72)=5.780. n=4 aCSF, n=2 DNSP-11. Analysis by two-way repeated 
measures ANOVA with Bonferroni’s post hoc test; Figure 4.16B: **P=0.0014, 
t(6)=5.620. 37.1% decrease, n=4 aCSF, n=4 DNSP-11 perfused.Analysis by two-
tailed t-test).  No differences between groups were observed in baseline 
dopamine.  Of four DNSP-11 perfused animals, two were excluded from (A) due 
to undetectable baseline concentrations of dopamine. Data points are mean nM 
± SEM.
A B 
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Figure 4.17 – Acute effects of DNSP-11 during microdialysis infusion on DOPAC 
overflow. 
No significant differences were observed in DOPAC overflow with acute 
microdialysis infusion. (P=0.8256.  Analysis by two-way repeated measures 
ANOVA with Bonferroni’s post hoc test; n=4 Controls, n=2 DNSP-11. Of four 
DNSP-11 perfused animals, two were excluded due to undetectable baseline 
concentrations of dopamine. Data points are mean nM ± SEM.) 
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Figure 4.18 – Acute effects of DNSP-11 during microdialysis infusion of HVA 
overflow. 
No significant differences were observed in HVA overflow with acute 
microdialysis infusion. (P=0.4906.  Analysis by two-way repeated measures 
ANOVA with Bonferroni’s post hoc test; n=4 Controls, n=2 DNSP-11. Of four 
DNSP-11 perfused animals, two were excluded due to undetectable baseline 
concentrations of dopamine. Data points are mean nM ± SEM.) 
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Chapter Five:  A study of the behavioral and physiological effects of 
intranasally administered DNSP-11 in a 6-hydroxydopamine lesion model of 
the substantia nigra 
 
Hypothesis: Efficacious doses of DNSP-11 can be delivered intranasally to enter 
the CNS in quantities sufficient to prevent the development of apomorphine-
induced rotation behavior from a moderate 6-hydroxydopamine lesion of the 
substantia nigra. 
 
Introduction 
Behavioral metrics are the ultimate measure in the study of interventions 
for neurological disorders, especially in a neurodegenerative disease primarily 
concerning motor function such as Parkinson’s disease.  The complexity of the 
neurological pathways can mean that molecular measures such as the presence 
of tyrosine hydroxylase or dopamine may not indicate a symptomatic relief in the 
organism.  Feedback circuitry, compensatory sensitization, secondary pathways, 
and molecular regulators may all stymie the translation of molecular measures to 
the ultimate amelioration of motor-output.  As such, neuroscience has often relied 
on behavioral measures.  The well-characterized unilateral 6-OHDA lesion model 
of parkinsonism in rodents provides an excellent foundation for the quantification 
of a variety of behavioral functions (Woodlee and Schallert, 2004; Ciucci et al., 
2008; Fleming et al., 2012).  One behavioral metric of particular importance is 
drug-induced rotation behavior in the unilateral 6-OHDA lesion model used in the 
present studies. 
The hypothesis that DNSP-11 will prevent the development of 
apomorphine-induced rotation behavior was tested in all animals in this study 
that were subjected to a unilateral 6-OHDA lesion (n=42).  Animals were 
assessed weekly for apomorphine-induced rotation behavior according to the 
study timeline (Figure 2.3).  Animals were weighed daily; and body temperature 
and activity level was recorded continuously using an implanted “MiniMitter” 
device (Chapter Two). 
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Drug-induced rotation behavior in unilateral lesion models of 
parkinsonism 
Ungerstedt and Arbuthnott first characterized rotation behavior as a 
method for quantifying nigrostriatal pathway function in rodents in 1970, and they 
hypothesized that rotation behavior would result from an imbalance between the 
pathways of the two hemispheres (Ungerstedt and Arbuthnott, 1970).  This 
asymmetry was validated in 1988 when Sonsalla, et al demonstrated changes in 
dopamine receptor function in rotating animals with an induced lesion (Sonsalla 
et al., 1988).   
Two drugs are used to induce rotation behavior in rodent models of 
Parkinson’s disease: apomorphine and d-amphetamine, and they have different 
modes of action, producing rotations in different directions relative to the lesion.  
Apomorphine has been shown to induce rotation behavior when lesion severity in 
the substantia nigra is greater than 90% cell loss, providing a relatively high-
fidelity, “binary” measure of animals with severe loss in the nigrostriatal pathway 
(Hudson et al., 1993) stabilizing by the 4th week.  The mechanism of action of 
apomorphine is due to its role as a dopamine receptor agonist.  In a highly 
denervated striatum a compensatory phenomenon referred to as “dopamine 
receptor super-sensitization” results in a high rate of activation of the striatum 
ipsilateral to the lesioned substantia nigra by dopamine analogues such as 
apomorphine (Kostrzewa, 1995).  This results in rotation behavior toward the 
contralateral hemisphere.  In other words, the animal rotates “away from” the 
lesion, or the circle formed by the animal’s rotations places the unlesioned 
hemisphere closest to the center.  d-Amphetamine causes the net efflux of 
intracellular dopamine into the extracellular space (see Chapter Four).  As such, 
amphetamine asymmetrically activates the unlesioned, innervated hemisphere, 
producing rotations in the ipsilateral direction, “toward” the lesion, thereby placing 
the lesioned hemisphere closer to the center of the rotation’s circle.  
Amphetamine’s mechanism of action also produces a relatively gradual increase 
in rotations as the nigrostriatal pathways become less symmetrical as the lesion 
becomes progressively worse (Hudson et al., 1993).  In these studies, 
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apomorphine based rotations were used, primarily to minimize variability in the 
behavioral measure.  It has been shown that a portion of normal, unlesioned rats 
can elicit rotation behavior after d-amphetamine administration (Hudson et al., 
1993).  In order to reduce the possibility of false negatives of DNSP-11 treatment 
effect, apomorphine was used. 
Total activity levels and body temperature as a sign of general health 
Efficacy of a compound is not the only important metric when evaluating a 
drug for ultimate translation to human subjects.  The safety of a drug on the 
organism is also of importance.  As such, the use of the MiniMitter device 
(described in Chapter Two) allowed the continual recording of body temperature 
and activity levels, providing indicators of the overall health of the animals in 
these trials.  The monitoring of body temperature provided a surrogate measure 
of inflammatory response to the nasal administration of the test subject, and 
overall activity levels similarly provided information regarding any overall 
neurophysiological effect the test subject may have on the animal both in the 
short- and long-term.  In conjunction with measurements of body-weight, these 
studies provide insight into the overall health of the animals and their reactions to 
the treatment regimen relative to the control treated groups. 
Materials and Methods 
Semi-quantitative, subjective behavior observations in unlesioned 
animals 
Animals were observed for the five minute period immediately following 
righting as a sign of recovery from the isoflurane anesthetic session.  The extent 
of their activity was recorded on a scale ranging from 0, no movement after 
righting from the supine position, to 5, constant movement after righting.  For 
instance, a score of “3” would indicate the animal was moving throughout the 
cage for approximately 3 of the 5 observed minutes.  These observations were 
only recorded in unlesioned animals in the dose-response study, and were done 
so by a researcher blind to the treatment groups. 
108 
 
Rotation behavior procedure 
To confirm that these effects correlate with the prevention of transition to 
the rotation behavior phenotype present in animals challenged with a unilateral 6-
OHDA lesion, all animals in the study (n=42) were tested every seventh day for 
apomorphine-induced rotation behavior, quantified by an automated rotometer 
system.  Animals were administered apomorphine (0.05 mg/kg, s.c.) and tests 
carried out in rotometer bowls with automated unbiased rotation measurement  
utilizing a thoracic harness connected to a counting head that interfaces with 
computer software (SDI Rotation, San Diego, CA USA) (Hudson et al., 1993; 
Hoffer et al., 1994).  The numbers of contralateral and ipsilateral rotations (in 
relation to 6-OHDA lesion hemisphere) were recorded for 2 hours in 5 minute 
intervals.  Rotation behavior was collected the day prior to 6-OHDA lesion 
induction and weekly thereafter until euthanasia (Figure 2.3).  Total ipsilateral 
rotations for the first 60 minutes of testing was subtracted from total contralateral 
rotations for the first 60 minutes of testing and that number used in analysis.  No 
animals were excluded from this study.  The rotometer bowls were cleaned with 
disinfectant prior to use. 
MiniMitter recording of activity and body temperature 
MiniMitter E-Mitter probe was surgically implanted subcutaneously in the 
back concurrently with 6-OHDA lesion induction surgery, as described in Chapter 
2.  The animal’s activity and body temperature was recorded at one minute 
intervals until the end of the experimental timeline.  These values were averaged 
over the 12 hour long day (light) and night (dark) cycles and compared across 
groups.  Additionally, the total activity for the 5 minutes following recovery from 
the anesthetic session used for daily intranasal dosing was summed and 
compared across groups. 
Body weight measurements 
The animals’ body weights were measured daily through the entirety of the 
study, beginning the day prior to lesion induction and concluding on the day of 
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endpoint analysis.  If the animal underwent anesthesia on a specified day, body 
weight was measured while the animal was anesthetized. 
Results 
Animal health and comfort 
Animals tolerated the treatment and daily anesthesic sessions well.  They 
did not exhibit signs of distress or discomfort.  All animals exhibited a smooth, 
well groomed coat, and none displayed signs of agitation, guarding, or audible 
vocalization.  There were no signs of nasal irritation such as edema or erythema. 
Drug-induced rotation behavior 
Animals challenged with a 6-OHDA lesion were tested weekly for 
apomorphine (0.05 mg/kg, s.c.) induced rotation behavior, beginning with 
baseline rotation the day prior to lesioning (day -1).  Rotations, both contralateral 
and ipsilateral to the lesioned hemisphere, were quantified by an automated 
rotometer system (SDI Rotation, San Diego, CA USA).  As predicted, Vehicle 
Only and Scrambled Peptide treated animals was not significant (Table 5.1, 
P=0.4201) and were combined in to one negative control group for further 
analysis.   A small set of animals began to exhibit rotation behavior during the 
second week (day 13), but during the third week (day 20) this level rose to 
significance.  Animals treated intranasally with DNSP-11 showed mean 
contralateral rotations of 0.25 (± 2.0, n=16), compared with animals treated with 
scrambled peptide or vehicle-only that exhibited a combined mean of 89.9 (± 
35.5, n=26), resulting in significance (Figure 5.1).  Furthermore, none of the 
animals treated intranasally with DNSP-11 exhibited rotation behavior at any 
timepoint during the study, either from the histological (Figure 5.2) or 
neurochemical (Figure 5.3) cohorts.  The control treated animals were present in 
two populations, those that exhibited rotation behavior (≥50  rotations/hour, n=7, 
range of 88 to 669 rotations), and those that did not rotate (<50 rotations/hour , 
n=19, range of -23 to 38 rotations).   
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Subjective behavior 
Of the unlesioned animals in the dose response study, animals treated 
daily with 1000 µg of DNSP-11 exhibited elevated mean subjective activity 
(Figure 5.4) or daily levels of subjective activity (Figure 5.5) immediately following 
intranasal treatment when contrasted with vehicle-only treated animals.  
Expository notes also suggest the 300 µg per day DNSP-11 treated animals were 
more active.  The animals given 1000 µg of DNSP-11 per day exhibited a mean 
daily post-treatment activity level of 2.9 ± 0.31 with a range of 2.5 to 3.4, 
compared with 1.8 ± 0.46 with a range of 1.4 to 2.6 for the saline-only treated 
animals (P<0.01, Figure 5.4), on a subjective scale of 0 to 5, with 5 being the 
most active and 0 being not active.  The animals given 1000 µg of DNSP-11 per 
day were significantly more active during the first and second week of treatment, 
but by the third week their activity levels had decreased in line with vehicle only 
treated animals (Figure 5.5).   
MiniMitter activity levels and body temperature 
There was no observed significant difference between groups of the 6-
OHDA lesioned animals in the measure of mean post-treatment activity (Figure 
5.6), nor did it show a significant difference in daily post-treatment activity (Figure 
5.7).  In addition, there was no difference between groups in mean or daily day-
time or night-time activity levels (Figure 5.8 through Figure 5.11) or body 
temperature (Figure 5.12 through Figure 5.15). 
Body weight 
Body weight was not significantly different between the DNSP-11 or 
negative control treated groups (Figure 5.16). 
Discussion 
These results support the hypothesis that intranasal DNSP-11 treatment 
would prevent the development of apomorphine-induced rotation behavior in 6-
hydroxydopamine lesioned rats.  Furthermore, the animals treated with DNSP-11 
did not show signs of distress, discomfort or nasal irritation.  Neither their activity 
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levels nor body weight were negatively impacted by DNSP-11 treated, providing 
some broad data on the safety of intranasal DNSP-11 treatment. 
Subjective behavior and activity 
None of the animals in the study exhibited signs of distress or 
discomforting, including edema or erythema of the nasal region, suggesting the 
treatment itself did not produce irritation.  The animals did not display guarding or 
unusual vocalization, suggesting the treatment regimen was well tolerated. 
Among the unlesioned animals in the dose-response study, those treated 
with DNSP-11 exhibited higher levels of subjective activity immediately following 
intranasal treatment, subjectively recorded by a researcher blind to the treatment 
groups.  This could suggest an acute and direct neuropsychological effect of 
DNSP-11 on the motor system, or olfactory stimulation leading to normal 
searching behavior.  To attempt to control for this and the observed 
neurochemical changes, later studies included a scrambled version of the DNSP-
11 peptide sequence (Table 2.1) as a negative control. 
Apomorphine-induced rotation behavior 
While apomorphine induced rotation behavior stabilizes by the 4th week 
after lesion, this study only evaluated rotation behavior to the 3 week timepoint. 
At that time point, a significant difference arose between those treated 
intranasally with DNSP-11 or with negative controls (Figure 5.1).  None of the 
DNSP-11 treated animals exhibited rotation behavior, indicating DNSP-11 may 
be able to prevent the progression of super-sensitization caused by striatal 
denervation within the 3 weeks observed in this study.  The negative control 
treated animals were present in two populations: those that did exhibit rotation 
behavior (88 to 669 rotations, n=7), and those that did not rotate (negative 23 to 
38 rotations, n=19), defined as <50 rotations per hour (Hudson et al., 1993), due 
to lesion variability.  All of the animals that exhibited rotation behavior were 
among the severely lesioned subgroup of animals  as defined by striatal 
dopamine content of <1000 ng/g (see Figure 4.10).  This behavior data supports 
the histological protection observed while suggesting that longer-term studies in 
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the 4 to 6 week time period may provide stronger efficacy data regarding the 
potential of intranasal DNSP-11 for protection against dopaminergic loss and the 
behavioral consequences.  In addition, the use of d-amphetamine induced 
rotation behavior, after pre-screening against animals that rotate prior to 
lesioning, may identify significant results at earlier time points. 
MiniMitter activity levels and body temperature 
MiniMitter data did not reveal any differences between treatment groups 
with regard to post-treatment activity (Figure 5.6 and Figure 5.7) average daytime 
or nighttime activity levels or body temperature (Figure 5.8 through Figure 5.15).   
The objective MiniMitter activity data does not mirror the subjective, 
blinded activity data.  This disparity may be due to a number of reasons.  The 
MiniMitter device, implanted in the back of the animal, may have emphasized 
activities that the subjective observer disregarded, such as shaking, shivering, or 
grooming behavior, resulting in relatively higher “noise” in the MiniMitter data.  
The animals implanted with the MiniMitter device were also challenged with a 6-
OHDA lesion of the substantia nigra while the subjectively observed animals 
were unlesioned, possibly altering this subjectively observed effect. 
Animals treated with DNSP-11 did not exhibit elevated body temperature 
values compared with saline or scrambled-peptide treated controls.  This may 
indicate that the peptide does not produce an inflammatory response that could 
be detected by the MiniMitter device, providing some broad and preliminary data 
on the safety of the DNSP-11 peptide when delivered intranasally. 
A further element of the MiniMitter studies was to determine if their use 
would equate to open-field testing and the Actical (Philips Respironics, Bend, OR 
USA) monitoring devices used in human and non-human primate studies of 
Parkinson’s disease and its models.  Significant differences between groups in 
this study were not observed, however unlesioned animals were not tested with 
the MiniMitter system providing no basis for comparison against normal rodents.  
Average activity over the 12 hour light or dark periods did not indicate significant 
differences in activity, but these values are during an extended length of time and 
are not similar to one hour open-field behavior testing.  The total activity 
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immediately after intranasal administration was not significantly different between 
groups.  Testing the device in normal unlesioned animals for comparison and 
using the device for before/after treatment measurements may allow for the 
discernment of effects elicited by treatments and the 6-OHDA lesion model. 
Body weight 
Subject body weight can be an indicator of the overall health and speed of 
recovery in animal studies.  The fact that the animals in this study exhibited 
statistically similar body weights throughout the experiment (Figure 5.16) may be 
an important finding.  A side-effect of GDNF treatment is weight loss (Hovland et 
al., 2007a).  Although the timeframes and means of delivery are different 
between the cited study and the present data, the present study suggests DNSP-
11 does not produce significant weight loss as a side effect.  This provides some 
important safety information regarding the repeated use of DNSP-11. 
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Table 5.1 – Number of apomorphine-induced turns per hour in control and 
DNSP-11 treated animals 
Group Day -1 Day 6 Day 13 Day 20 n= 
Vehicle 
Only Group 
   2.714 
± 7.819 
     3.429 
± 11.581 
      8.500 
±  21.533 
     69.214 
± 179.436 
14 
Scrambled 
Peptide 
   1.167 
± 5.606 
     3.500 
± 10.318 
   33.000 
± 63.356 
   114.083 
± 187.615 
12 
DNSP-11 
Peptide 
  -0.438 
± 6.750 
     6.750 
± 12.902 
    -1.063 
± 10.299 
   0.250 
± 8.153 
16 
 
None of the animals treated with intranasal DNSP-11 exhibited rotation behavior 
at any time point.  On day 13, one animal in the Vehicle Only group and two 
animals in the Scrambled Peptide group exhibited rotation behavior, defined as 
>50 turns per hour (Hudson et al., 1993).  By the 20th day after 6-OHDA lesion 
induction, three Vehicle Only and four Scrambled Peptide treated animals 
exhibited rotation behavior.  This resulted in a significant difference between 
control and DNSP-11 treatment groups (overall effect of treatment P=0.0782, 
F(2,39)=2.722. *P=0.0248, t(156)=2.530 with respect to Vehicle, and $$$P=0.0002, 
t(156)=4.003 with respect to Scrambled).  As predicted, the overall effect of 
treatment between the Vehicle Only and Scrambled Peptide treated animals was 
not significant (P=0.4201, F(1,24)=0.6730) at any time point (Day -1 through Day 
13: P>0.9999, Day 20: P=0.9246).  No animals were excluded from this analysis.  
Data displayed as “mean rotations per hour ± standard deviation”.  Analysis 
performed by two-way repeated measures ANOVA with Bonferroni’s post hoc 
test. 
 
$$$ * 
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Figure 5.1 – Rotation behavior in negative control and DNSP-11 treated lesioned 
animals. 
Animals treated with DNSP-11 intranasally exhibited no abnormal rotation 
behavior on the 20th day after 6-OHDA lesioning of the substantia nigra, 
contrasted with negative control treated animals.  As predicted, vehicle and 
scrambled peptide treated animals did not exhibit a significant difference in effect 
(P=0.4201).  (Overall effect of treatment P=0.0782. *P=0.0248 with respect to 
Vehicle, and $$$P=0.0002 with respect to Scrambled.  Vehicle treated, n=14; 
Scrambled peptide treated, n=12; DNSP-11 treated, n=16.)  No animals were 
excluded from this analysis.  Data displayed as “mean rotations per hour ± SEM”.  
Analysis by two-way repeated measures ANOVA with Bonferroni’s post hoc. 
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Figure 5.2 – Individual rotation behavior of the histological cohort. 
Of animals in the histology cohort, none of the animals treated with DNSP-11 
exhibited apomorphine-induced rotation behavior on day 20. 
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Figure 5.3  -- Individual rotation behavior of the neurochemistry cohort. 
Of animals in the neurochemistry cohort, none of the animals treated with DNSP-
11 exhibited apomorphine-induced rotation behavior on day 20. 
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Figure 5.4 – Average subjective activity levels recorded by observer blind to 
treatment immediately following intranasal administration. 
Average subjective activity levels immediately following intranasal administration 
were significantly different in the group of animals administered 1000 µg per day 
of DNSP-11 for three weeks (##P=0.0038 overall; **1000 µg P<0.01).  Activity 
levels in the 300 µg daily dose cohort were not recorded, but expository notes 
suggest elevated activity compared to the concomitantly treated 0 µg animals.  
Subjective behavior was assessed by a research blind to treatment. (n=6 animals 
per group. Analysis by one-way ANOVA with Bonferroni’s post hoc.  Shown as 
mean ± SEM.) 
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Figure 5.5 – Daily subjective activity levels recorded by observer blind to 
treatment immediately following intranasal administration. 
Animals given 1000 µg of DNSP-11 intranasally began the treatment regimen 
with significantly elevated subjective activity levels, especially on day 2; and 
these activity levels decreased as the treatment progressed to the final week.  
Vehicle-only treated animals exhibited significantly lower activity levels, and that 
subjective activity level remained low throughout the treatment.  The 100 µg 
treated animals were not significantly different from saline vehicle only treated 
animals. Subjective behavior was assessed by a research blind to treatment. 
(##P=0.0043 overall; ****Day 2 activity levels, P<0.0001 between 1000 µg and 0 
µg vehicle-only treated groups. **Day 8 and 9, P<0.01 between 1000 µg and 0 
µg groups. Analysis by repeated measures two-way ANOVA with Bonferroni’s 
post hoc.  Shown as mean ± SEM.) 
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Figure 5.6 – Average post-treatment activity levels recorded by MiniMitter. 
The animals’ activity levels for the five minutes immediately following recovery 
from isoflurane anesthetic used during the intranasal treatment session shows no 
significant differences between negative control or DNSP-11 treated animals 
(P=0.7168 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 n=10. Analysis by 
one-way ANOVA with Bonferroni’s post hoc test. Shown as mean ± SEM). 
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Figure 5.7 – Daily post-treatment activity levels recorded by MiniMitter. 
The animals’ activity levels for the five minutes immediately following recovery 
from isoflurane anesthetic used during the intranasal treatment session shows no 
significant differences between negative control or DNSP-11 treated animals 
(P=0.6466 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 n=10.  Analysis by 
repeated measures two-way ANOVA with Bonferroni’s post hoc test. Shown as 
mean ± SEM). 
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Figure 5.8 – Average daytime activity levels recorded by MiniMitter. 
The 12-hour “light” period activity levels in the animals were not significantly 
different between groups (P=0.5398 overall; Vehicle, n=8; Scrambled, n=6; 
DNSP-11 n=10. Analysis by one-way ANOVA with Bonferroni’s post hoc test. 
Shown as mean ± SEM). 
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Figure 5.9 – Daily daytime activity levels in animals as recorded by MiniMitter. 
Daily daytime “light” activity levels were not significantly different between groups 
(P=0.5414 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 n=10. Analysis by 
repeated measures two-way ANOVA with Bonferroni’s post hoc test. Shown as 
mean ± SEM).  Note that Days 5, 12 and 19 the animals were off-treatment and 
only body weight measurements were taken. 
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Figure 5.10 – Average nighttime activity levels recorded by MiniMitter. 
The 12-hour “dark” period activity levels in the animals were not significantly 
different between groups (P=0.0973 overall; Vehicle, n=8; Scrambled, n=6; 
DNSP-11 n=10. Analysis by one-way ANOVA with Bonferroni’s post hoc test. 
Shown as mean ± SEM). 
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Figure 5.11 – Daily nighttime activity levels recorded by MiniMitter. 
Daily nighttime “dark” activity levels were not significantly different between 
groups (P=0.0927 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 n=10. 
Analysis by repeated measures two-way ANOVA with Bonferroni’s post hoc test. 
Shown as mean ± SEM). 
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Figure 5.12 – Average daytime body temperature recorded by MiniMitter. 
The 12-hour “light” period body temperature in the animals was not significantly 
different between groups (P=0.1449 overall; Vehicle, n=8; Scrambled, n=6; 
DNSP-11 n=10. Analysis by one-way ANOVA with Bonferroni’s post hoc test. 
Shown as mean ± SEM). 
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Figure 5.13 – Daily daytime body temperature recorded by MiniMitter. 
Daily daytime light-period body temperature was not significantly different 
between groups (P=0.1456 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 
n=10. Analysis by repeated measures two-way ANOVA with Bonferroni’s post 
hoc test. Shown as mean ± SEM). 
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Figure 5.14 – Average nighttime body temperature recorded by MiniMitter. 
The 12-hour night-period body temperature in the animals was not significantly 
different between groups (P=0.2454 overall; Vehicle, n=8; Scrambled, n=6; 
DNSP-11 n=10. Analysis by one-way ANOVA with Bonferroni’s post hoc test. 
Shown as mean ± SEM). 
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Figure 5.15 – Daily nighttime body temperature recorded by MiniMitter. 
Daily nighttime dark-period body temperature was not significantly different 
between groups (P=0.2454 overall; Vehicle, n=8; Scrambled, n=6; DNSP-11 
n=10.  Analysis by repeated measures repeated measures two-way ANOVA with 
Bonferroni’s post hoc test. Shown as mean ± SEM). 
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Figure 5.16 – Daily animal body weight post-lesion. 
Animals were weighed daily before and after lesion induction no significant 
difference between groups was observed (P=0.2225 overall, n=42.  Negative 
Controls, n=14 vehicle and 12 scrambled treated; DNSP-11 (300 µg), n=16. 
Analysis by repeated measures two-way ANOVA with Bonferroni’s post hoc test. 
Shown as mean ± SEM). 
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Chapter Six:  An immunohistochemical study of the endogenous DNSP-11 
sequence in the rat brain 
 
Hypothesis: The DNSP-11 sequence is endogenously present in the rat brain as 
a peptide that has differential patterns of spatial and temporal localization from 
that of mature glia cell line-derived neurotrophic factor (GDNF). 
 
Introduction 
The dopamine neuron stimulating peptide-11 (DNSP-11) peptide was 
identified as a theoretical cleavage product from the prosequence of GDNF, and 
we and others have shown that the sequence is biologically active in the present 
study and in the literature, both in vitro and in vivo (Immonen et al., 2008; Bradley 
et al., 2010; Kelps et al., 2011), but questions remain regarding its endogenous 
cleavage and localization in the brain.  Lending further support to a biological role 
for DNSP-11, the peptide sequence shares homology across species: homo 
sapiens and macaca mulatta share 100% homology, and homo sapiens shares 
73% homology with both mus musculus and rattus norvegicus (P1L, P2L, R9H).  
Furthermore, DNSP-11 immunoreactivity has been observed to colocalize with 
TH+ cells of the substantia nigra in the post-natal day 10 rat brain (Bradley et al., 
2010).  While DNSP-11 and GDNF are likely co-expressed and processed, their 
target cell populations and trafficking may be quite different.   
Roles of pro-protein and signal peptides in the CNS 
Putative peptides have been identified in the pro-region of other 
neurotrophic factors expressed in the CNS.  These peptides are, like DNSP-11, 
flanked by dibasic amino acids that are purported to be cleavage sites.  Two of 
the most studied pro-region peptides are located within the proNGF protein, 
referred to as LIP1 and LIP2, and have defined biological activities through 
specific signaling cascades (Clos and Dicou, 1997; Dicou et al., 1997; Dicou, 
2006), and their endogenous identification has been linked to conditions of aging 
(Dicou, 2008). 
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Pro-forms of other proteins have differential effects and distinct binding 
from their mature forms.  A well studied example of this is brain-derived 
neurotrophic factor (BDNF), which can bind to either p75NTR or the Trk-family of 
receptors, if it is secreted as proBDNF or mature BDNF (Buttigieg et al., 2007).  
Many members of the TGFβ family of proteins can be secreted as pro-proteins, 
especially the bone morphogenetic proteins (BMPs), and this affects the 
targeting of the protein (Gregory et al., 2005).  The GDNF protein is a member of 
the TGFβ family of proteins and its pro-region contains the DNSP-11 sequence 
flanked by consensus sites for cleavage by prohormone convertase (K26R27 
and H/R40R41R42).  Based on these consensus sites and the evidence of 
biological effects of DNSP-11, it is reasonable to suggest that the DNSP-11 
sequence is endogenously processed and has a native function.  Similar to other 
proteins, many possibilities exist for the proGDNF molecule: a) the DNSP-11 
sequence itself may be cleaved to form a bioactive peptide in its own right, b) the 
proGDNF protein may be secreted whole with the DNSP-11 sequence 
representing the smallest necessary binding sequence, c) the whole pro-region 
may be cleaved as a signal peptide containing the active DNSP-11 sequence, or 
d) any combination of cleavage patterns may produce a biologically active 
derivative of proGDNF.  Of note, the consensus site for cleavage contains minor 
differences between rats (H40) and humans (R40), possibly resulting in a 
difference in processing between species (Duckert et al., 2004).  Based on the 
wide array of effects elicited by the DNSP-11 sequence both in animal models 
and a range of cell culture lines (Bradley et al., 2010; Turchan-Cholewo et al., 
2010; Kelps et al., 2011; Bradley et al., 2012), it seems possible that the 
conserved DNSP-11 sequence acts as a natural ligand for a receptor, perhaps 
involved in metabolic homeostasis and developmental cell sparing. 
Homologous sequences in the CNS 
Neuropeptide Y (NPY) is a 36 amino acid peptide that shares five 
consecutive amino acids beginning with amino acid 12 (NPY sequence: 
YPSKPDNPGE DAPAEDMARY YSALRHYINL ITRQRY; compared to the 
DNSP-11 sequence: PPEAPAEDRSL.  For full proGDNF precursor, see Figure 
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1.6).  This five amino acid sequence homologue is found in the rat and human 
CNS, as determined by protein BLAST in silico analysis (Altschul et al., 1997).  
NPY is typically observed in the hypothalamus, amygdala and cortex, with little to 
no immunoreactivity detected in the midbrain (Dawbarn et al., 1984; de Quidt and 
Emson, 1986b) nor in tyrosine hydroxylase positive neurons (Everitt et al., 1984).   
In addition to NPY, there also exists an approximately 42.9 kDa protein 
referred to as the TRK-Fused Gene product (Tfg) which contains a homologous 
sequence to DNSP-11 (Tfg amino acids 194-206 sequence: PPSAPTEDRSG, 
DNSP-11 sequence: PPEAPAEDRSL) and which is also expressed in the rat 
brain (Maebayashi et al., 2012). Tfg immunoreactivity in the CNS is prevalent in 
regions including the mesencephalic nucleus of the trigeminal nerve and dorsal 
raphe nucleus, as well as the cytoplasm of Purkinje cells of the cerebellum and 
vestibular and cochlear nuclei of the pons. 
The use of expression patterns to target DNSP-11 for increased 
efficacy and decreased off-target effects 
While the endogenous developmental and maintenance roles of DNSP-11 
are interesting in their own right, the localization of DNSP-11 within the CNS may 
provide insight into its effectiveness as an exogenously applied therapy.  Any 
observed anatomical localization of an endogenous, or exogenously applied, 
DNSP-11 signal may indicate a reactive cell population, possibly utilizing unique 
receptors and signaling cascades.  This information can provide insights into the 
possible functions of DNSP-11 and may help explain potential effects of 
exogenously administered DNSP-11.  With this information, modifications to the 
peptide sequence, delivery approach or formulation may help increase on-target 
effects while minimizing side effects.   
Materials and Methods 
Animals 
A combination of both young adult and post-natal day 10 Fischer 344 rats 
naïve to treatment were euthanized and processed for immunohistochemical 
visualization of brain tissue.  A total of 9 young adult (3 to 6 month old) male rats 
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were euthanized and their brains sectioned either sagittally (n=6) or coronally 
(n=3) for anatomical localization of signal.  Post-natal day 10 animals (n=4) of 
undetermined sex and one young adult female rat sectioned sagittally (n=1) were 
also used. 
Equipment and Reagents 
The immunoprecipitation kit by Life Sciences (Cat. No. 143.21D, 
Invitrogen, Oslo, Norway) was used.  A custom DNSP-11 polyclonal antibody 
(see below) was used for immunohistochemistry, immunoprecipitation, and 
ELISA. Tyrosine hydroxylase antibody was purchased from Millipore Chemicon 
(MAB318, Millipore Chemicon, Temecula, CA).  GDNF antibody was purchased 
from R&D Systems (AF-212-NA, R&D Systems, Minneapolis, MN).  Secondary 
antibodies include peroxidase-conjugated anti-rabbit IgG (PI-1000, Vector 
Laboratories, Burlingame, CA), Alexafluor anti-goat 568 and Alexafluor anti-rabbit 
488 fluorescent (Life Sci. Invitrogen Molecular Probes).  VectaShield H-1400 
Hard-Set Mounting medium for coverslipping dual-fluorescent specimens was 
used (Vector Laboratories, Burlingame, CA).  Fluorescent images acquired on a 
Nikon microscope.  Refrigerators and freezers were continuously monitored for 
temperature variations.  Other reagents were purchased from Fisher Scientific 
unless otherwise specified. 
Custom antibody to DNSP-11 
The custom polyclonal antibody to DNSP-11 (PPEAEPDRSL-NH2) used in 
these experiments was obtained under contract from α-Diagnostics laboratory, 
was raised in rabbit and affinity purified against the synthesized, amidated 
DNSP-11 peptide in a CN-Br activated agarose matrix and eluted in 0.1M 
glycine-HCl and neutralized to pH 8.0 with 1M Tris and 0.1% BSA added for 
stabilization.  Titer by ELISA was quantified at 1:10K-100K.  Pre-absorption of 
the antibody with 10:1 (mass:mass) human or rat DNSP-11 peptide completely 
prevented reactivity with tissue.  A custom antibody to the rat DNSP-11 
sequence (LLEAEPDHSL-NH2) was obtained under the same contract 
conditions, resulting in a similar titer, produced indistinguishable tissue 
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localization, and pre-absorption with peptide similarly prevented tissue reactivity.  
However, antibodies raised against the human sequence produced more intense 
visual signal in rat brain tissue and was used for visualization. 
Tissue preparation for immunohistochemistry 
Adult rats were perfused with approximately 200 mL ice cold saline 
followed by ice cold 4% paraformaldehyde, while post natal rats were not 
perfused.  The animals’ brains were removed whole and placed in ice cold 4% 
paraformaldehyde fixative overnight for immunohistochemical analysis. Rat 
brains were sectioned to 30 µm thickness and stored in cryoprotectant solution 
(30% sucrose, 30% ethylene glycol in 100 mM KPBS) at -20°C until 
histochemical processing.  I would like to acknowledge April Dawn Richardson-
Hatcher, Ph.D. for the prepararation of tissue from four post-natal day 10 rats.   
Immunohistochemical processing 
Every 12th section was blocked with 4% normal goat serum for 1 hour at 
room temperature.  The sections were then immunolabeled with antibody to a 
custom polyclonal human DNSP-11 (1:1000, α-Diagnostic, San Antonio, Texas 
USA) raised in rabbit and incubated overnight at 4°C. The sections were 
incubated with peroxidase-conjugated secondary antibody (1:1000, Vector Labs, 
Burlingame, CA USA) and visualized with nickel enhanced 3,3’-diaminobenzidine 
(NiDAB) chromogen. 
Dual-fluorescence immunohistochemical processing 
Sections were incubated with the polyclonal primary antibody against 
DNSP-11 (α-Diagnostic, 1:1000) overnight at 4 °C, then incubated in Alexa Fluor 
488 goat anti-rabbit secondary antibody (1:1000; Molecular Probes Inc., Eugene, 
OR) for 1 hour at room temperature.  The same sections were subsequently 
incubated in an anti-GDNF antibody (1:500, Chemicon Millipore, Temecula, CA 
USA) overnight at 4 °C, followed by 1 hour at room temperature in Alexa Fluor 
568 goat anti-mouse IgG secondary antibody (1:1000; Molecular Probes Inc.).   
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Tissue homogenization 
Rat brain tissue from 3 month old male Fischer 344 rats was dissected, 
placed in cold lysis buffer (10mM TrisHCl, pH 7.4, 150mM NaCl, 0.5% Triton X-
100 and 0.1% Proteinase Inhibitor Cocktail (Sigma P8340)), and homogenized 
by sonication.  The homogenate was allowed to incubate on ice for one hour, 
followed by the removal of cell debris by centrifugation at 14,000 g at 4°C for 5 
minutes. 
Immunoprecipitation 
Immunoprecipitation kit was purchased from Life Sciences (143.21D, 
Invitrogen, Oslo, Norway) and was performed as follows.  A total of 10 mg of 
Dynabeads were coupled with 70 µg of polyclonal, custom DNSP-11 antibody by 
overnight incubation at 37°C under constant movement.  Beads were washed, 
and then tissue homogenate was incubated with the antibody-conjugated beads 
for 30 minutes at 4°C under constant movement.  Immunoreactive compounds 
were then eluted and retained at -70°C.  A total of 3 animals were used per 
immunoprecipitation resulting in an average 0.1 to 0.2 g of tissue per 
immunoprecipitation.  The resultant fractions containing the immunoprecipitated 
contents were concentrated by lyophilization, and verified by an SDS-PAGE gel 
to confirm the purity of the immunoprecipitation eluent by Coomassie blue and 
silver-stain visualization.  I would like to acknowledge Kristen A. Kelps in the 
laboratory of Luke H. Bradley, Ph.D. for performing immunoprecipitations. 
Peptide identification 
Immunoprecipitated fractions from brain tissue homogenate underwent 
protein identification, compared to the synthetic amidated 11-amino acid rat 
sequence of DNSP-11, as performed by LC-MS/MS in the University of Kentucky 
Proteomics Core Facility (Lexington, KY). 
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Results 
Differential immunostaining patterns for GDNF and DNSP-11 
To characterize the location of the endogenous DNSP-11 peptide within 
the rat brain (Table 6.1, Figure 6.1), immunohistochemical staining of sagittal and 
coronal sections of the rat brain were performed using a polyclonal antibody 
raised to the DNSP-11 sequence.  Intense immunoreactive signal of neuronal 
cell bodies was apparent in the locus coeruleus (LC) (Figure 6.2 and Figure 6.3), 
with strong signal in the ventral tegmental area (VTA), substantia nigra pars 
compact (SNc) (Figure 6.4) and glomeruli of the olfactory bulb (OB).  Moderate 
signal was observed in granule-like cells of the dentate gyrus (DG) and CA1-CA3 
of the hippocampus (Figure 6.5), the nucleus of Purkinje-like cells of the 
cerebellum, and neurons of the facial motor nucleus and mesencephalic nucleus 
of the trigeminal nerve.  Weaker signal appeared in granule-like cells throughout 
the cortices of the brain, including but not limited to the olfactory cortex, 
accessory olfactory bulb, cerebral cortex (Figure 6.1).  Both the antibodies to the 
rat and human DNSP-11 sequences showed comparable immunoreactivity, but 
the antibody raised against the human sequence resulted in more intense 
visualization and detection by ELISA to a lower concentration of the peptide.  
Pre-absorbing both antibodies with either the rat or human DNSP-11 sequence 
produced no non-specific signal. 
It has been previously shown that DNSP-11 signal colocalizes to tyrosine 
hydroxylase positive neurons at post-natal day 10 in the Sprague Dawley rat 
(Figure 6.6) (Richardson, 2009; Bradley et al., 2010) and differential expression 
patterns of GDNF and DNSP-11 in embryonic and post-natal animals described 
(Richardson, 2009).  Here, dual-fluorescence immunoreactive signals for DNSP-
11 and GDNF in post-natal day 10 Fischer 344 rats revealed midbrain (Figure 
6.7) and dorsal raphe (Figure 6.8) neurons containing DNSP-11 signal without 
GDNF.  Furthermore, dual-fluorescence studies indicated some colocalization of 
DNSP-11 and GDNF signals within the neuronal cell bodies of the SN, which 
may represent the uncleaved prosequence; however, DNSP-11 signal was also 
found to be differentially localized from GDNF signal in the, SN and VTA (Figure 
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6.9) and the LC (Figure 6.10).  Of note, DNSP-11 signal distinct from GDNF 
signal was observed in the nucleus, but not cytoplasm, of Purkinje-like cells of 
the cerebellum (Figure 6.11).  DNSP-11 signal was present in the DG of the 
hippocampus without discernible GDNF signal, and DNSP-11 and GDNF signals 
were highly colocalized in the adult facial motor nucleus, the adult striatum, 
cerebellum, and medial lemniscus (not shown).  
Immunoprecipitation 
Peptide identification from the immunoprecipitated fractions were 
inconclusive.   While compounds were pulled down by the antibody, none had 
the same LC retention time as the synthetic amidated rDNSP-11 peptide, and the 
mass spectroscopy identified breakdown pattern of synthetic rDNSP-11 was not 
identified in the immunoprecipitate.  A total of three animals were used in this 
study, and one was excluded due to no detectable proteins pulled down by the 
immunoprecipitation column. 
Discussion 
Limitations of the technique 
The antibody used in these studies was a custom, polyclonal antibody 
raised in rabbit against the synthetic 11-amino acid amidated DNSP-11 
sequence.  While its sensitivity in ELISA is high, and signal is blocked with 
excess of the synthetic DNSP-11 peptide, the specificity of the antibody is not 
known and the peptide cannot be used to quantitatively assay DNSP-11 
concentrations in the brain.  Previous studies have shown that the antibody is 
effective at identifying the distribution of DNSP-11 in situ after intracranial 
injection (Bradley et al., 2010); however, the possibility of the polyclonal antibody 
binding to other compounds within the CNS is considerable.  Indeed, the 
polyclonal antibody used in these studies strongly binds NPY as determined by 
ELISA.  Taken at face value, this data only indicates that the antibody raised to 
synthetic DNSP-11 encounters binding partners in the observed regions of the 
brain, which may include at least the known preproGDNF and NPY proteins but 
may also include the DNSP-11 sequence.  An exhaustive identification of the 
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binding partners of this antibody has not been performed, but based on 
immunoprecipitation results it is unlikely that the 11-amino acid DNSP-11 
sequence exists as a free, isolated, amidated peptide.  It should also be noted 
that the consensus cleavage site for the DNSP-11 sequence is conservatively 
mutated between rats (H40) and humans (R40), and that this introduces the 
possibility of minor differences in processing across species, based on in silico 
analysis (Duckert et al., 2004).  Future studies would benefit from a sensitive, 
specific monoclonal antibody to the DNSP-11 sequence. 
Sequence homologs in the rat CNS 
The immunoreactivity presented in this study may be complicated by the 
presence of both neuropeptide Y (NPY) and TRK-Fused Gene product (Tfg) 
which contain partially homologous sequences to DNSP-11 (see Table 6.1).  
However, it has been reported in the literature that NPY does not localize to 
catecholaminergic neurons such as the LC, SN or VTA based on radiographic 
binding assays and immunohistochemical analysis (de Quidt and Emson, 
1986a).  Furthermore, Tfg immunoreactivity is restricted to the mesencephalic 
nucleus of the trigeminal nerve, the dorsal raphe nucleus, Purkinje cells of the 
cerebellum, and the vestibular and cochlear nuclei.  As such, NPY and Tfg do 
not, individually or in combination, recapitulate the immunoreactive patterns 
observed in this study utilizing the custom polyclonal DNSP-11 antibody (see 
Table 6.1).  In addition, the extensive differential localization of GDNF and 
DNSP-11 signals, both temporally and spatially, suggest the immunoreactivity is 
not explained by the presence of the unprocessed preproGDNF protein.  Future 
studies may focus on the dual-fluorescence signals between DNSP-11, NPY and 
Tfg, or other potentially homologous proteins. 
Differential immunoreactive signals for DNSP-11 and GDNF in post-
natal and young adult rats 
The DNSP-11 peptide sequence is theoretically processed from the pro-
region of GDNF.  In the absence of specific transport mechanisms GDNF and 
DNSP-11 should highly colocalize both spatially and temporally in the rat CNS.  It 
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has been shown that the DNSP-11 peptide does not bind to GFRα1 or RET 
(Bradley et al., 2010), the canonical receptors of GDNF, and due to the 
differences in effects observed in the literature between GDNF and DNSP-11 
(Bradley et al., 2010; Turchan-Cholewo et al., 2010; Kelps et al., 2011), it is 
hypothesized that GDNF and DNSP-11 are distinct biologically active 
compounds.    The data obtained through dual-fluorescence 
immunohistochemical analysis showing differential localization of GDNF and 
DNSP-11 signals supports the hypothesis that DNSP-11 is present and is 
subjected to different transport or expression mechanisms than that of GDNF, 
and that there are cellular populations differentially sensitive to DNSP-11. 
DNSP-11 and GDNF were found to colocalize at post-natal day 10, the 
time of maximal GDNF expression in the rat, but the signals did not exclusively 
colocalize.  A subset of neurons of the developing mesencephalon were 
intensely immunoreactive for DNSP-11 while not exhibiting any detectable 
immunoreactivity to GDNF (Figure 6.7).  While beyond the scope of this study, 
some possibilities present themselves: first, DNSP-11 may be processed from 
the pro-region of GDNF and undergoes transport by a mechanism specific to 
DNSP-11; and second, that splice variants of the GDNF gene may allow 
differential expression of DNSP-11 and GDNF.  There are currently seven known 
splice variants of the GDNF gene in the human, and two of them (variant 005 and 
006) produce a variant from the pro-region that omits a 27 amino acid section 
containing the DNSP-11 sequence (omitted section of human splice variants: 
GKRPPEAPA EDRSLGRRRA PEALSSDS) (Flicek et al., 2013).  While 
speculative, it should not be ruled out that an as yet unidentified splice variant of 
the GDNF gene may allow differential expression of DNSP-11 and GDNF. 
Expression of GDNF is known to decrease markedly in the adult rat, but it 
was observed that the DNSP-11 signal remains intense in the mesencephalon of 
adult rats (Figure 6.9).  This observation supports the hypothesis of differential 
expression levels or a prolonged half-life of endogenous DNSP-11 in the rat 
CNS.  It may be speculated that endogenous DNSP-11 has a biological function 
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in the monoaminergic neuron populations identified here as containing DNSP-11 
signal, such as the locus ceruleus, substantia nigra, and raphe nuclei. 
The DNSP-11 sequence as a processed biological peptide 
The highest intensity signal for DNSP-11 was observed in the locus 
ceruleus, the norepinephrinergic center of the CNS (Figure 6.10).  It has been 
shown in the literature that the GDNF gene is necessary for the development and 
maintenance of the neurons of the locus ceruleus.  In a conditional GDNF-null 
mouse model, it was shown that the approximate 60% reduction of GDNF mRNA 
and protein levels in these mice during adulthood results in the complete loss of 
the catecholaminergic neurons of the locus ceruleus with only moderate losses in 
the substantia nigra and VTA (Pascual et al., 2008), indicating that the GDNF 
gene is necessary for normal maintenance and survival of adult 
catecholaminergic neurons, especially the locus ceruleus.  This is an interesting 
finding in light of the observation by others that the locus ceruleus contains no 
detectable mRNA for GDNF and only trace levels of mRNA for its receptors 
GFRα and RET in the rat (Trupp et al., 1997), contrasted with the substantia 
nigra which is characterized by extensive levels of GDNF receptor mRNA.  The 
SN and VTA, with extensive GDNF receptor expression, only underwent 
moderate loss in these conditional knock-out animals, while the locus ceruleus, 
with very low levels of GDNF receptor expression, underwent a near total loss.  
This indicates that the locus ceruleus may be highly sensitive to GDNF gene 
product expression levels or the effects of GDNF gene products on receptors 
other than the canonical GDNF receptors. 
The observed localization of the DNSP-11 signal in the rat CNS may 
provide evidence of the sensitivity of cell populations to DNSP-11 and may allow 
for increased therapeutic effect through targeting specific brain regions.  Indeed, 
loss of the locus ceruleus in human Parkinson’s disease patients precedes and is 
greater than the loss of the substantia nigra neurons (German et al., 1992; Patt 
and Gerhard, 1993; Braak et al., 2003; Zarow et al., 2003).  This loss contributes 
to many of the secondary symptoms and may exacerbate the primary motor 
symptoms.  Shown within this work is data suggesting DNSP-11 affects 
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monoamine systems (Chapter Four), and while inconclusive the 
immunohistochemical studies of this chapter support the hypothesis that these 
nuclei interact with DNSP-11. 
Immunoprecipitation studies indicate that the binding partners of the 
antibody raised to DNSP-11 do not match the LC-MS identity for the synthetic, 
amidated 11-amino acid DNSP-11 sequence.  The results do not rule out the 
endogenous presence of DNSP-11, but suggest that it may be in a form other 
than that of the synthetic peptide.  The endogenous DNSP-11 sequence may be 
covalently modified or it may be contained within a larger signal peptide.  
Additionally, endogenous DNSP-11 may degrade quickly under the conditions of 
the immunoprecipitation, or be present at concentrations too low to quantify.  
While the antibody used in these studies binds NPY and DNSP-11, 
immunoreactive signal was identified in brain regions not typically associated 
with NPY expression.  Also, in other regions where NPY expression is found the 
antibody did not result in signal (Table 6.1).  The detection and isolation of 
endogenous DNSP-11 would benefit from the production and use of a highly 
specific monoclonal antibody. 
Although the studies in this chapter produced many questions, the insights 
gleaned may guide future studies on possible cell populations responsive to 
DNSP-11 and the possible existence of the DNSP-11 sequence as an active 
element of endogenous biological processes.  
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Table 6.1 – An overview of expression patterns for DNSP-11 and sequence 
homologues, GDNF, NPY, and Tfg in the adult. 
 DNSP-11 GDNF NPY Tfg 
Homologous 
sequence PPEAPAEDRSL-NH2  
-PPEAPAEDRSL- 
(proGDNF) 
-GEDAPAEDMAR- 
 
-PPSAPTEDRSG- 
 
Cortex 
- ± ++ - 
Striatum 
± + - - 
Amygdala 
- - ++ - 
Hypothalamus 
- - ++ - 
Hippocampus 
+ + + - 
Substantia 
nigra ++ + - - 
Ventral 
tegmental area ++ - - - 
Raphe nuclei 
+ - - ++ 
Locus ceruleus 
+++ - ± - 
Mesencephalic 
nucleus of 
Trigeminal 
+ + - + 
Cerebellar 
Purkinje cell 
nucleus 
+ - - - 
Cerebellar 
Purkinje cell 
cytoplasm 
- + - + 
This table summarizes the localization of various proteins related and/or 
homologous to DNSP-11 in the adult rat.  Note that information for NPY, Tfg, and 
GDNF is based on a survey of the literature. 
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Figure 6.1 – Whole sagittal section of the rat brain immunoreacted for DNSP-11. 
An overview of immunoreactive hotspots of DNSP-11 signal in a sagittal view of 
the rat CNS.  Especially intense intracellular signal was observed in the locus 
ceruleus, VTA and SN, glomeruli layer of the olfactory bulb (OB), and dentate 
gyrus of the hippocampus (DG).  Diffuse signal was also present in the striatum 
(CPu).  Representative section (n=6 sagittal, n=3 coronal). 
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Figure 6.2 – DNSP-11 signal in the locus ceruleus and cerebellum in sagittal 
view. 
A sagittal view of the locus ceruleus and cerebellum shows intense DNSP-11 
signal in the neuronal cell bodies and projections of the locus ceruleus and light 
signal in the Purkinje cell layer of the cerebellum. (LC, locus ceruleus; PC, 
Purkinje cell layer of cerebellum; ic, inferior colliculus; 4V, fourth ventricle.) 
  
LC 
PC 
ic 
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Figure 6.3 – A detailed view of DNSP-11 signal in the locus ceruleus. 
Observed in this sagittal view of the locus ceruleus of naïve adult male Fischer 
344 rats is intense immunoreactivity for DNSP-11, including cytoplasmic 
localization and vesicle-like concentrations in neuronal projections. 
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Figure 6.4 – DNSP-11 signal in the VTA and SN of adult rats. 
DNSP-11 signal was intense in neurons of both the VTA and substantia nigra 
pars compacta in the adult rat. 
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Figure 6.5 – DNSP-11 signal in the dentate gyrus and cornu ammonis of the 
hippocampus. 
Moderate DNSP-11 immunoreactivity was observed in granule-like cells of the 
dentate gyrus (DG) and cornu ammonis (CA) formations of the hippocampus. 
(LV, lateral ventricle; 3V, third ventricle.) 
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Figure 6.6 – DNSP-11 signal highly colocalizes to TH-positive neurons in the 
midbrain of post-natal day 10 Sprague Dawley rats. 
In immunohistochemical experiments performed by April Dawn Richardson-
Hatcher, Ph.D., contained within her dissertation work (Richardson, 2009), it was 
observed that DNSP-11 signal highly colocalizes with TH+ neurons at post-natal 
day 10. 
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Figure 6.7 – DNSP-11 signal, but not GDNF signal, is present in a developing 
post-natal day 10 midbrain cell. 
Shown here is a representative neuron in the midbrain of a post-natal day 10 
Fischer 344 rat with only immunoreactive signal for DNSP-11.  DNSP-11 is 
thought to be processed from the pro-region of GDNF, suggesting a high degree 
of colocalization.  However, DNSP-11 signal does not exclusively colocalize with 
GDNF signal, suggesting DNSP-11 may have unique and efficient active 
transport mechanisms and specific reactive cell populations. 
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Figure 6.8 – DNSP-11 signal in the raphe of post-natal day 10 animals. 
In the serotonergic raphe nucleus of post-natal day 10 animals, DNSP-11 signal 
is present in the cytoplasm of neurons, while GDNF signal is only weakly present 
and differentially localized.  DNSP-11 signal in the raphe was also observed in 
the adult rat CNS. 
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Figure 6.9 – DNSP-11 signal remains intense in adulthood, while GDNF signal 
dissipates. 
The time of maximal GDNF expression in the rodent is post-natal day 10, which 
would theoretically be the time of maximal DNSP-11 expression was well.  While 
GDNF and DSNP-11 signals do colocalize extensively, they do not exclusively 
colocalize.  In the adult, 3 month old Fischer 344 male rat, GDNF expression is 
markedly reduced, while the DNSP-11 signal remains intense.  This suggests 
that GDNF and DNSP-11 may be differentially expressed or be subject to 
different post-signal processing or half-lives in vivo.  (A-C) Post-natal day 10 
animals.  (A) Merged DNSP-11 and GDNF signals.  DNSP-11: green, GDNF: 
red.  (B) GDNF signal.  (C) DNSP-11 signal.  (D-F) Young adult animals.  (D) 
Merged DNSP-11 and GDNF signals.  DNSP-11: green, GDNF: red. (E) GDNF 
signal. (F) DNSP-11 signal. 
 
  
POST-NATAL DAY 10 ADULT 
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Figure 6.10 – DNSP-11 signal is intense in the adult locus ceruleus where GDNF 
is not expressed. 
In the adult male 3 month old Fischer 344 rat, DNSP-11 does not exclusively 
colocalize with GDNF.  DNSP-11 signal is highly concentrated in the locus 
ceruleus (LC), a region with no mRNA for GDNF and only low levels of mRNA for 
the GDNF receptor GFRα and its co-receptor RET (Trupp et al., 1997).  This 
suggests differential transport methods for DNSP-11 and GDNF.  In addition, 
DNSP-11 is present in the cells of the mesencephalic nucleus of the trigeminal 
nerve (MeV), involved in proprioception of the muscles of mastication. 
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Figure 6.11 – DNSP-11 signal presence in the Purkinje cell layer of the adult 
cerebellum is differentially localized from GDNF signal. 
Here we see DNSP-11 signal localized to the nucleus of Purkinje-like cells of the 
cerebellum in the adult rat CNS.  While GDNF signal is also present within these 
cells, it is restricted to small vesicle-like cytoplasmic concentrations.  
 
 
 
 
 
 
 
 
Copyright © James William Hendry Sonne 
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Chapter Seven:  Synopsis, Conclusions, and Future Directions 
In this body of work, intranasally administered DNSP-11 has been shown 
to protect tyrosine hydroxylase positive cell bodies of the substantia nigra and 
striatal fiber densities in 6-OHDA lesioned young adult male Fischer 344 rats 
(Chapter Three); to modulate the dopaminergic neurochemistry of normal Fischer 
344 rats and 6-OHDA lesioned rats (Chapter Four); and to prevent apomorphine-
induced rotation behavior in 6-OHDA lesioned rats (Chapter Five).  While future 
studies are needed, the data strongly supports the hypothesis that intranasally 
administered DNSP-11 has therapeutic potential for Parkinson’s disease.  
Furthermore, dual-fluorescence immunohistochemical visualization of post-natal 
day 10 and young adult Fischer 344 rat brain tissue provides evidence that 
DNSP-11 is endogenously present in the rat brain (Chapter Six). 
The 6-OHDA lesion parameters used in the present study follow the 
parameters used in studies on the effects of GDNF authored by Kearns et al. in 
1995 and 1997 also in the laboratory of Don M. Gash, Ph.D.  In those studies, 
the lesion produced approximately 91% loss of TH+ neurons of the substantia 
nigra two weeks after lesioning, compared with 92.1% loss three weeks after 
lesioning in the present study.  In those previous studies, when GDNF was 
administered as a single injection intranigrally 24 hours prior to 6-OHDA lesion 
induction, nigral TH+ cell loss was significantly reduced to 53% two weeks after 
lesioning.  In the present study in which DNSP-11 was repeatedly administered 
for three weeks with the first dose 30 minutes prior to 6-OHDA lesion induction, 
TH+ cell loss was reduced to 75.2%.  In the previous study published in 1997 
that looked at the 3 week post-lesion time point, it was identified that pre-
treatment with injected GDNF was most effective 6 hours prior to lesion 
induction, and both DA and DOPAC were significantly higher in the lesioned 
hemisphere of GDNF treated animals compared with citrate buffer control treated 
animals.  In the present study, DA was significantly higher only in a subgroup of 
partially lesioned animals.    In the animals simultaneously treated with GDNF 
and 6-OHDA, a 75% TH+ cell loss was observed, similar to the present study. 
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The similarity of the lesion and time points of analysis between this and 
the previous studies of GDNF allow more direct comparison of the effects of 
intranigral GDNF and intranasal DNSP-11.  While the effects observed in this 
intranasal DNSP-11 study did not reach the same magnitude as the intranigral 
GDNF studies, the positive impact of intranasal DNSP-11 is clear.  It may be 
possible to reach effect parity with simple changes to the dose of DNSP-11, the 
time point of initial treatment, or frequency of administration.  Of note, no 
significant protective effects of GDNF were observed with pretreatment of less 
than 6 hours before 6-OHDA lesion induction in the previous study (Kearns et al., 
1997), while the present study administered intranasal DNSP-11 30 minutes prior 
to lesioning and repeatedly afterward.  This could suggest that DNSP-11 enters 
the CNS quickly and rapidly protects cell populations, or that DNSP-11 treatment 
produces strong restorative effects after lesioning, as observed in previously 
published work on rats with a stable 6-OHDA lesion of the medial forebrain 
bundle four weeks prior to DNSP-11 injection (Bradley et al., 2010). 
The similarities of effects from intranasal DNSP-11 and intranigral GDNF, 
along with the strong prevention of rotation behavior with intranasal DNSP-11, 
provide exciting, positive data on the potential for an easy-to-administer, non-
invasive preventive and restorative therapy for parkinsonism.  Future studies 
should seek to rapidly advance this potential therapy toward clinical trials by 
focusing on faster assays and shorter time points of analysis to identify the 
sources of variability in the treatment. 
Answers and Questions 
 This work began with the goal of determining whether the intranasal 
administration of DNSP-11 could result in the transport of efficacious quantities of 
the peptide into the brain to produce a protective effect.  This goal was 
accomplished, but many new questions were raised in the course of this study. 
Data reported in Chapter Three indicates that DNSP-11, when 
administered intranasally, is transported throughout the CNS in biologically 
relevant quantities.  Repeated intranasal administrations of DNSP-11 over a 
three week time period resulted in significantly higher numbers of tyrosine 
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hydroxylase positive substantia nigra neurons in a unilateral 6-hydroxydopamine 
lesion rat model.  The projections of these neurons to the striatum were likewise 
higher in DNSP-11 treated rats.  This supports the hypothesis that DNSP-11 has 
cellular protective effects in the rat.  Furthermore, DNSP-11 treatment modulated 
monoamine neurotransmitter content and prevented apomorphine-induced 
rotation behavior, a hallmark of the unilateral 6-OHDA lesion model of 
Parkinson’s disease.   
These data replicate previously published data on DNSP-11 injected 
intracranially, directly to the substantia nigra (Bradley et al., 2010; Fuqua, 2010; 
Littrell, 2011).  In these studies it was shown that a single intra-nigral injection of 
DNSP-11 in stably lesioned animals reduced rotation behavior and modulated 
the dopaminergic system of the rat.  DNSP-11 also protects cultured cells from a 
variety of cellular and mitochondrial toxins (Bradley et al., 2010; Turchan-
Cholewo et al., 2010; Kelps et al., 2011).   
Effects of DNSP-11 
While this study resulted in many answers, many more questions were 
raised.  The most important of these questions surrounds the modulation of 
dopamine release observed in both normal and lesioned animals.  While it was 
found that dopamine turnover was increased in normal animals after three weeks 
of intranasal treatment this was due to increases in the metabolites of dopamine 
and not due to an increase in dopamine.  A subgroup of partially lesioned 
animals in this study exhibited an increase in dopamine content of the striatum 
with DNSP-11 treatment.  However, a small group of naïve animals infused with 
DNSP-11 during striatal microdialysis revealed a significant decrease in 
potassium-evoked, calcium-dependent release of dopamine in the striatum, 
suggesting acute effects.  For an overview of the effects observed in this study, 
refer to Table 7.1.   
What is the mechanism behind this modulation of the dopamine system?  
Based on the animals’ physiological parameters, observed health and behavior, 
histological, neurochemical and apomorphine-induced rotation metrics, it 
collectively and firmly supports that DNSP-11 produces protective or restorative 
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effects on the motor system.  The loss of striatal dopamine content is the major 
factor in the motor impairments of Parkinson’s disease, and increases in striatal 
dopamine are believed to be the mechanism behind many of the symptomatic 
treatments currently available at the clinical level for Parkinson’s disease, such 
as L-DOPA and MAO-inhibitors.   
While increases in striatal dopamine were observed in a subgroup of 
partially lesioned DNSP-11 treated animals in the present study, focusing solely 
on the dopamine system may be insufficient to explain the observed effects.  
Some treatments for Parkinson’s disease, such as deep-brain stimulation, 
produce their symptomatic relief through the targeting of downstream nuclei in 
the basal ganglia circuitry such as the subthalamic nucleus or substantia nigra 
pars reticulata.  Other striatal inputs may play a role in Parkinson’s disease, such 
as serotonin inputs from the raphe nuclei, norepinephrinergic inputs from the 
locus ceruleus or glutamatergic input from the thalamus and cortex.  
Furthermore, data presented in this study and in the literature (Immonen et al., 
2008) indicate that DNSP-11 may have profound effects on other nuclei in the 
body such as the raphe nuclei (Chapter Four, Chapter Six), the locus ceruleus 
(Chapter Six), and the hippocampus (Chapter Six).  Many of these effects were 
beyond the scope of this study, but are deserving of future efforts. 
Converging data points to the role of DNSP-11 on mitochondria.  
Protective effects of DNSP-11 against mitochondrial toxins in cell culture has 
been published in the literature (Bradley et al., 2010; Kelps et al., 2011) and 
strong changes in mitochondrial respiration and electrical potential are observed 
with DNSP-11 treatment (Turchan-Cholewo et al., 2010; Bradley et al., 2012).  
This may explain some of the cellular protective effects as well as neurochemical 
effects of DNSP-11.  Synaptic mitochondria show a strong capacity to buffer 
calcium.  While merely speculation, it is possible that DNSP-11 transiently 
increases mitochondrial respiratory reserve capacity through the increased 
buffering of calcium, leading to a decrease in cytosolic calcium and the calcium-
dependent, potassium-evoked release of dopamine observed in this and other 
studies (Fuqua, 2010).   
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If DNSP-11 is a potent anti-apoptotic compound and can induce increases 
in mitochondrial respiration, it may also be useful as a treatment for a variety of 
other diseases of degeneration or metabolic imbalance, including metabolic 
syndrome (Mitchell et al., 2013), Alzheimer’s disease (Silva D. F. et al., 2012), 
and even cancer.  It has been reported in the literature that cancerous cells 
upregulate aerobic glycolysis, shutting down their mitochondria and the 
mitochondrial apoptotic pathways.  Stimulation of mitochondria and increases in 
their respiration reactivate these apoptotic pathways inducing cell death in 
cancerous cells (Scatena, 2012).  Future work on the effects of DNSP-11 and its 
mechanisms may warrant the evaluation of its effects in other models and 
disorders. 
The identification and characterization of the GDNF pro-region 
While immunoprecipitation studies resulted in the elution of bound 
compounds, these compounds did not match the LC-MS/MS profile of the 
synthetic, amidated rat sequence of DNSP-11 (Chapter Six).  The polyclonal 
antibody used in these studies was confirmed to bind both the rat and human 
DNSP-11 sequences to a high titer by ELISA, but the specificity of the antibody 
was not established.  Indeed, it was noted that there exists homologous amino 
acid sequences in the central nervous system in the form of Neuropeptide Y 
(NPY) and TRK-Fused Gene product (Tfg).  While data in the literature indicates 
the immunoreactive patterns observed in the CNS are inconsistent with both 
NPY and Tfg expression, the possibility remains that the observed signal in the 
CNS is from compounds other than the DNSP-11 sequence.  The 
immunoprecipitation data suggests that, if the DNSP-11 sequence is 
endogenously expressed, it is covalently modified and/or processed to produce a 
peptide dissimilar to the synthetic amidated peptide, that it may degrade quickly 
under the conditions of the immunoprecipitation, or that it is present in quantities 
too low to detect.   
The observed immunoreactive cell populations in the CNS (Chapter Six) 
and the observed neurochemical changes (Chapter Four), may provide insight 
into the effects of DNSP-11 in order to optimize its therapeutic use.  While it is 
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hypothesized that the endogenous DNSP-11 sequence from the pro-region of 
GDNF produces biological effects, the acquisition of a sensitive monoclonal 
antibody to DNSP-11 would have benefits including the isolation and 
characterization of the endogenous DNSP-11 sequence.  Furthermore, genetic 
knock-out studies focusing on the pro-region of GDNF could provide information 
on the developmental and maintenance roles of endogenous DNSP-11. 
Mechanisms of action of DNSP-11 and the search for faster assays 
The mechanisms of action of DNSP-11 are yet to be elucidated, but some 
clues do exist.  DNSP-11 produces the strongest protective actions against 
mitochondrial toxins in cell culture, especially toxins against complex I, by 
inhibiting caspase 3 activation (Kelps et al., 2011; Bradley et al., 2012).  DNSP-
11 has also been shown to bind to GAPDH, an anti-apoptotic nuclear factor 
(Bradley et al., 2012), and to phosphorylate ERK1/2, part of an anti-apoptotic 
pathway (Turchan-Cholewo et al., 2010; Bradley et al., 2012) which suggests a 
possible membrane-bound trophic factor receptor.  These many different 
proposed signaling pathways may be part of a multifaceted cascade, but the 
determination of the cellular target and downstream signaling pathways would 
provide a tool for optimizing the DNSP-11 peptide.  It is also possible that DNSP-
11, after rapid internalization, acts directly on downstream signaling cascades, 
bypassing a membrane-bound receptor.  Having the ability to determine the 
activity of a cellular signaling pathway would allow the rapid evaluation of 
changes to the peptide, vehicle and delivery techniques.   
The studies contained within this work required daily administration over 
three weeks, and although they show the efficacy of intranasal DNSP-11, the 
time and resources required to perform them are not ideal for quickly advancing 
DNSP-11 as a therapy.  These studies were impaired by lengthy time periods, an 
administration routine prone to variability, and endpoints with low fidelity for the 
identification of the sources of variability.  Any small change to the dosing 
regimen, peptide, or formulation would require an excessive length of time to test 
by this study design.  Faster assays of the effects of intranasal DNSP-11 are 
required.  One such possibility is in the radiolabeled 125I-DNSP-11 studies by 
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Mallory J. Stenslik.  These studies can provide detailed information about the 
results of different time points and formulations on transport to the central 
nervous system, allowing for the identification of sources of variability from the 
dosing of the compound.  However, an ideal assay would provide data on the 
biological effectiveness of the administration at such short time periods.  Such an 
assay may be found in the cellular signaling cascades involved in the biological 
effects of DNSP-11, perhaps including ERK1/2 phosphorylation or mitochondrial 
effects previously shown in cell culture studies (Turchan-Cholewo et al., 2010; 
Bradley et al., 2012).   
Furthermore, DNSP-11 may activate transcription factors producing long-
term as well as short-term effects.  The effects observed in the present study can 
be interpreted as long-term effects, but may be the result of short-term changes, 
for instance on mitochondrial potential, resulting in cellular protection as opposed 
to long-term changes in cellular transcription.  It may be possible to positively 
identify the short-term effects as the dominant mechanism by blocking protein 
synthesis thus removing transcriptional activation as the possible protective 
effect.  Strong and acute mitochondria effects in cell culture observed in 
published studies (Turchan-Cholewo et al., 2010; Bradley et al., 2012) may 
indicate the potential of an assay of ex vivo mitochondrial respiration and/or 
mitochondrial potential after intranasal administration.  This assay would require 
euthanasia and is prone to variability in mitochondrial extraction.  While these 
assays are interesting possibilities they are still not ideal for in vivo analysis. 
Rapid changes to potassium-evoked release of dopamine was identified 
by microdialysis in a small group of naïve animals (Chapter Four) within two 
hours of the perfusion of a 50 µM DNSP-11 aCSF solution through a 
microdialysis probe placed in the striatum, but using microdialysis to assay 
changes to intranasal administration of the peptide may be unwieldy.  Such acute 
changes may indicate the possibility of other assays, such as changes to blood-
oxygen level dependent (BOLD) contrast by MRI after DNSP-11 administration.  
It may also be possible to implant electrodes to measure striatal dopamine, or 
other basal ganglia nuclei and neurotransmitters, with high precision both before 
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and after intranasal administration.  The benefits of BOLD-MRI and electrode 
implantation are the rapid acquisition of the data and repeatability within the 
same animal.  Furthermore, BOLD-MRI in particular is an assay with the potential 
to be easily translated to trials in non-human primates and even humans.   
Regardless of the specific mechanism used, faster assays of the biological 
effects of DNSP-11 are necessary for the rapid advancement of DNSP-11 toward 
therapeutic use.  While long-term studies provide the benefits of behavioral 
assays and safety studies in an animal model, they are cumbersome for the 
purposes of optimizing DNSP-11 as a therapeutic.  Whether the assay evaluates 
mitochondrial respiration, cellular signaling cascades, or neuronal activity, the 
development of a rapid assay that positively identifies the effects of DNSP-11 
soon after administration would provide the biggest advance in development of 
DNSP-11 by allowing high-throughput analysis of optimizations.  As the 
treatment progresses, long term efficacy and toxicology studies can be 
performed across species and sexes.  
Conclusion 
Within this body of work, data has been shown that supports the 
hypothesis that intranasal administration of DNSP-11 does produce protective 
effects in a 6-hydroxydopamine lesion model of Parkinson’s disease.  Tyrosine 
hydroxylase positive neurons were higher in DNSP-11 treated animals (Chapter 
Three), striatal dopamine content was higher by DNSP-11 treatment in a 
subgroup of partially lesioned animals (Chapter Four), and apomorphine-induced 
rotation behavior was prevented in the DNSP-11 treated animals (Chapter Five).  
This is strong evidence that intranasal DNSP-11 protected the basal ganglia 
dopamine system from the 6-OHDA lesion.  It was also shown that DNSP-11 
modulates the dopaminergic system in both normal and lesioned animals 
(Chapter Four).  The acute effects of infused DNSP-11 on potassium-evoked 
dopamine release raise questions about the mechanism of action of DNSP-11 
(Chapter Four).  Animals treated with DNSP-11 did not lose excessive weight, 
exhibited no detrimental changes in body temperature or activity levels, and did 
not show signs of distress or discomfort from the treatment (Chapter Five) 
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providing evidence of the safety of the treatment.  The endogenous DNSP-11 
sequence was not positively identified, and the specificity of the polyclonal 
antibody to DNSP-11 was not validated, but endogenous immunoreactive 
patterns with the antibody do not match patterns of homologous sequences 
found in the brain, including that of NPY, Tfg, or the preproGDNF unprocessed 
parent protein (Chapter Six). 
The data obtained in this study supports much of the data previously 
published on DNSP-11.  DNSP-11 administered either intranasally or 
intracranially shares some effects with GDNF while having the potential to 
provide greater benefits than current therapies such as L-DOPA (Table 7.2).  
Intracranially injected DNSP-11 has been shown to rapidly enter the cytoplasm of 
tyrosine hydroxylase positive neurons, to increase dopamine and metabolite 
concentrations in the normal and stably lesioned rat striatum, and to reduce 
rotation behavior.  Furthermore, DNSP-11 increases TH+ neuron count, neurite 
length and branching in primary cultured embryonic neurons.  DNSP-11 also 
protects against known mitochondrial toxins in cell culture, reducing caspase-3 
activation. (Bradley et al., 2010; Fuqua, 2010; Turchan-Cholewo et al., 2010; 
Kelps et al., 2011; Littrell, 2011; Bradley et al., 2012) 
With the increasing average age of the population and increasing 
individual longevity, the impact of Parkinson’s disease is growing (Dorsey et al., 
2007; Collier et al., 2011).  The disease progresses insidiously and it profoundly 
impacts not just the individual but families as well as society.  A protective 
therapeutic can potentially delay the manifestation of serious symptoms until 
much later in life, diminishing the personal, societal, and economic impact of this 
neurodegenerative disease.  For the reasons provided in this dissertation, DNSP-
11 is a good candidate for further development as a prevention and treatment for 
Parkinson’s disease. 
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Table 7.1 – Overview of the effects observed in this study 
 Intranasal DNSP-11 
 Normal Rats Lesioned Rats 
Partial Severe 
Dopamine Content inconclusive ↑↑ no change 
Dopamine Metabolite Content  ↑↑ inconclusive no change 
TH+ substantia nigra cell bodies not tested ↑↑ 
TH+ striatal fiber density not tested ↑↑ 
Baseline Dopamine Release no change no change ↓ 
Baseline Dopamine Metabolites not change no change ↓ 
K+-Evoked Dopamine Release ↓↓ no change ↓↓ 
Apomorphine-induced rotations not tested ↓↓ 
 
Overview of the effects observed with various endpoints in the studies 
composing this dissertation.  Up arrows indicate positive changes with respect to 
controls, down arrows indicate negative changes.   
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Table 7.2 – Overview of the effects of DNSP-11 and GDNF  
 DNSP-11 GDNF 
(Kearns et al., 
1995, 1997) Present study (Bradley et al, 2010) 
Administration Intranasal Intracranial Intracranial 
Organism Rodent Rodent Rodent 
Lesion toxin 6-OHDA 6-OHDA 6-OHDA 
Lesion location Acute SN Stable MFB Acute SN 
Treatment timepoint Repeated Post-lesion Pre-lesion 
Post-lesion timepoint 3 weeks 5 weeks 2 and 3 weeks 
TH+ nigral cell count + inconclusive ++ 
TH+ Striatal fiber density + inconclusive ++ 
Dopamine content inconclusive + ++ 
Dopamine metabolites + ++ ++ 
Striatal dopamine release inconclusive ++ not tested 
Behavioral protection ++ ++ not tested 
 
This table represents data from the present work on intranasal DNSP-11, 
published reports on intracranial DNSP-11 (Bradley et al., 2010) and from work in 
the same laboratory evaluating the effects of GDNF using the same lesioning 
parameters (Kearns et al., 1995, 1997).  Most significant from the Kearns 
articles, significant effects of GDNF were observed with pretreatment 6+ hours 
prior to lesion induction; simultaneous application of GDNF and the 6-OHDA 
toxin did not produce significant effects.  While the most effective dose or timing 
of intranasal DNSP-11 administration may not yet be identified, intranasal 
treatment with DNSP-11 produced strong protective or restorative effects similar 
to GDNF treatment.  This study has provided important evidence for the efficacy 
of a non-invasive administration route for the DNSP-11 peptide to protect or 
restore dopaminergic neurons from a 6-hydroxydopamine rodent model of 
Parkinson’s disease.   
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